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Estrutura-Função da proteína Vif do HIV-1 e sua regulação 
SUMÁRIO 
O Vírus da Imunodeficiência Humana tipo 1 (HIV-1) é um retrovírus complexo que 
codifica uma proteína acessória, Vif (Viral Infectivity Factor), necessária para uma 
produtiva infecção. A presença de Vif na célula produtora de vírus é um dos factores 
essenciais para o aumento da infecciosidade viral, podendo esta ser aumentada até 
cerca de 1000 vezes.  
Há mais de uma década que é sabido que a proteína Vif é necessária para a replicação 
do HIV-1 em algumas células, chamadas não permissivas. No entanto em outras, 
chamadas permissivas, a replicação viral ocorre mesmo que na ausência de Vif. A razão 
para este facto permaneceu desconhecida até á descoberta, em 2002, da desaminase 
de citidina humana, human apolipoprotein B mRNA-editing enzyme-catalytic 
polypeptide-like 3G (APOBEC3G) como sendo a proteína responsável por restringir a 
replicação de HIV-1 que não expressa Vif. Este factor de restrição celular encontra-se 
presente maioritariamente no baço, gónadas, monócitos e linfócitos periféricos.  
Na ausência de Vif, A3G, é encapsidado no virião em formação por um sistema 
dependente de Gag. Desta forma, A3G é transportado para a próxima célula alvo onde 
vai actuar no momento da transcrição reversa, desaminando a cadeia simples, negativa 
do cDNA viral. Este processo resulta na inactivação do processo replicativo por 
hipermutação do genoma ou mesmo pela degradação do cDNA viral por um 
mecanismo dependente da enzima DNA uracil glicosilase. 
Após a identificação de A3G e mais tarde de APOBEC3F (A3F), ficou claro que o 
mecanismo pelo qual o HIV-1 escapava á acção destes factores de restrição era através 
da proteína Vif. Vif actua inibindo a entrada de A3G e A3F nos viriões através da 
diminuição dos níveis celulares destes factores de restrição. Um dos mecanismos que a 
Vif utiliza implica a degradação proteossomal destas enzimas. Para isso, a Vif recruta 
uma série de proteínas celulares para formar um complexo Culina5- os desta forma 
para degradação proteossomal. 
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Desta forma, torna-se essencial compreender de que forma a proteína A3G, 
documentada como sendo a que exerce maior actividade contra o HIV-1, pode ser 
estimulada na célula de maneira a poder escapar aos efeitos da Vif e 
consequentemente inibir a replicação viral. Assim, decidimos modelar o tempo de 
meia-vida do A3G como forma de monitorizar a sua acção na célula desde o momento 
em que é traduzido até á sua encapsidação no virião. Este mecanismo de modelação 
do tempo de meia-vida de uma proteína é conhecido pelo nome de “N-end Rule” e 
consiste na introdução de diferentes amino ácidos no inicio da região N-terminal de 
uma proteína resultando em diferentes tempos de meia-vida da mesma, de acordo 
com a identidade do resíduo introduzido. Ao interferir com a estabilidade desta 
proteína, fomos capazes de a direccionar para degradação no proteossoma duma 
forma independente da Vif. Os resultados apresentados neste trabalho confirmaram a 
importância do tempo de meia-vida do A3G para a manutenção da sua actividade 
antiviral. Ao diminuir os tempos de vida do A3G na célula, fomos capazes de 
determinar que o tempo de meia-vida mínimo do A3G para que este seja incorporado 
nos viriões é de aproximadamente 13 minutos. Neste caso, concluímos que a Vif terá 
que actuar nos estágios iniciais da vida do A3G de forma a impedir que este seja 
encapsidado nos viriões. A análise da actividade catalítica dos nossos diferentes A3Gs 
revelou que a sua actividade enzimática no citoplasma da célula não parece ser 
importante para a sua actividade antiviral e que a actividade catalítica destes variantes 
não aumenta de acordo com o aumento do tempo de meia-vida destes. Esta 
estratégia, permitiu-nos compreender de que forma o tempo de meia-vida do A3G 
pode influenciar a sua actividade antiviral, quer ao nível da sua encapsidação nos 
viriões como ao nível da sua actividade catalítica na célula. 
A identificação de padrões de interacção entre a Vif e o A3G é um dos maiores desafios 
para o desenvolvimento de novas terapias antivirais. Tem sido demonstrado que o 
impedimento da interacção Vif-A3G resulta num aumento da actividade antiviral deste 
último. Assim, decidimos estudar a interacção entre estas duas proteínas através de 
duas estratégias que, embora já tenham sido utilizadas em estudos semelhantes com 
outras proteínas, foram aqui usadas pela primeira vez no contexto da interacção Vif-
A3G.  
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A primeira estratégia consistiu na fusão de fragmentos da Vif e do A3G a domínios de 
interacção do factor de transcrição de levedura GCN4 (Zip), que forma homodimeros. A 
presença de Zip em fusão com estas proteínas obrigará estas a se encontrarem 
espacialmente permitindo-nos assim mutagenizar partes de ambas as proteínas e 
concluir acerca da importância de certos domínios na interacção. Esta estratégia 
permitiu-nos demonstrar a importância da região C-terminal da Vif na interacção com 
o A3G. Os resultados obtidos indicam que esta região da Vif, por si só, não é suficiente 
para induzir a degradação do A3G e sugerem que a interacção Vif-A3G deverá envolver 
um co-factor celular adicional que se deverá ligar á região N-terminal da Vif.  
 
Estudámos também a orientação espacial da interacção Vif-A3G através da fusão 
destes, a domínios interactivos de Zips anti-paralelos. Os resultados obtidos mostraram 
a importância da orientação espacial das duas proteínas, demonstrando que esta 
deverá ocorrer em orientação paralela. Demonstrámos também que, para uma eficaz 
interacção entre Vif e A3G, estas deverão se encontrar espacialmente próximas uma da 
outra.  
 
De forma a mostrar a especificidade da interacção Vif-A3G, decidimos estudar a 
interacção da Vif com uma proteína com a qual Vif não interage. Desta forma, 
utilizámos a proteína EGFP em fusão com Zip. Desta interacção não resultou 
degradação, levando-nos a concluir que a interacção Vif-A3G é específica reforçando 
uma vez mais a nossa hipótese de existência de um factor celular essencial para uma 
eficaz interacção e degradação do A3G.  
 
A segunda estratégia usada no estudo da interacção Vif-A3G consiste num sistema de 
complementação proteica baseado na enzima TEM-1 β-lactamase. Desta forma, os 
domínios inactivos da enzima são fundidos a cada uma das proteínas em causa, através 
de uma ponte de aminoácidos que fornece plasticidade à fusão. Se ocorrer interacção 
proteína-proteína os dois domínios inactivos da enzima tornam-se funcionais e capazes 
de hidrolizar o anel β-lactâmico do substrato comercial CENTA. Desta forma, 
introduzimos mutações em resíduos previamente descritos como tendo um papel 
fundamental na actividade de ambas as proteínas. 
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Os resultados obtidos mostram que alguns resíduos no A3G, descritos como sendo 
importantes para a interacção com a Gag do HIV-1, estão também envolvidos na 
interacção com a Vif.  
 
Para além da interacção Vif-A3G, o método explorado neste trabalho permitiu testar 
interacções da Vif com outros membros da família APOBEC, nomeadamente A3F, A3C e 
A2. Destes, apenas o A3G e o A3F estão descritos como possuindo actividade 
antiretroviral. Por outro lado a relevância da interacção da Vif com A3C ou A2 
permanece por esclarecer. Através do nosso ensaio, não fomos capazes de detectar 
interacção entre a Vif e o A3C. No entanto, conseguimos recuperar esta interacção ao 
substituir a região DRMR da Vif por alaninas. Tendo em conta os nossos resultados, 
colocámos a hipótese de esta região da Vif estar envolvida na selecção do APOBEC a 
inactivar. Surpreendentemente, a Vif foi capaz de interagir com A2, apesar de esta 
proteína não ter qualquer efeito sobre a replicação do HIV-1. Isto faz-nos colocar a 
hipótese que a interacção da Vif com os vários APOBECs parece ser promíscua. Ou seja, 
a Vif pode possivelmente ligar-se com diferentes afinidades, a muitos dos APOBECs 
conhecidos. Então, é possível que o facto de a Vif interagir com certas proteínas da 
família APOBEC não ter de ser necessariamente devido ao facto de estas exercerem 
actividade antiviral sobre o HIV-1.  Neste caso particular do A2, é possível que, apesar 
de interagir com Vif, esta enzima não tenha qualquer actividade antiviral devido á 
ausência de um co-factor que poderá ser fundamental na actividade desta enzima.  
 
 
Palavras Chave: HIV-1; proteossoma; N-end Rule; Factor de transcrição de levedura 
GCN4; Ensaio de Complementação Proteica.  
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The Structure-function relationship of HIV-1 Vif protein and its 
regulation 
 
SUMMARY 
 
One of the critical determinants of HIV-1 infectivity is the capacity of the virus to infect 
new cells. The viral Vif protein is one of the critical factors involved in the increase 
infectivity of the virus. Vif protein is required for HIV to replicate in some human cell 
types (termed ‘non-permissive’ cells), but not others (‘permissive’ cells). The reason for 
this is the expression, in non-permissive cells, of a potent antiretroviral enzyme: 
APOBEC3G (A3G) and its paralog APOBEC3F (A3F). Each of these enzymes contains two 
RNA-binding motifs and incorporates into assembling HIV-1 capsids where they cause 
lethal dC-to-dU hypermutations in the single-stranded viral DNA that transiently forms 
during reverse transcription. One of the mechanisms that Vif uses to overcome this 
viral block is by reducing A3G/A3F intracellular expression levels recruiting it for 
polyubiquitination and proteasomal degradation in the 26S proteasome.  
 
In order to understand how A3G half-life can influence its antiviral activity, both at the 
level of viral encapsidation and catalytic activity in the cell, we decided to model the 
intracellular half-life of A3G by targeting it to the N-end rule pathway. This system 
allowed us to show that A3G variants with different stabilities are capable to be 
targeted for proteasomal degradation in a Vif-independent manner. Our results 
confirmed the importance of A3G steady-state expression for the maintenance of its 
antiretroviral activity indicating that in order to counteract A3G activity, Vif has to act 
at the very early stages of A3G life-time, probably within the first 13 minutes after its 
synthesis, in order to impede its incorporation into virions. In addition, we show that 
active deamination in the cytoplasm does not seem to be important for antiviral 
activity of A3G and deamination activity does not increase with the half-life of A3G.  
 
Identification of protein biding partners between Vif and A3G proteins is one of the 
major challenges for the development of new antiviral drugs, as disruption of A3G-Vif 
interaction is predicted to stimulate natural antiviral infectivity. 
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In this work, we used two different approaches to study the interaction of Vif with 
A3G. One strategy was based on an oligomerization-assisted interaction whereby 
fragments of Vif and A3G were fused to independently folding and interacting domains 
of homodimerizing GCN4 leucine zipper-forming sequences. This allowed us to show 
that the C-terminal region of Vif alone is not sufficient to induce A3G degradation and 
that binding of Vif to A3G must involve an additional co-factor that is probably linked 
to the N-terminus of Vif and may be essential for the interaction and consequent 
degradation of A3G.  
 
The other strategy involved a Protein Complementation Assay (PCA).  We produced 
several mutants of both Vif and A3G bearing mutations on key residues that are 
thought to be crucial for the interaction between these two proteins. By using this 
strategy we were able to show that some mutations in A3G protein that had been 
described as being involved in the interaction with HIV-1 Gag, were also important for 
the interaction with Vif. As a result, we were able to achieve a quantitative assessment 
of HIV-1 Vif-A3G interactions, which allowed us to do a fine dissection of the regions 
involved in this interaction. 
 
Finally, we found that a region in Vif (DRMR) may be important for the selection of the 
APOBEC protein to inactivate. By studying the interaction of Vif with A2 protein we 
reached the conclusion that an additional co-factor may be required in order to A2 to 
be able to exert antiviral action. Therefore, we provided supporting information for a 
new direction of the study of Vif-A3 problematic regarding the involvement of an 
additional co-factor. 
 
 
Keywords: HIV-1; Vif; APOBEC3G; proteosome; N-end rule; GCN4 leucine zipper; 
Protein Complementation Assay  
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Chapter 1 
 
GENERAL INTRODUCTION 
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1. The Human Immunodeficiency type-1 virus 
 
1.1. HIV-1  
 
The Human Immunodeficiency virus type-1 (HIV-1) belongs to the family Retroviridae, 
generus Lentivirus. Lentiviruses are small, enveloped, positive-strand RNA viruses that 
differentiate from other retroviruses by the presence of a large number of non-
structural proteins. These viruses code for the reverse transcriptase enzyme (RT), 
which enables them to replicate their RNA genome through a DNA intermediate.  
HIV-1 was first discovered in 1983 and was described as the causative agent of the 
Human Acquired Immunodeficiency Syndrome (AIDS) (Barre-Sinoussi et al., 1983). The course of 
HIV-1 infection is characterized by a progressive loss of CD4-positive cells leading to 
immune dysfunction and opportunistic infections (Teeuwsen et al., 1990; Clerici et al., 1991). HIV-1 is 
the prevalent virus and is the responsible for an actual global pandemic.  A small 
percentage of HIV cases are attributed to a less virulent HIV virus, the HIV virus type 2 
(HIV-2). HIV-2 was first identified in 1986 from samples isolated from west african 
patients (Clavel et al., 1986). HIV-2 infections are most prevalent in some countries such as 
Guinea-Bissau and Portugal.  
Substantial progress has been made in the past 25 years since the discovery of HIV-1. 
Studies toward understanding the biological function of each protein, and the three-
dimensional structures of many components, such as portions of the RNA genome, 
have been determined. Despite this significant progress, new challenges continue to 
arise and more efforts have to be done to continue with these studies. 
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1.2. HIV-1 life cycle 
 
HIV-1 begins its life cycle by binding 
to a CD4 receptor and one of two 
co-receptors, CCR4 or CXCR5, on the 
surface of a CD4+ T - lymphocyte. 
The virus enters the cells by fusion 
with the host cell and releases its 
genetic material, two copies of RNA, 
into the cytoplasm of the cell. The 
HIV-1 enzyme called reverse 
transcriptase (RT) will then convert 
the single stranded HIV RNA to 
double-stranded HIV DNA. The 
newly formed HIV DNA will then 
enter the host cell´s nucleus where 
it will be integrated within the host 
cell’s DNA by the action of another 
HIV enzyme called, integrase (IN). 
Once integrated into the host’s 
genome the HIV DNA may remain 
inactive for several years, producing 
a few or no copies of HIV.  The 
integrated HIV DNA is called 
provirus. Activation of HIV provirus requires a host enzyme called RNA polymerase II. 
When the host cell receives a signal to become activated, the provirus will use the cell’s 
RNA polymerase to create copies of its genetic material as well as viral transcripts that 
will be expressed from the promoter located in the 5’ long terminal repeat (LTR), with 
Tat greatly enhancing the rate of transcription. A set of spliced and genomic-length 
RNAs are then transported from the nucleus to the cytoplasm, where they can be 
translated into long chains of HIV proteins, or polyprecursors. This step is regulated by 
Rev. After translation of viral mRNAs, the Gag and Gag-Pol polyprecursors become 
localized to the cell membrane. The core viral particle is then assembled from the 
Fig 1. Schematic representation of HIV-1 life-cycle. 
(From: Allison O’Brien) 
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Gag and Gag-Pol polyprecursors (later processed to MA, CA, NC, p6, PR, RT, and IN), Vif, 
Vpr, Nef, and the genomic RNA, and an immature virion begins to bud from the cell 
surface. The newly assembled virion is released from the host cells through a process 
called budding. During budding, the new virion “steals” part of the cell’s outer 
envelope. This envelope, which acts as a covering, is studded with protein/sugar 
combinations called HIV glycoproteins. These glycoproteins are essential for the virus 
to infect a new target cell as they are necessary to bind CD4 and co-receptors. A new 
cycle of infection is now ready to begin. 
 
1.3. The HIV-1 structure and  genome 
 
The viral genome contains two strands of RNA of positive polarity and the mature virus 
consists of a bar-shaped electron dense core which contains the viral genome along 
with the enzymes RT, IN, PR, and ribonuclease. The viral core is surrounded by a lipid 
envelope containing the antigen gp120 that is involved in the binding of the virus to 
the target cell by interactions between CD4 and CC or CXC chemokine co-receptors 
(Fig. 2).  
 
Fig.2. Structure of HIV-1 virion 
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HIV-1 genome, like other retrovirus, has three major structural genes: Gag, Pol and 
Env. The major components coded by the Gag gene include the core proteins p55, p40, 
p24 (capsid, CA), p17 (matrix, MA), and p7 (nucleocapsid, NC). The Pol gene codes for 
the enzyme proteins p66 and p51 (RT), p11 (PR), and p32 (IN). Finally, the Env gene 
codes for the envelope glycoproteins, which include the outer envelope glycoprotein 
gp120 and transmembrane glycoprotein gp41 derived from the glycoprotein precursor 
gp160. The genome also contains several non-structural genes such as, Tat (trans-
activator), Rev (regulator of expression of virion protein), Nef (negative factor), Vif 
(virion infectivity), Vpr and Vpu (viral proteins R and U, respectively). In addition to the 
structural and non-structural proteins, the viral genome contains a number of cis-
acting sequences, such as the Tat-acting region (TAR), the primer binding site (PBS), the 
dimer initiation site (DIS), the packaging sequence (psi), the polypurine tract (PPT 
located at the 3’ end of the genome and a second cPPT present at the center of the 
genome) and the Rev-responsive element (RRE). These sequences play important roles 
during the viral life-cycle such as transcription (TAR), translation and nuclear export 
(RRE), packaging (psi), dimerization of viral genomic RNA (DIS) and reverse 
transcription (PBS, PPT and cPPT). 
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(Figure from: Journal of Virology 2006 3:60) 
 
Fig.3. Schematic representation of the HIV-1 genome and viral mRNA transcripts.  Polyprotein precursors 
of HIV-1, Gag/Pol, Env/Vif/Vpr/Vpu, and Tat/Rev/Nef. Viral mRNAs are first produced and most are doubly 
spliced to produce the Tat, Rev and Nef proteins. The U3 region of the 5’ LTR is responsible for the 
initiation of viral transcripts and basal transcription activity is modulated by the availability of specific host 
cell factors acting on the LTR. The first viral transcripts to appear in the cytoplasm of the infected cell are 
the so called 2kb mRNAs that will originate the non-structural proteins Tat, Rev and Nef.  
 
1.4. Non-structural proteins 
 
The first viral transcripts originated from the viral LTR are multiply spliced mRNAs that 
will originate the non-structural proteins Tat, Rev, and Nef. Upon translation in the 
cytoplasm, Tat reaches the nucleus where it is responsible for the trans-activation of 
viral RNA transcription and enhancing the processivity of transcribing 
RNA polymerases. Under some conditions, Tat increases the production of viral mRNAs 
up to 100-fold being essential for viral replication.  
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The Rev protein is important for the regulation of viral gene expression. Unspliced viral 
genomic RNA and single spliced mRNAs are exported from the nucleus into the 
cytoplasm where translation of the structural genes and remaining non-structural 
genes will take place. Rev is important in this switch because it overcomes the default 
pathway in which mRNAs are spliced prior to nuclear export and functions by binding 
to the RRE site located in the Env coding region. This will promote the export of viral-
containing mRNAs from the nucleus. There is evidence that entry into the splicing 
pathway may also be important for Rev function because mutating 5’ splice sites on 
RRE-containing mRNAs eliminates Rev activity. Furthermore, Rev can directly inhibit 
splicing by preventing entry of additional snRNPs during the later stages of spliceosome 
assembly (Kjems J, Sharp PA. 1993).  
The HIV Nef, like Tat and Rev, is expressed early in the HIV life-cycle. It’s an N-
terminally myristoylated protein that is involved in reducing the levels of cellular CD4 
by facilitating the routing of CD4 from the cell surface and Golgi apparatus to 
lysossomes. This process results in receptor degradation and prevents inappropriate 
interactions with Env. By down-regulating CD4, Nef facilitates Env incorporation into 
the virions, promotes particle release and possibly affects CD4+ T-cell signalling 
pathways (Mangasarian A, Trono D. 1997). Nef contains a consensus SH3 domain binding sequence 
(PXXP) that mediates binding to several Src-family proteins such as, Src, Lyn, Hck, LcK, 
and Fyn, indicating an involvement in the regulation of tyrosine kinase activities. These 
interactions appear to be important for enhancing viral infectivity but not for 
downregulating CD4 (Greenway A and McPhee D. 1997; Moarefi I. et al., 1997; Benichou S. et al., 1997). 
It was also shown that Nef is involved in the down-regulation of MHC class I molecules 
([103] Le Gall S, Heard JM, Schwartz O. 1997), which may help protect infected cells from killing by 
cytotoxic T cells (Le Gall S. et al., 1997). Nef mutant viruses also exhibit decreased levels of viral 
DNA synthesis following infection (Guatelli JC. 1997). This defect can be overcome if Nef is 
supplied in trans in virus-producing cells but not in target cells, suggesting possible 
roles in virus assembly, maturation, or entry. Such roles are consistent with the 
observation that approximately 70 Nef molecules are incorporated per virion; these 
virion-associated proteins are cleaved by PR at residue 57 to generate a soluble C-
terminal fragment (Guatelli JC. 1997). The mechanism of Nef incorporation has not been 
defined but is probably relatively nonspecific, because Nef can also be incorporated 
into Mo-MLV particles (Bukovsky A. et al., 1997). 
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1.5. Structural proteins 
 
The structural proteins Gag, Pol, and Env are translated in the form of polyprotein 
precursors that, with exception of Env, are processed by the viral-encoded protease.  
Gag is initially expressed into a polyprotein precursor of 55 kDa that upon cleavage by 
viral protease yields the matrix (MA, p17), capsid (CA, p24), nucleocapsid (NC, p7), and 
p6. The Env polyprecursor is cleaved by viral protease and originates the surface 
protein or gp120 (SU), and the transmembrane or gp41 protein (TM). These proteins 
are structural components that make up the core of the virion and outer membrane 
envelope. The three Pol proteins, PR, RT, and IN, provide essential enzymatic functions 
and are also encapsidated within the particle. 
 
 
2. The HIV-1 Viral Infectivity Factor (Vif) protein  
 
2.1.  The viral Vif protein 
 
“Vif” stands for Viral Infectivity Factor and it is a 23-kDa, primarily cytoplasmic protein 
that is expressed from a partially spliced mRNA in a Rev-dependent manner in the late 
phase of HIV-1 replication (Trono D. et al., 1995 1995; Emerman M. et al., 1998). Vif was originally 
discovered in the mid 1980s and was initially called sor (Fisher A. G. et al., 1987; Strebel K. et al., 1987). 
It is found among all the lentiviruses with exception of equine infectious anemia virus. 
Vif was named after the first functional studies demonstrated that virions generated in 
the absence of this protein were 1,000 times less efficient in establishing an infection 
(Fisher, A. G. et al, 1987; Strebel, K. et al., 1987). Cell-to cell transmission was also reported to require 
Vif activity (Fisher, A. G. et al, 1987)  and several studies demonstrated that the requirement for 
Vif was cell type dependent (Fan L., and K. Peden. 1992; Gabuzda D. et al., 1992; Sakai H. et al., 1993; Sova P., and D. J. 
Volsky, 1993; Von Schwedler et al., 1993). HIV-1ΔVif viruses are able to replicate in most CD4
+ cell 
lines (permissive cells) although in other cell such as, macrophages, H9, and peripheral 
blood mononuclear cells (PBMCs) (nonpermissive) these mutants are unable to 
replicate. Many studies showed that when ΔVif and wild-type viruses were produced in 
semipermissive cells, no quantitative difference was observed during the first 
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replication cycle up to virus production, inclusive. However, ΔVif virus progeny was 
strongly restricted for the pre-retrotranscription steps, indicating a severe impairment 
in the construction of the viral particle in the absence of Vif (Sova, P. and D. J. Volsky, 1993; Von 
Schwedler et al., 1993; Marianne C. et al., 1995; Borman, A. M. et al., 1995). Also, Vif defective virions, when 
produced from nonpermissive cells, have an abnormal protein profile (Sakai H. et al., 1993; 
Borman A. M. et al., 1995) and an altered ultrastructural morphology (Borman A. M. et al., 1995; Hoglund S. et 
al., 1994). The cellular specificity of Vif function could theoretically have two possible 
explanations: (I) permissive cells might express a protein that functions similarly to Vif 
to enhance HIV-1 infectivity 50-100 fold (Madani N. et al., 1998; Gabuzda D. et al., 1992; Simon J. H. et al., 1998; 
Sheehy A. M. et al., 2002), such that the viral Vif is unnecessary, or (II) nonpermissive cells might 
contain a potent inhibitor of HIV-1 that is neutralized by Vif (Rose M. K. et al., 2004). 
A major clue to the solution of this enigma came in 1998 by two independent groups, 
Madani and Kabat and Simon et al., which discovered that in somatic cell fusion 
experiments, heterokaryons formed by the fusion of permissive and non-permissive 
cells were found to be non-permissive (Madani N. et al., 1998;  Simon JH et al., 1998). These findings 
suggested the presence of an endogenous cellular factor that would confer a non-
permissive phenotype to the cell that was overcome by the viral Vif protein. The 
cellular specificity of HIV-1 Vif protein is represented in the figure below (Fig. 4 a, b). 
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(Figure from: Kristine M. Rose et al., 2004) 
 
Fig. 4. Schematic representation of the cell-specific replication behaviour of ∆Vif and Wt HIV-1 Virions.  
(a) In the absence of Vif (HIV-1 ΔVif), infectious viral particles produced in permissive cells are able to 
infect permissive and non-permissive cells. Although, progeny virions from infected non-permissive cell 
that appear to have a normal protein and genomic RNA content, are unable to successfully complete 
proviral DNA synthesis in the next cycle of infection, regardless of whether the target cells are permissive 
or non-permissive. (b) In the presence of Vif (HIV wt) infectious viral particles are able to infect permissive 
and non-permissive cells and produce infectious particles that are able to complete the next round of 
infection, regardless of cell type.   
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2.2. Structural motifs important for Vif function 
 
The HIV-1 Vif protein contain two conserved motifs S144LQXLA149 and S23L(I/V)X4YX9Y40, 
which are common among all lentivirus (Oberst and Gonda, 1992), and two basic motifs 
W89RKKR93 and P156KKIKP161 (Huvent I. et al., 1998). In addition, there are two well conserved 
antigenic sequences: I87EWRKKRY94 and D172RWNKPQ178 (Wieland U. et al., 1991). The W
89RKKR93 
motif is homologous to the nuclear localization sequence (NLS) of SV40 T antigen (Huvent 
I. et al., 1998). The Vif molecule also contains two cysteines, at positions 114 and 133, which 
are extremely well conserved among HIV-1, HIV-2, and in several SIV isolates (Ma X. et al., 
1994). Some authors have demonstrated that both residues are required for Vif function 
(Ma X. et al., 1994), whereas others showed that Cys
133 is not essential to HIV-1 infectivity in 
non-permissive cells (Sakai K. et al., 1999).  
Vif is phosphorylated in vivo and in vitro at residues Ser144, Thr155, and Thr188 by 
serine/threonine protein kinases (Yang X. et al., 1996) and at residues Thr
96 and Ser165 by 
p44/42 mitogen-activated protein kinase (MAPK) (Yang X. and Gabuzda D., 1998). Mutations of 
the Ser144 and Thr96 residues result in impairment of Vif activity and inhibition of viral 
replication (Yang X. and Gabuzda D., 1998; Yang X. and Gabuzda D., 1999; Jacqué JM. et al., 1998). However, it remains 
unclear whether these mutations interfere with the primary structure of the protein or 
instead, lead to loss of phosphorylation.  
Studies using Vif mutants showed that Vif does not tolerate more than five or six amino 
acid deletions (with exception to the carboxyl-terminal truncations) without loss of its 
function. Also, Vif substitutions of amino acids distributed throughout the protein lead 
to disruption of its function.  
Finally, the proline-rich C-terminal region of Vif (amino acids 151-164) is essential for 
multimerization (Yang et al., 2001). Deletions in this region of Vif lead to viruses that are 
replicative- defective, indicating an important role of this region for HIV-1 replication 
(Yang et al., 2001). 
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2.3. Cellular localization 
 
Vif is predominantly a cytoplasmic protein, which can exist associated with the cellular 
membrane. However, Vif is not an integral part of the membrane but it’s binding might 
involve membrane-associated proteins (Michaels FH. Et al., 1993; Goncalves J. et al., 1994). Association of 
Vif with the cytoplasmic site of cellular membranes requires basic residues that are 
located at the C-terminal region of the protein (amino acids 171-192) (Goncalves J. et al., 1995). 
Thus, this region appears to be essential for a stable association with the cellular 
membranes and for Vif function during viral replication (Goncalves J. et al., 1995). Vif can also 
exist as a soluble cytosolic protein. A small portion of Vif protein can also be found in 
the nucleus of the cell. Although, the specific role of Vif inside the nucleus remains to 
be elucidated. Vif can also be found associated with microvesicles present into the 
extracellular culture medium (M K Karczewski and K Strebel., 1996).  
 
2.4. Vif incorporation into HIV-1 viral particles 
 
The issue of Vif incorporation into viral particles has always been controversial. Initial 
reports suggested that the amount of Vif protein packaged into virions was estimated 
to be on the order of 1 molecule of Vif for every 20 to 30 molecules of p24, or between 
60 and 100 molecules of Vif per viral particle (Liu, H. et al., 1995). Some authors reported that 
Vif was involved in the late stages of viral assembly and maturation (Gabuzda, D. et al., 1992; 
Hoglund, S. et al., 1994; Sakai, H. et al., 1993; Simm, M. et al., 1995; von Schwedler, U. et al., 1993). In addition, it was also 
demonstrated that Vif colocalizes or interacts with Gag (Bouyac, M. et al., 1997; Huvent, I. et al., 1998; 
Simon, J. et al., 1997). In contrast, some authors referred that virions released from infected 
cells contained a small amount or no Vif (Camaur, D., and D. Trono., 1996; Dettenhofer, M., and X. F. Yu., 1999; 
Simon, J. et al., 1998). 
This apparent contradiction may have been resolved by Kao et al. who reported that 
Vif was efficiently packaged into virions from acutely infected cells (60 to 100 copies 
per virion), while packaging into virions from chronically infected H9 cells was near the 
limit of detection (4 to 6 copies per virion) (Kao et al., 2003). In addition, Kao et al. 
demonstrated that de novo synthesis of cytoplasmic Vif was rapidly translocated to a 
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detergent-resistant cellular compartment, where it was accumulated in a packaging-
resistant form (Kao et al., 2003).  
Sucrose density gradients have showed that Vif cosediments with capsid proteins even 
after detergent treatment of virus preparations, suggesting that Vif associates with the 
inner core of HIV particles (M K Karczewski and K Strebel., 1996; Liu, H. et al., 1995). These results indicate 
that Vif represents an integral component of HIV and SIV particles and raise the 
possibility that it plays a direct role in early replication events. Further, Khan et al. 
demonstrated that packaging of Vif was dependent on the packaging of viral genomic 
RNA in both permissive and restrictive HIV-1 target cells (Khan A. et al., 2001). In addition, 
mutations in the nucleocapsid zinc finger domains abrogated packaging of viral 
genomic RNA and abolished packaging of Vif (Khan A. et al., 2001). Thus, Vif incorporation into 
virions seems to be dependent on the zinc-finger domain of NC protein, which is 
responsible for viral RNA packaging and it is also dependent on the RNA packaging 
signal of the viral genomic RNA.  
In contrast, Sova et al. demonstrated that deletion of the nucleocapsid (NC) domain 
does not affect Vif incorporation, and that Vif are also incorporated into the virus-like 
particles (VLPs) (Sova P. et al., 2001). 
Despite controversy surrounding the Vif incorporation issue, it is now widely accepted 
that Vif is specifically packaged into viral particles through interactions with the viral 
genomic RNA, co-packaged cellular RNAs and the nucleocapsid (NC) domain of Gag 
(Svarovskaia ES. Et al., 2004; Khan A. et al., 2001; Dettenhofer M. et al., 2000; Zhang H. et al., 2000; Bouyac M. et al., 1997; Simon JH. Et 
al., 1999; Henriet S. et al., 2005). Vif defective viruses produced from non-permissive cells display 
defects not only on viral assembly events but also during post-entry steps of infection, 
resulting in a failure to complete reverse transcription and integration (Chowdhury IH. Et al., 
1996; Courcoul M. et al., 1995; Gonçalves J. et al., 1996; Simon JH. And Malim M., 1996; Von Schwedler et al., 1993; Carr JM et al., 2006). 
Moreover, viral particles produced in the absence of Vif show structural defects such as 
aberrant core morphology and reduced stability (Simon JH, Malim MH. Et al., 1996; Ohagen A, and Gabuzda 
D., 2000; Hoglund, S., et al., 1994). 
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2.5. Interaction of Vif with Gag precursor 
 
Vif interacts with the cytoplasmic side of plasma membrane, an association mediated 
by intrinsic membrane components and the C-terminal domain of Vif (Goncalves et al., 1994, 
1995; Simon et al., 1997). Vif was shown to directly interact with the HIV-1 pr55Gag precursor 
using in vitro GST systems, in vitro translated proteins, and in vivo in the context of 
infected cells, as well as in transfected cells co-expressing Gag and Vif (Bouyac M. et al., 1997). 
In contrast, co-immunoprecipitation assays from HIV-1 infected cells did not find a 
direct association between Vif and Gag, suggesting that Vif and Gag may associate 
through a protein mediator (Henzler T. et al., 2001). Indeed, Zimmerman et al. demonstrated 
that the host cell protein, HP68, specifically interacts with Gag and Gag-Pol precursors 
after translation in HIV-1 infected cells promoting their assembly into immature capsids 
(Zimmerman C. et al., 2002). In addition, HP68-Gag and HP68-Gag-Pol complexes were also found 
to contain Vif molecules indicating its pivotal role during virus assembly (Zimmerman C. et al., 
2002).  
The affinity of Vif for RNA was shown to decrease in the presence of Gag precursors, 
suggesting a displacement and exchange of RNA-bound proteins during genome 
packaging (Zhang et al., 2000). Strebel and co-workers showed that virus-associated Vif had 
the ability to interact with Gag precursor molecules and to modulate Gag maturation 
(Akari H. et al., 2004).  
Despite some controversy, it is now usually accepted that Vif and pr55Gag co-localize 
in the cytoplasm (Simon JH. et al., 1999) and mutations in the NC domain of pr55Gag 
significantly reduce Vif packaging. In addition, Vif also associates with the HIV-1 
genomic RNA in vitro and in vivo (Dettenhofer, M. et al., 2000; Khan, M. et al., 2001). Vif binds the viral 
RNA in the cytoplasm of infected cells, forming a 40S mRNP complex that most likely 
mediates viral RNA interactions with HIV-1 pr55Gag (Zhang H. et al., 2000). Finally, RNA binding 
properties of Vif and its association with the nucleoprotein complex during virus 
assembly seems to be crucial for efficient virions assembly and subsequent 
optimization of viral particles morphology (Hoglund H. et al., 1994). 
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2.6. Interaction of Vif with viral Envelope Glycoproteins 
 
Initial studies proposed that Vif could target envelope glycoproteins, mediating the 
processing of the C-terminus of gp41 protein (Guy B. et al., 1991) or the incorporation of 
gp120 glycoprotein (Sakai H. et al., 1993; Borman AM. et al., 1995). 
Despite these initial studies, it was demonstrated that Vif does not influence virus 
binding/entry and virion incorporation of Env. It is generally accepted that Vif enhances 
HIV-1 infectivity at the post-entry step(s) independently of the Env function (Akari H. et al., 
1999; Camaur, D., and D. Trono, 1996).  
 
2.7. Interaction of Vif with viral Protease (PR) 
Protease-dependent proteolytic processing of Vif was demonstrated both in vitro and 
in vivo (Khan M. et al., 2002). In vivo processing of Vif is cell type independent and is restricted 
to cell-free virus preparations (Khan M. et al., 2002). Vif is incorporated into the virion where it 
will be proteolytic processed by the viral PR originating a 17-KDa and a 7-KDa 
processing sub-products (Khan M. et al., 2002; Baraz L. et al., 2002). The processing site in Vif is 
mapped to Ala150, which is located in a highly conserved domain among HIV-1, HIV-1, 
and SIV Vif isolates (Khan M. et al., 2002). Mutations in Vif that have an effect on proteolytic 
processing also impair Vif function (Khan M. et al., 2002). This seems to indicate a pivotal rule 
of the intravirion processing of Vif protein for the production of infectious viruses (Khan 
M. et al., 2002). Vif inhibits the autoprocessing of truncated HIV-1 Gag-Pol polyproteins 
expressed in bacterial cells (Kotler M. et al., 1997), and interacts with the N-terminal domain of 
HIV-1 PR through its central region. This was demonstrated by Baraz L. et al., which 
showed that peptides derived from two regions of N-Vif encompassing residues 
Tyr30Val65 and Asp78Val98, inhibited PR activity both in vitro and in vivo (Baraz L  et al., 1998). 
Later, in 2004, Kotler and co-workers showed that peptides derived from the N-
terminal region of PR abrogate Vif function in non-permissive cells (Hutoran M. et al., 2004). 
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2.8. The role of Vif in Reverse Transcription 
 
Reverse transcription in HIV infected cells occurs in a nucleoprotein complex termed 
the reverse transcription complex (RTC). RTCs containing RT and integrase activity are 
heterogeneous in size and density on sucrose velocity and equilibrium gradients (Carr JM. 
et al, 2006). RTCs from ΔVif virus produced in non-permissive cells display a reduction in 
the major RTC form and more of the reverse transcription products in rapidly 
sedimenting structures (Carr JM. et al, 2006). ΔVif virions can assemble in permissive cells and 
infect non-permissive cells and initiate the process of reverse transcription, but this 
process fails to complete (Frankel, A. D. and Young, J. A., 1998). This Vif-dependent infectivity is 
manifested only in primary lymphocytes and macrophages and in a limited number of 
T-cell lines (Gabuzda, D. H. et al., 1994; Inubushi, R. and Adachi, A., 1999). 
Analysis of HIV-1 ΔVif reverse transcription process in non-permissive cells showed a 
specific block in the synthesis of minus- and plus-strand viral DNA products, being 
uncapable to produce full-length viral DNA genomes (Trono D., 1992; Goncalves J. et al., 1996; Nascimbeni 
M. et al., 1998). The Vif protein was found to modulate the RNA- and DNA-dependent DNA 
synthesis activity of the viral reverse transcriptase in two ways: (i) by stimulating the 
binding of the tRNAlys primer on the viral template, affecting the initiation of reverse 
transcription, (ii) by increasing the polymerization rate of HIV-1 RT (Reynel C. et al., 2004). Vif 
has been shown to bind HIV-1 RNA (Dettenhofer, M. et al., 2000) and to form multimers in vivo 
through a self-association domain located at its C-terminus (Yang, S. et al., 2001). This domain 
was also found to be essential for the Vif-dependent stimulation of HIV-1 infectivity. 
Reynel et al. showed that a Vif mutant lacking the C-terminal 56 amino acids failed to 
stimulate reverse transcription. Conversely, another Vif mutant lacking the N-terminal 
43 amino acids, which are involved in RNA binding and interaction with the viral 
protease, was able to stimulate RT activity. In addition, Vif was found to promote the 
bypass of an abasic site by HIV-1 RT (Reynel C. et al., 2004). Despite all these findings, it 
remains unclear whether Vif plays a direct role in reverse transcription. Recently, 
Henriet et al. have showed that Vif does play a role during the early phase of reverse 
transcription. This activity is performed in coordination with other components of the 
viral core such as Gag and its maturation products and during the dimerization of viral 
genomic RNA (Henriet S. et al., 2007). In addition, Henriet et al. raised the possibility that Vif 
might be a temporal regulator during viral assembly, suggesting a model in which Vif 
interacts with genomic RNA and NC-derived products preventing RNA 
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dimerization/packaging and premature initiation of reverse transcription. Vif, together 
with Gag precursors, may also promote the placement of tRNALys3 on to the PBS, 
stabilizing NC intermediates to increase the efficiency of the early steps of reverse 
transcription (Henriet S. et al., 2007). 
 
3. Vif and APOBEC3G (A3G) 
 
3.1.  The discovery of A3G as an anti-retroviral factor 
 
Since identification of HIV-1 in the early 1980`s (Barre-Sinoussi, F. et al., 1983), scientists have only 
been able to grow the virus in a sub-set of immortalized human T-cell lines, termed 
“permissive”.  The reason why some cell-lines were permissive for HIV-1 replication 
whereas others did not support a productive viral growth (nonpermissive) remained 
unclear for many years until the function of the HIV-1 Vif protein was unveiled. HIV-1 
Vif protein has a major role in HIV-1 replication in all of its in vivo cellular targets 
(nonpermissive cells), and Vif defective viruses (HIV-1∆Vif) are unable to replicate in 
some cell lines but grow unhindered in others. These findings were made over 15 years 
ago but the molecular mechanism underlying this cell-specific difference was 
maintained a mystery until 1998, when heterokaryon experiments suggested that Vif 
acted to overcome an inhibitory host cell factor (Madani N. et al., 1998; Simon JH et al., 1998). Later, in 
2002, Malim and co-workers (Sheehy A.M. et al., 2002) reported the identification of the 
apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) as 
the HIV-1 replication inhibitor. APOBEC3G (A3G), initially named CEM15, is a member 
of the cytidine deaminase family of nucleic acid-editing enzymes, with an unknown 
physiological role in normal cells. A3G protein is present mainly in lymphocytes and 
monocytes (Jarmuz A. et al., 2002). However, A3G mRNA can also be found in the thymus, 
suggesting that it may be induced late in the maturation of T cells (Mariani R. et al., 2003).  
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3.1.1. APOBEC3G family and evolution 
 
A3G belongs to a family of polynucleotide cytidine deaminases (CDAs), whose 
members include APOBEC1 (A1), APOBEC2 (A2), APOBEC4 (A4), which edit 
apolipoprotein B mRNA and generate a premature stop codon; activation induced 
deaminase (AID), which is expressed in B cells and is needed for somatic 
hypermutation and class switch recombination during antibody gene diversification, 
and seven other related genes (Conticello et al., 2005; Harris and Liddament, 2004; Jarmuz et al., 2002; Rogozin et al., 
2005). A3G and other APOBEC3 (A3) family members are encoded by genes clustered in 
chromosome 22, which have evolved from a single gene in mice to eight genes (A3A-H) 
in primates during mammalian evolution (Jarmuz A. et al., 2002; Conticello SG. et al. et al., 2005(a)). 
Surprisingly, expansion of the APOBEC3 gene cluster (Jarmuz A. et al., 2002; Conticello SG et al., 2005 (b)) 
contrasts with the decline in retro-transposon activity in primates (Maksakova IA et al., 2006) 
raising the possibility that these genes may have evolved to prevent genomic instability 
caused by endogenous retro-elements (Sawyer SL et al., 2004). 
Endogenous retro-elements in mammals are mobile through retro-transposition, an 
intracellular process that involves reverse transcription. They include autonomous long 
interspersed nucleotide elements (LINEs), non-autonomous short interspersed 
nucleotide elements, and elements with long terminal repeats, such as endogenous 
retrovirus. It is likely that they have played an important role in genome evolution as 
they occur in high copy number in ancestral genomes (Kazazian HHJ, 2004). However, it is still 
a mystery whether A3G and other APOBEC3 proteins can target or edit other cellular 
sequences that are unrelated to viral elements and how these activities are regulated 
in the cell. In this regard, it is of great importance to identify potential cellular factors 
that may be involved in A3G regulation or contribute to its cellular and antiviral 
functions.   
CDAs catalyze the deamination of cytosine to uracil in the DNA and/or RNA strands, 
affecting multiple physiological functions. All members of the APOBEC protein family 
contain one or two copies of a His/Cys-X-Glu-X 23-28-Pro-Cys-X2-4-Cys coordination motif 
that is characteristic of CDAs. These proteins also contain a key glutamate required for 
proton shuttling during catalysis and two key aromatic residues involved in RNA 
substrate binding (Bennett et al., 2006; Huthoff and Malim, 2005; Lehmann et al., 2007; Smith et al., 2004; Teng et al., 1993; 
Wedekind et al., 2003, 2006). A1 was the first CDA to be identified and is involved in lipid 
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metabolism (Teng et al., 1993). A1 is expressed in human gastrointestinal tissues and 
specifically edits C6666 in apolipoprotein B (APOB) mRNA to generate a truncated 
functional form of APOB (Lee et al., 2004; Teng et al., 1993). AID is expressed in B cells and is 
essential for both somatic hypermutation and class switch recombination during 
antibody gene diversification through C-to-U editing of DNA at the immunoglobulin loci 
(Di Noia and Neuberger, 2007; Di Noia et al., 2007; Eto et al., 2003; Harris et al., 2002; Lee et al., 2004; Rada et al., 2004). These 
processes are an integral part of the DNA-level modifications that drive maturation of 
the vertebrate antibody response to pathogens. A2 is expressed most prominently in 
cardiac and skeletal muscle and is regulated by NF-k -B in human hepatocytes (Liao et al., 
1999; Matsumoto et al., 2006; Prochnow et al., 2007). A4, which is a new member of APOBEC family, is 
expressed primarily in the testis (Rogozin et al., 2005). However, physiological functions of A2 
and A4 are still unknown. A3s are capable not only of retroviral defenses but are also 
active against mobile genetic elements (Bogerd et al., 2006a,b; Esnault et al., 2006; Kinomoto et al., 2007; 
Muckenfuss et al., 2006; Niewiadomska et al., 2007; Stenglein and Harris, 2006). A3G, A3F and A3C are expressed in 
many tissues, including spleen, peripheral blood lymphocytes, ovary and testis (Hill et al., 
2006; Peng et al., 2006; Pido-Lopez et al., 2007; Sheehy et al., 2002; Stopak et al., 2007; Ying et al., 2007). However, little or 
no A3B mRNA is detectable in these tissues and it is more prevalent in various cancer 
cells. A3A is highly expressed in immature monocytes (Peng et al., 2007). 
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(Figure from: Ya-Lin Chiu and Warner Greene, Annu. Rev. Immunol. 2008) 
Fig. 5. Domain organization of A3 proteins and their relative locations on the human chromosome 22. A3 
proteins have evolved from one gene in mice to eight genes (A3A-H) in primates. A3B, A3D, A3E, A3F, and 
A3G exhibit additional duplications of the cytidine deaminase domain (CDA), the intervening linker and 
pseudoactive domains. CDA motifs harbour one histidine and two cysteine residues, and the glutamic acid 
residue that are involved in the hydrolytic deamination of cytosine. A3G, followed by A3F, displays the 
most potent effects against HIV. Other A3 family members can inhibit weakly the wild-type HIV (A3B and 
A3D/E). The presence of two cytidine deaminase domains seems to be important for the antiretroviral 
activity of APOBEC enzymes, as none of the deaminase members bearing only one catalytic domain have 
shown inhibitory effects on HIV-1.  
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3.1.2. APOBEC3G cellular localization 
A3G is located in the cytoplasm of the cell and has been shown to be an exclusive DNA 
mutator (Suspene R, et al., 2004). A3G exists has either an enzimatically active low-molecular-
mass (LMM) form consistent in size with monomers or dimmers of the enzyme, or as 
an enzimatically inactive high-molecular-mass (HMM) ribonucleoprotein complex 
larger than 2 MDa (Chiu YL. Et al., 2005). LMM A3G is encountered in resting CD4 T cells and 
monocytes where it acts as a powerful antiviral restriction factor for HIV-1 (Chiu YL. Et al., 
2005). Conversely, resting CD4
+ T cells in lymphoid tissues and macrophages are 
permissive to HIV-1 infection as A3G is expressed predominantly in HMM complexes 
due to the lymphoid microenvironment (Kreisberg JF et al., 2006). In lymphoid tissues, cytokines 
such as IL-2 and IL-5 are responsible for the stimulation of HMM complexes, which in 
turn will confer the permissive phenotype for HIV-1 infection (Kreisberg JF et al., 2006). These 
findings may explain the reason why A3G does not attack reverse transcripts from 
incoming viruses in activated CD4+ T cells and macrophages.  
A3G has been shown to localize throughout the cytoplasm and to concentrate within 
punctuate cytoplasmic bodies (Wichroski,M.J. et al., 2005), which were found to be mRNA 
processing (P) bodies (Wichroski M.J. et al., 2006). P-bodies are specialized compartments found 
in the cytoplasm of yeast and mammalian cells where nontranslating mRNAs 
accumulate and are subject to degradation or storage (Cougot N. et al., 2004; Sheth U. et al., 2003; 
Teixeira D. et al., 2005). In addition to P-bodies, biochemical studies carried out by Wichroski et 
al.  (Wichroski M.J. et al., 2006) showed evidence that APOBEC3G localizes to a ribonucleoprotein 
(RNP) complex with other P-body proteins which are involved in cap-dependent 
translation (Andrei MA. Et al., 2005), translation suppression (Minshal N. et al., 2001; Coller J. and Parker R., 2005), 
RNA interference-mediated post-transcription gene silencing (Lian A. S. et al., 2005; Liu J. et al., 2005 
(a); Liu J et al., 2005 (b); Meister G. et al., 2005; Pillai R. S. et al., 2005; Rehwinkel J. et al., 2005; Sen G. L. et al., 2005) and mRNA 
decapping (Cougot N et al., 2004; Sheth U. et al., 2003;  Coller J. Parker R, 2004).   
A3G recruitment to HMM RNP complexes leads to inhibition of its enzymatic activity. 
However, in vitro treatment with RNase (Chelico, L. et al., 2006; Chiu, Y. L. et al., 2005) has been shown 
to lead to complex disassembly suggesting that the recruitment of A3G to large RNP 
complexes may be a mechanism of enzymatic activity regulation.  
In order to identify potential cellular regulatory mechanisms for controlling A3G 
function, Malim and co-workers have used tandem-affinity purification (TAP) to 
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identify proteins that interact with A3G, and confocal microscopy to examine sub-
cellular localization and relative proximities of these proteins in intact cells (Gallois-Montbrun 
S. et al., 2006).  Interestingly, a number of RNA binding proteins were found to interact with 
A3G suggesting an indirect interaction through common RNA molecules (e.g. PABPC1, 
HuR, YB-1, and the hmRNP proteins) as treatment with RNase resulted in the loss of 
many of these interactions (Gallois-Montbrun S. et al., 2006).  Some of these proteins are involved 
in mRNA biogenesis and metabolism, whereas other proteins such as Ro60 and La are 
known to interact with some RNA Polymerase III transcripts (Wolin, S.L., and Cedervall T., 2002; Wolin, 
S. L., and Steitz J. A., 1983). RNA binding proteins such as, PABPC1, RNA helicase A and hmRNP U 
that were identified to interact with A3G have previously been implicated in various 
steps in the HIV-1 life cycle (Afonina, E. et al., 1997; Hartman, T. R. et al., 2006; Valente, S. T. and Goff S. P., 2006), 
although it still remains to be addressed whether these proteins can influence the 
antiviral activities of A3G.  
Localization studies (Gallois-Montbrun S. et al., 2006) revealed that A3G is not only dispersed 
throughout the cytosol but is also concentrated in cytoplasmic P-bodies interacting 
with other constituent proteins, which is in agreement with the work developed by 
Wichroski et al. (Wichroski M.J. et al., 2005; Wichroski M. J. et al., 2006). Although, in contrast to the work 
developed by Wichroski et al., not all the interactions with A3G were RNase sensitive 
reflecting the importance of direct protein-protein contact in complex formation (Gallois-
Montbrun S., et al., 2006). Malim and co-workers also reported that heat-shock induces 
redistribution of A3G and certain P-body proteins towards other RNP-rich cytoplasmic 
microdomains termed stress granules (SGs) (Gallois-Montbrun S., et al., 2006).  
 
3.2. HIV-1 restriction by A3G and A3F proteins 
 
The antiviral activity of A3G is suppressed in the presence of HIV-1 Vif protein, which 
prevents its packaging into assembly virus particles through protein degradation in the 
proteasome (Marin M. et al., 2003; Sheehy AM. Et al., 2003; Stopak et al., 2003). In the absence of Vif (HIV-
1∆Vif), A3G is recruited into budding virions through its interaction with the 
nucleocapsid (NC) component of the Gag Polyprotein and/or HIV genomic RNA (Cullen BR, 
2006; Mangeat B and Trono D., 2005; Chiu Y. L. and Greene W. C., 2006).  
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In non-permissive cells, A3G is incorporated into the progeny ∆Vif viruses and will block 
infection in the next target cell by deamination dependent and deamination 
independent mechanisms (Fig. 6). HIV-1 WT viruses encoding an active Vif protein 
successfully replicate in non-permissive cells in the presence of A3G because Vif 
mediates proteasome degradation of A3G and it is able to replicate in both permissive 
and non-permissive cells. However, Vif may also inhibit A3G activity through 
mechanisms independent of proteasomal degradation (Kao S. et al., 2003; Kao S. et al., 2004; Mehle A. et 
al., 2004b; Santa-Marta M. et al., 2005; Stopack K. et al., 2003), as it will be discussed later in this section. 
More recently, two other members of the APOBEC family, APOBEC3F (A3F) and to a 
lesser degree, APOBEC3B (A3B), were reported to have similar antiviral activities (Bishop et 
al., 2004; Liddament et al., 2004; Zheng et al., 2004).  
 
 
  (Figure from: Ya-Lin Chiu and Warner Greene, Annu. Rev. Immunol. 2008) 
Fig. 6. Schematic representation of the multifaceted antiviral actions of virion incorporated A3G. In the 
absence of Vif, A3G present in the cytoplasm of HIV-1 producer cells is incorporated into budding virions. 
A3G incorporated into viral particles will then be carried to the next target cell where it will be released 
and act as a potent of HIV-1 replication. Two independent mechanisms of HIV-1 inhibition are represented 
here: the deamination-independent mechanism (1), and the deamination-dependent mechanism of HIV-1 
restriction (2).  
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3.2.1. A3G incorporation into HIV-1 Virus particles 
 
During the HIV-1∆Vif deficient replication, A3G associates with the nucleocapsid (NC) 
component of the Gag Polyprotein and/or HIV genomic RNA during viral assembly and 
is packaged into progeny virions RNA (Cullen BR, 2006; Mangeat B and Trono D., 2005; Chiu Y. L. and Greene W. C., 
2006).  Nevertheless, some authors have reported that viral genomic RNA is not 
necessary for A3G incorporation into virions and that binding of A3G to RNA is 
nonspecific (Cen S. et al., 2004; Navarro F. et al., 2005). The interaction between A3G and the NC 
domain of HIV Gag is essential for this process and was demonstrated by in vitro GST 
pull-down experiments (Alce T. M. et al., 2004; Douaisi M. et al., 2004), coimmunoprecipitation assays 
(Cen S. et al., 2004; Luo K. et al., 2004; Luo K et al., 2004; Zennou V et al., 2004), and in vitro translated binding 
assay (Schafer A, et al., 2004). A3G interacts with the first 11 amino acids of the N-terminal 
domain of NC on the membrane of the producer cell and incorporates into budding 
virions (Cen S. et al., 2004; Luo K. et al., 2004; Luo K et al., 2004; Zennou V et al., 2004). 
 
3.2.1.1. Intravirion A3G complexes 
 
In activated, virus producing T cells, A3G resides in HMM RNP complexes of 5 to 15 
MDa. A different situation occurs in resting CD4 T cells and monocytes, where it acts as 
a powerful antiviral restriction factor for HIV-1 (Chiu Y.L. et al., 2005). 
It is widely agreed that to be able to exert its antiviral activity, A3G needs to be 
incorporated into the budding viral particles. However, the molecular form of A3G that 
is actually incorporated into virions remained unclear for some time. Recently, the 
work developed by Soros et al. demonstrated that newly-synthesized A3G (LMM) is 
incorporated into the viral particles, and not the pre-existing HMM A3G (Soros V. B. et al., 
2007). Pulse-chase radiolabeling and biochemical fractionation studies showed that A3G 
is initially LMM and is recruited within 30 min into stable cellular HMM RNA-protein 
complexes. In less than 90 minutes, newly synthesized A3G is preferentially 
incorporated into virions, whereas “mature” A3G, already assembled into HMM 
complexes, is apparently less available for virion incorporation (Soros V. B. et al., 2007). In 
addition, Fast Protein Liquid Chromatography (FPLC) analysis of virion lysates 
containing A3G revealed the presence of large RNA-protein complexes, distinct from 
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the cellular HMM complexes, which contained A3G (Soros V. B. et al., 2007). This finding was 
surprising since it was thought that A3G present into viral particles would remain in an 
enzymatically active LMM form as it deaminates the viral minus-strand DNA in the 
target cell. Instead, A3G incorporated into virions assembles into large RNA-protein 
complexes distinct from the cellular HMM complexes. In this large intravirion A3G 
complex (IVAC) the enzymatic activity of A3G is negatively regulated by RNA binding, 
indicating that A3G is incorporated into virions as a large enzymatic-latent RNP 
complex (Soros V. B. et al., 2007). The enzymatic activity of A3G was shown to be restored by 
addition of RNase H, indicating that HIV-1 RNase H may play a central role in triggering 
the activity of virion associated A3G (Soros V. B. et al., 2007). Finally, as a consequence of this 
work, two mechanisms of A3G activity were proposed: (I) enzymatically inactive A3G 
bound to HIV RNA may impair the generation of minus-strand DNA by blocking 
movement of RT on its viral RNA template; and (II) minus-strand DNA is eventually 
generated setting the stage for enzyme-dependent antiviral action of A3G.  RNase H 
degrades viral RNA allowing the A3G to deaminate the minus-strand DNA (Soros V. B. et al., 
2007) 
Several mechanisms of action were also proposed for Vif protein, which include: (I) Vif 
targeting of newly LMM A3G (unbound to RNA); (II) Vif targeting ribosome-associated 
A3G, and degrading newly LMM A3G; or (III) Vif targeting the RNA-associated A3G (Soros 
V. B. et al., 2007). Indeed, such scenario is consistent with the observation that Vif partially 
inhibits the synthesis of A3G (Stopak K. et al., 2003; Kao S. et al., 2003).  
 
3.2.1.2. Deamination-dependent mechanism of HIV-1 restriction 
 
Once packaged, A3G acts as a potent inhibitor of HIV-1 infectivity by a mechanism that 
results in genome degradation, incomplete cDNA synthesis, and a detrimentally high 
mutation rate within the HIV-1 genome, which has been largely attributed to 
deamination of the viral cDNA [Fig. 5 (2)] (Mariani R. et al., 2003; Goff SP 2003; Gu Y. and Sundquist WI. 2003; 
Harris R. S. et al., 2002; Klarman G. J. et al., 2003; Mangeat B. et al., 2003). Viral A3G targets ssDNA for 
degradation by deamination of deoxycytidines (dC) converting them into deoxyuridines 
(dU) primarily at dCdC sites (Cullen BR. 2006; Mangeat B. and Trono D. 2005; Chiu YL. and Greene WC. 2006). The 
presence of dU residues may initiate non-template DNA repair by uracil DNA 
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glycosylase (Yu B. Q. et al., 2005) in order to eliminate the unwanted uracil residues. 
Glycosylase action will then produce abasic sites, which are targeted by host cell 
endonucleases for strand cleavage leading ultimately to degradation of minus ssDNA 
abrogating the HIV life cycle. However, this process is apparently imperfect as some 
deaminated minus-strand ssDNA can escape degradation and serve as a template for 
plus-strand synthesis. Due to the presence of deoxyuridines instead of deoxycytidines, 
massive dG→dA hypermutations are introduced into the plus strand viral DNA, 
compromising HIV production. 
 
3.2.1.3. Deamination-independent mechanism of HIV-1 restriction 
 
Recently, two independent studies have indicated that A3G antiviral function can be 
dissociated from its enzymatic activity, suggesting a distinct mechanism for HIV-1 
restriction (Chiu Y. L. et al., 2005; Newman E. N. et al., 2005). The study carried by Newman and 
colleagues showed that certain amino acid substitutions in the C-terminal cytidine 
deaminase “core” domain of A3G (A3G has two such domains) originate mutant 
proteins that are unable to mutate DNA, yet maintained the antiviral activity (Newman E. N. 
et al., 2005). On the other hand, when unstimulated CD4 T cells (where A3G is expressed as 
an active LMM form), are treated with A3G-specific small interfering RNAs (siRNA) the 
early replication block encountered by HIV-1 was greatly relieved (Chiu Y. et al., 2005). When 
HIV-1 reverse transcripts formed in resting primary CD4+ T cells from blood were 
examined for evidence of A3G-induced dG→dA hypermutations only 8% of the 
transcripts contained such mutations suggesting an antiretroviral activity independent 
of deoxycytidines deaminase activity (Chiu Y. L. et al., 2005). Studies carried out by Iwatani and 
colleagues indicated that initiation of HIV reverse transcription and/or processivity of 
reverse transcriptase (RT) could be inhibited by A3G (Iwatani et al., 2007). Furthermore, other 
groups showed that the CDA-deficient A3 proteins reduce the accumulation of viral 
reverse transcription products in target cells, and this effect is most obvious for A3F 
proteins (Bishop et al., 2006; Holmes et al., 2007). However, CDA independent effects cannot be 
observed when the mutant proteins are expressed at physiological levels (Miyagi, E. et al., 
2007), making these non-enzymatic A3 effects on RT controversial.  
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Recently, Judith Levi and co-workers demonstrated that A3G inhibits all RT-catalyzed 
DNA elongation reactions, with no effect on RNase H activity or NC’s ability to promote 
tRNA annealing (Iwatani et al., 2007). They reported that A3G inhibits (−) ssDNA and (+) ssDNA 
synthesis, minus and plus-strand cDNA transfer, and the elongation of minus and plus 
strand DNAs (Fig. 7). Also, Guo et al. showed that the reduction of early reverse 
transcripts in A3G-expressing cells infected with HIV-1 Vif is correlated with decreased 
tRNA priming in vitro (Guo et al., 2006). These studies indicate that the presence of A3G 
results in the formation of aberrant viral 3’-long terminal repeat (LTR) DNA ends, and 
suggest that A3G interferes with cleavage and removal of the tRNA primer.  
Sequence analyses of 2-LTR circle junctions from unintegrated DNA synthesized in the 
presence of A3G showed that DNA at the U5 end sometimes had an additional six RNA 
bases derived from the 3’-terminus of tRNALys3 (Mbisa et al., 2007). This result suggested 
that A3G causes a defect during tRNA removal that limits plus-strand transfer, resulting 
in viral DNA ends that are will not be able to efficiently integrate in the host cell DNA 
(Mbisa et al., 2007). All this process of successive inhibition of reverse transcription has a 
cumulative effect and could explain the reduction of integrated viral DNA. However, 
the decrease in plus-strand DNA transfer does not account for all observed decreases 
in viral cDNA synthesis by A3G (Aguiar R. S. and Peterlin B. M., 2008). In parallel, A3G could be co-
immunoprecipitated with NC and integrase (IN) in HIV-1 Vif-positive viruses (Luo et al., 2007). 
Indeed, A3F co-immunoprecipitation with virion-associated integrase (IN) was 
observed. GST-pull down assays do not show binding between A3G and RT, suggesting 
that interactions between A3G and viral proteins may inhibit the process of reverse 
transcription (Iwatani et al., 2007).  
In summary, these studies strongly support additional mechanisms that could account 
for the observed CDA-independent A3G-mediated antiviral activity. Despite these 
studies, recent work using cell lines that express stably comparable amounts of both 
proteins suggests that the antiviral activity of CDA defective A3G is significantly lower 
than its wild-type counterpart (Miyagi et al., 2007). Therefore, Miyagi et al. concluded that 
despite some A3G deaminase-independent effect on HIV-1 reverse transcription, 
efficient inhibition of Vif-defective HIV-1 requires catalytically active A3G (Miyagi et al., 2007). 
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Fig.7. Schematic representation of HIV-1 restriction 
mechanism independent of A3G deamination. Negative 
strand DNA synthesis begins with tRNALys3 priming in primer-
binding site (PBS). After the strong stop, the DNA is 
transferred to the 3-LTR and RNaseH degrades the viral RNA. 
RT copies the entire viral genome to the PBS. Some positive 
strand DNA synthesis occurs from the PPT. After additional 
RNase H digestion, the transcribed DNA anneals with the 
positive strand DNA, which completes the synthesis of double 
strand DNA. Pink dashes in the minus strand DNA denote 
areas of hypermutation (G-to-A) induced by the CDA activity 
of A3 proteins. However, A3G can interfere at different steps 
of reverse transcription reactions in a CDA independent 
manner. Thus, A3G inhibits (−) ssDNA and (+) ssDNA synthesis 
(represented as numbers (1) and (2)), minus- and the plus 
strand cDNA transfer (numbers (1) and (3)), as well as the 
elongation of minus and plus-strand DNAs. Also, A3G 
interferes with cleavage and removal of the tRNA primer (step 
(3)). These findings suggested that A3G causes a defect during tRNA removal that limits plus-strand 
transfer, resulting in viral DNA ends that are inefficient substrates for integration. (Aguiar R. S. and Peterlin 
B. M.. 2008). 
 
3.3.  How does Vif counteract A3G activity? 
 
A3G needs to be incorporated into the HIV-1 budding virions in order to have access to 
the target cell and exert its antiviral action. A3G protein has an antiviral activity by 
introducing deleterious mutations in the viral minus strand DNA during reverse 
transcription and /or by impairing accumulation of its products.  
The first indication of Vif function was the finding that  in its presence, HIV-1 wild-type 
virions contained 100-fold less A3G than Vif defective virions and were  >100-fold 
infectious (Mariani R. et al., 2003;  Marin M. et al., 2003; Stopack et al., 2003; Sheehy AM. Et al., 2003; Mehle A. et al., 2004b; Kao 
S. et al., 2003). It soon became clear that Vif acts by depleting A3G from cells. Therefore, Vif 
counteracts A3G antiviral action both by inhibiting its synthesis (Stopak K. et al., 2003) and 
stimulating its degradation by the 26S proteasome (Cullen BR, 2006; Mangeat B and Trono D., 2005; Chiu Y. 
and Greene W., 2006). Consequently, A3G is no longer available for recruitment into the 
virions. The mechanism by which Vif stimulates A3G degradation in the 26S 
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proteasome has long been deciphered (Cullen BR, 2006; Mangeat B and Trono D., 2005; Chiu Y. and Greene W., 
2006). Vif binds A3G and induces its degradation by forming an E3 ubiquitin ligase 
complex with cullin 5 (Cul5), elongin B (EloB), and elongin C (EloC) that targets these 
proteins for degradation by the ubiquitin-proteasome pathway (Bogerd H. et al., 2004; Lui B. ert al., 
2005; Marin M. et al., 2003; Mehle A. et al., 2004a, b; Sheehy et al., 2003; Stopack K., et al., 2003; Yu X. et al., 2003; Yu Y. et al., 2004). 
 
3.3.1. Vif domains involved in the interaction with A3G. 
 
The Vif-A3G interaction is of particularly interest in a way that it provides a compelling 
target for novel therapeutic strategies for treating HIV-1 infections. Disruption of A3G-
Vif interaction is predicted to rescue A3G expression and virion packaging, therefore 
stimulating natural antiviral infectivity. Similarly, pharmacologic studies to suppress 
A3G proteasome-mediated degradation have been shown to enhance A3G expression 
and consequently inhibit HIV-1 infection (Yu, X. et al., 2003). In order to facilitate the rational 
design of inhibitors for A3G-Vif interaction, molecular biology experiments have been 
employed to define features of A3G that are involved in the interaction with Vif. 
In order to protect against A3G, Vif uses multiple regions for protein interaction such as 
the N-terminal region, the SLQ(Y/F)LA motif and a highly conserved H-X5-C-X17-18C- X3-5-
H motif upstream of the BC box.  The N-terminal region of HIV-1 Vif is important for 
binding and neutralization of A3G and A3F and also contributes to species-specific 
recognition (Marin M, et al., 2003; Schrofelbauer, B. et al, 2006; Simon, V., 2005; Tian, C. et al, 2006; Indrani P. et al, 2006).   
The highly conserved cysteine residues at positions 114 and 133 and the SLQ(Y/F)LA 
motif at residues 144 – 149 are required for Vif function and HIV-1 replication (Goncalves, J. 
et al., 1994; Ma, X. et al., 1994). In contrast, a deletion in the Vif region 142 to 154 that removes 
the SLQ(Y/F)LA motif shows a remarkably effect in reducing A3G levels and support 
virus replication. This suggests a relationship between the ability of Vif to reduce A3G 
levels and to support virus replication.   
Vif associates with the Cul5-EloB-EloC complex by binding directly to EloC via a BC box 
motif at positions 144 to 153 and to Cul5 via hydrophobic residues at positions 120, 
123, and 124 within a zinc-binding region (residues 100 to 142) formed by a conserved 
H-X5-C-X17–18C-X3–5-H (HCCH) motif (Mehle A. et al., 2004a; Mehle A. et al., 2006). The S
144 LQXLA150 
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motif is essential for targeting A3G for proteasomal degradation. Substitution of the 
SLQ portion of the SLQXLA motif has been reported to be sufficient to prevent A3G 
degradation (Kobayashi, M. et al., 2005; Sheehy AM. et al., 2003; Yu, X. et al., 2003). The zinc binding-motif HCCH 
has also been reported to be involved in A3G degradation and necessary for the 
specificity of Vif-Cullin 5 interaction (Luo, K. et al., 2005; Xiau Z. et al., 2006). 
The species-specific recognition by Vif is determined by a single amino acid at position 
128 in A3G, which is aspartic acid in humans and lysine in African green monkey (AGM) 
(Bogerd H. et al., 2004; Mangeat B. et al., 2004; Schrofelbauer B. et al., 2004; Xu H. et al., 2004). Substitution of D128 in 
human A3G for K128, found in African Green Monkey (AGM) A3G, results in a mutant 
(D128K-A3G) deaminase that is resistant to the effect of Vif. This may be either 
because the mutant protein is no longer able to interact with Vif or due to subsequent 
downstream steps that may be inhibited  (Schrofelbauer, B. et al., 2006; Bogerd, H. et al., 2004; Mangeat, B. et 
al., 2004; Xu, H et al., 2004).  
Mutations in the Vif conserved region D14RMR17 similarly alter its species-specific 
effect. Alteration of the Vif conserved sequence DRMR to SERQ or SEMQ, which is the 
sequence in SIVAGM  Vif, causes Vif to interact with AGM A3G, rhesus (Rh) A3G, as well 
as D128K-A3G (Schrofelbauer B. et al., 2006). This loss of species restriction is probably caused by 
an overall increase in the negative charge of amino acids 14-17 in HIV-1 Vif that 
promotes effective interaction with the positive charge of lysine present at residue 128 
in AGM A3G and Rh A3G. The DRMR region, localized at the N-terminal domain of Vif is 
important for interaction with A3G (Schrofelbauer B. et al., 2006). Although, additional binding 
sites may be required for stabilization of this interaction (Schrofelbauer B. et al., 2006). 
Schrofelbauer et al., have also reported the importance of the D14RMR17 in A3F 
inhibition and in the D128K-A3G Vif resistant mutant (Schrofelbauer B. et al., 2006; Bogerd, H. et al., 2004; 
Mangeat, B. et al., 2004; Xu, H., et al., 2004). 
More recently, Pathak and co-workers have shown that the HIV-1 Vif region Y40RHHY44 
is also important for binding to A3G and that a mutation in this region increases Vif 
ability to suppress A3F. Although, the region reported as important for A3F-Vif binding 
is D14RMR17. Pathak and co-workers showed that Vif binding to D128K-A3G region is 
dependent on the Y40RHHY44 but not the D14RMR17 region. Consistent with previous 
observations, they showed that substitution of Vif`s region D14RMR17 with SEMQ in Vif, 
similar to SERQ amino acids in SIVAGM Vif, is required for subsequent neutralization of 
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D128K-A3G. Therefore, Y40RHHY44 domain is necessary for binding to A3G and the 
D14RMR17 domain may be involved in a secondary step that is necessary for A3G 
degradation (Russell A. and Pathak V., 2007). 
 
3.3.2. Mechanisms of Vif action not involving degradation of A3G. 
 
Vif-mediated A3G degradation plays an important role in overcoming the antiviral 
action of A3G. However, Vif may also act by sequestering A3G from sites of virion 
assembly, impairing A3G incorporation into viral particles (Kao S. et al., 2007, Mehle A. et al., 2004b; 
Stopak K. et al., 2003). Moreover, Vif has been reported to be associated with the plasma 
membrane, the site of virion assembly, localizing Vif in proximity to A3G (Simon JH et al., 1997). 
One study indicates that Vif can enhance virion infectivity under conditions where it 
only moderately reduces the steady-state levels of A3G (Kao S. et al., 2004). In addition, the 
non-phosphorylated  Vif S144A mutant leads to progeny virions with poor infectivity 
despite being able to effectively deplete A3G (Mehle A. et al., 2004b). More recently, the work 
developed in Klaus Strebel  group showed that Vif was able to inhibit virion 
encapsidation and the antiviral activity of an A3G degradation resistant mutant (C97A) 
(Opi S. et al., 2007).  
Two major mechanisms have been suggested to explain this alternative mechanism of 
Vif action: (I) physical exclusion of A3G from sites of virion assembly and budding; 
and/or (II) inhibition of A3G encapsidation by competing for binding to NC or viral 
genomic RNA (Mariani R. et al., 2003; Opi S. et al., 2007; Kao S. et al., 2004). 
Additionally, two studies have showed a possible link between Vif and Vpr accessory 
proteins and HIV-1 cytopathicity and cell cycle arrest. These findings were supported 
by Terry Finkel and co-workers (Wang J. et al., 2007), which demonstrated that Vif contributes 
to the arrest of HIV-1 infected cells in the G2 phase of the cell cycle. However, the 
mechanism by which Vif induces G2 arrest or why HIV-1 uses two accessory proteins 
(Vif and Vpr) for the same purpose still remains to be explained. One possible 
explanation is the need for producing as much virus as possible in the short period that 
the infected cell is alive in order to ensure viral propagation. Cells arrested in the G2 
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phase have shown to produce more virus (Goh, W.C. et al., 1998), ultimately leading to cell 
death (Stewart, S. A. et al., 1997; Yuan, H. et al., 2003). 
 
 
 
 
Fig. 8. Schematic representation of Vif 
mediated inhibition of A3G. (a) (1), (b). 
Vif binds A3G and promotes the 
coordinated activation of three classes of 
enzymes: E1, E2, and E3. E1 is the 
ubiquitin activating enzyme and is 
responsible for transferring ubiquitin to 
the E2 ubiquitin-conjugating enzyme. E3 
is a multiprotein complex that specifically 
recognises the substrate and mediates its 
ubiquitin-dependent degradation. E3 is 
the ubiquitin ligase, which transfers 
ubiquitin to the substrate.  Part of the E3 
complex is composed by Vif, elongin B, 
elongin C, cullin-5 (CUL5) and RING-box-1 
(RBX1).  Vif binds A3G and targets the 
RING-type E3 complex to A3G promoting 
its ubiquitination by bringing the 
activated E2 into close proximity to the 
substrate.  (2) Vif may also impair 
translation of A3G mRNA. (3) Vif action of 
sequestering A3G from sites of virion 
assembly impairs A3G incorporation into 
viral particles. (Figure from: Ya-Lin Chiu and Warner Greene, Annu. Rev. Immunol. 2008) 
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3.3.3. Additional Vif domains involved in the interaction with A3G. 
 
The Thr96, Ser144, and Thr188, are highly conserved phosphorylation sites in Vif. A 
mutation of Thr96 or Ser144, impairs but is not sufficient to abolish viral replication (Yang  X. 
et al., 1996; Yang X. and Gabuzda D., 1998).  The T96A, S144A, and T188A mutants retain the ability to 
decrease A3G levels (Mehle A. et al., 2004b), indicating that some mutations that reduce Vif 
function during HIV-1 replication still retain the ability to decrease A3G levels.  
The central hydrophilic domain, E88WRKKR93, and the proline-rich P161PLP164 domain, 
have been shown to be important for enhancing the steady-state levels of Vif and for 
binding to tyrosine kinases, respectively (Douaisi M., et al., 2005; Fujita M., et al., 2003). One may 
speculate on the E88WRKKR93 motif function for maintaining sufficient levels of Vif for 
A3G inhibition. Mutations in the Vif PPLP motif were shown to reduce the infectivity of 
virions produced in T-cells and eliminate Vif-Vif interaction in vitro (Yang et al., 2001). It has 
been suggested that multimerization of Vif may be necessary for A3G binding and that 
the PPLP region may be essential for this behaviour (Miller J. H. et al., 2007). In addition, this 
region has also been identified as part of a novel “SOCS-box” motif implicated in 
binding to EloC (Mehle A. et al., 2004 a; Yu Y. et al., 2004) and to be involved in the Vif interaction with 
the cellular Hck tyrosine kinase (Hassaine G. et al., 2001; Yang B. et al., 2003). Recently, Donahue J. et 
al. demonstrated that mutation of the Vif PPLP motif impaired the ability to bind to 
A3G, and did not affect EloC and Cullin5 binding (Donahue J. et al., 2008). 
Other studies have identified other regions in the Vif protein that are responsible for 
A3G and A3F inhibition but are not located in the SLQXLA and HCCH motifs. As an 
example, Simon et al., reported that any single amino acid substitutions in Vif 
sequences isolated from HIV-1 infected patients were sufficient to prevent AG3 
neutralization (Simon V., et al., 2005). Also, a subset of mutants has been reported to be 
functional against A3G but not A3F and vice versa (Russel R. and Pathak V., 2007).  
 
 3.4 Structural domains involved in A3G functionality 
All members of the APOBEC protein family have one or two copies of His/Cys-X-Glu-X 
23-28-Pro-Cys-X2-4-Cys coordination motif that is characteristic of CDAs. As mentioned 
before, A3B, A3D, A3E, A3F, and A3G contain duplications of the CDA domain. 
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Although, the two CDA domains are not equivalent, as only the C-terminal CDA motif 
displays deaminase activity (Holmes, R.K. et al., 2007; Newman E.N. et al., 2005). 
Cristal structures of CDAs from Escherichia coli (Betts et al., 1994), Bacillus subtilis (Johansson et al., 
2002), Saccharomyces cerevisiae (Xie et al., 2004) and most recently humans (Chung et al., 2005) are 
available. These structures offer an opportunity to perform homology modelling and 
help to determine common trends and differences among the organization of APOBEC 
family members. Analysis of these structures revealed a core β1β2α1β3α2β4β5 
arrangement in which the five β-strands form a mixed sheet that supports the parallel 
positioning of two α-helices that contain the His, Cys and Glu residues that are required 
for zinc-coordination, proton transfer and catalysis (Wedekind et al., 2003). Based on these 
structures the model for APOBEC proteins was predicted (Huthoff H. and Malim M., 2005) and is 
shown in Fig.9. 
 
(Figure from: Huthoff H. and Malim M., J. Virology, 2007) 
Fig. 9. Model of the N-terminal CDA domain of A3G. The predicted positions of α-strands (yellow) and β-
strands (purple) are indicated. The amino acid D128, responsible for the species-specific recognition of 
A3G by Vif is indicated. The Zinc-coordinating motifs are indicated by dark circles.   
 
Substitution of the aspartic residue (D128), which naturally occurs in human A3G with 
the lysine residue found in AGM A3G abrogates the interaction with HIV-1 Vif and 
confers sensitivity to the SIVAGM Vif protein. Experiments, by alanine-scaning and 
multiple substitutions at the A3G residues P129 and D130 confirmed the central role 
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played by the aspartic acid at position 128 and showed the crucial role of proline-129 
and aspartic acid-130, as important contributory residues (Huthoff H. and Malim MH. 2007) (Fig. 
10). 
In addition, a four amino-acid sequence comprising residues 124 to 127 was shown to 
be responsible for an efficient A3G incorporation into HIV-1 virions (Huthoff H. and Malim MH. 
2007) (Fig. 10).  
 
 
(Adapted from Hendrik Huthoff and Michael Malim, J.V, 2007) 
Fig. 10.  Schematic representation of amino acids involved in Vif recognition of A3G and in virion 
incorporation.  The amino acid region 124 to 127 is strongly conserved among A3G proteins from different 
species and is involved in A3G packaging into HIV-1 virions.  Alanine substitutions in this region generated 
proteins with reduced level of antiviral activity against HIV-1ΔVif. The presence of tryptophan in position 
127 was shown to be particularly important for the maintenance of A3G antiviral activity (Huthoff H. and Malim M, 
2007). The negative charge of D128 and D130 region appears to be crucial for an efficient Vif recognition.  
 
Several groups have shown that Vif-induced degradation of A3G requires their physical 
interaction of the two proteins and that a single amino acid change in A3G at residue 
128 was sufficient to abolish this interaction (Bogerd, H. P. et al.,2004; Mangeat, B. et al., 2004; Schrofelbauer, 
B. et al., 2004). Amino acid substitutions in the region 128 to 130 by amino acids carrying 
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side chains with different properties indicated that the interaction between Vif and 
A3G is largely determined by electrostatic interactions involving residues 128 and 130 
(Huthoff H. and MalimM., 2007). Substitution of proline in residue 129 to alanine or glycine 
displayed a strong Vif-resistant phenotype indicating that a specific structural 
interaction is also required for an efficient inhibition of A3G by Vif (Huthoff H. and MalimM., 2007). 
, In addition to electrostatic determinants, one study reported that A3G residues 54 to 
124 were sufficient to coimmunoprecipitate with Vif, which suggests the presence of 
additional interaction domains between Vif and A3G (Conticello SG. Et al.,2003). Interestingly, 
two research groups have shown that HIV-2 and SIVMAC Vif proteins were able to 
mediate degradation of both wild-type A3G and the D128K mutant (Gaddis N.C. et al., 2004; Xu, H. 
et al., 2004). This observation indicates that Vif proteins have different requirements for 
functional interactions with A3G. 
Vif neutralization of A3F requires different amino acids regions in Vif, indicating that 
the interaction between Vif and A3F is different from the interaction with A3G (Simon V. et 
al., 2005; Tian C. et al., 2006). In fact, A3F contains an ERD motif instead of the DPD motif found 
in A3G. The DPD motif, found at residues 128 to 130 in A3G, is involved in Vif-response 
and was shown to be unique of this protein (Huthoff H. and Malim M., 2007).  
A3G is recruited into budding virions through its interaction with the NC component of 
the Gag polyprotein and nonspecific RNA binding (Cen S. et al., 2004; Navarro F. et al., 2005; Cullen BR, 2006; 
Mangeat B and Trono D., 2005; Chiu Y. L. and Greene W. C., 2006). A3G proteins, with mutations at positions 
124, 125 and 126 were shown to interact with HIV-1 Gag in a RNA-dependent manner 
(Doehle B. P. et al.,2005; Zennou V. et al., 2004). However, the mutant W127A did not show this 
property (Huthoff H. and Malim M., 2007). This observation by Huthoff H. and Malim M. suggests 
that Gag-A3G-RNA interaction cannot be the sole responsible for A3G packaging. It is 
possible that a spatial proximity between A3G and the membrane budding sites also 
may be a contributing factor for A3G packaging. Therefore, it is conceivable that this 
motif may be involved in determining the correct subcellular localization of A3G (Huthoff H. 
and Malim M., 2007). In addition, it is possible that the motif encompassing amino acids 124 to 
127 of A3G may bind to an as-yet-unidentified molecular partner that may specify virus 
incorporation (Huthoff H. and Malim M., 2007).  A schematic representation of A3G structure 
involved in recognition of Vif is indicated in figure 11.  
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(Adapted from: Melanie Kremer and Barbara S. Schnierle, Curr. HIV. Res. 2005) 
Fig. 11. Structural domains of A3G involved in the interaction with Vif and in virion incorporation. A3G 
has two CDA domains, the catalytically inactive amino-terminal domain (CDA 1) is responsible for the 
interaction with Vif and viral incorporation; the C-terminal domain (CDA 2) is responsible for the catalytic 
activity of the protein.   
 
3.4.1 Model structure of A3G based on the crystal structure of APOBEC2 (A2). 
Based on the crystal structure of A2 (Prochnow C. et al., 2006), the N-terminal domain of A3G 
was predicted by theoretical methods (Zhang K. L. et al., 2007).  While Huthoff H. and Malim M. 
provided a genetic analysis of the A3G N-terminal residues 119 to 146 (as described 
above) (Huthoff H. and Malim M., 2007), Zhang K. L. et al.  analysed 48 of the 194 residues of the 
N-CDA domain (Zhang K. L. et al., 2007). The model developed by Zhang K. L. et al., was based 
on a sequence identity of 27%, which should be satisfactory in its global fold as 
supported by the good ANOLEA energy score profile (Zhang K. L. et al., 2007). This latest 
analysis confirmed the results obtained by the first authors and extended it. They 
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defined residues 124 to 127 of A3G as having a role in its viral packaging, and extended 
it to include residue R122. Residues 128 to 130 were confirmed as crucial for the 
interaction with Vif. However, in this analysis, D130 mutants did not display a Vif-
resistant phenotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Figure from Zhang K. L. et al, PLoS ONE.2(4):e378, 2007) 
 
Fig. 12. Structure of A2 dimer and the predicted model of A3G. (A) A2 protein is composed of two outer 
monomers and two middle monomers. Modelling of the A3G N-CDA domain was based on the outer 
monomer of A2 in order to resolve the structure between residues 22 and 33 of A3G. (B) The resulting A3G 
model displays a very similar pattern to the A2 dimer. The active and pseudo active sites represented here 
were based on the corresponding homologous active site of A2.  
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As previously shown, amino acid substitutions in residue P129 displayed a strong Vif-
resistant phenotype and this region was indicated as being important for a structural 
interaction with Vif (Huthoff H. and MalimM., 2007). In the study developed by Zhang K. L. et al., 
this region was not tested but its biological relevance was highlighted by its inclusion in 
a patch of residues under positive selective pressure in primates, together with D128 
(Zhang K. L. et al., 2007).  
 
 
 
(Figure from Zhang K. L. et al, PLoS ONE.2(4):e378, 2007) 
 
Fig. 13. Representation of surface charge changes and structure alterations on A3G model. Mutational 
analysis of 48 out of 194 residues of A3G N-CDA showed that residues R122, W127 and D128 form a 
cluster at the surface of the protein and contribute to changes in surface charge or structure. (A) Model of 
A3G wild-type N-CDA region. (B-D) Effect of mutations R122A, W127L, and D128K on surface charge and 
structure. The red colour represents negative potential, the blue colour represents positive potential, and 
the white colour expresses zero potential (Zhang K. L. et al., 2007). 
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As it can be seen in the figure above, mutations in amino acids R122, W127 and D128 
modified the shape and the charge of the protein indicating that those differences in 
this region are the molecular basis for disruption of A3G interaction with Vif and 
packaging into HIV-1 virions.  
Detailed models of the A3G structure are important for a rational drug design. 
Pharmacological inhibition of the Vif-A3G interaction appears to one of the best 
therapeutic approaches, as disruption of this interaction would enable A3G to be free 
to exert its antiviral action in the cell.  
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Aims of the Study 
The aim of this dissertation is to study the structure-function relationship of HIV-1 Vif 
protein and to determine how its function is regulated in the cell. In order to achieve 
this, we focused mainly in understanding the cellular interplay between Vif and one of 
its targets, the endogenous antiretroviral factor: A3G.  
To achieve this goal we conducted three research projects that are described in detail 
in chapters 2, 3, and 4 of this thesis.  
 
The main objectives are summarized below: 
 
Chapter 2: the objective is to understand how A3G half-life can influence its antiviral 
activity, both at the level of viral encapsidation and catalytic activity in the cell.  
 
Chapter 3: the objective is to study the in vivo interaction of Vif-A3G using a novel 
approach based on oligomerization assisted by the interaction between two GCN4 
leucine zipper domains. We want to approach the degree of importance of Vif C-
terminal region for an efficient degradation of A3G, and to ascertain on the topology of 
Vif-A3G interaction. 
 
Chapter 4: the objective is to use a Protein Complementation Assay (PCA) to study 
specific domains that may have a key role in Vif-A3G interaction. Furthermore, we also 
want to study Vif interaction with others members of APOBEC family, namely: 
APOBEC3F, APOBEC3C, and APOBEC2.  
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ABSTRACT 
The human APOBEC3G (A3G) is a potent inhibitor of HIV-1 replication and its antiviral 
activity is suppressed in the presence of HIV-1 Vif protein. One of the mechanisms by 
which Vif overcomes A3G, is by reducing A3G intracellular expression levels recruiting it 
for polyubiquitination and proteasomal degradation in the 26S proteasome.  
In this study, we used a system that allowed us to insert different A3G N-terminal 
residues resulting in different steady-states according to the identity of the amino acid 
used. By modelling the intracellular half-life of A3G, we showed that A3G can also be 
targeted by the ubiquitin proteolytic system in a Vif-independent manner. 
Furthermore, our results revealed that A3G variants with a half-life of approximately 13 
minutes were still able to incorporate into viral particles, whereas less than 5 minutes 
old A3G variants were not. Interestingly, in an in vitro deamination assay, all A3G 
variants displayed similar catalytic activity, despite the differences of their intracellular 
steady-state. This indicates that newly synthesized A3G, with less than five minutes of 
life, is already active in the cell. These findings showed us the importance of the A3G 
steady-state levels for the maintenance of its antiretroviral activity and point out that 
modelling A3G steady-state can predict how protein half-life can influence the antiviral 
activity of the deaminase, both at the level of its catalytic activity in the cell and viral 
encapsidation. 
  
 
 
 
 
 
 
 
Modelling A3G steady-state 
 48 
 
INTRODUCTION 
The human apolipoprotein B mRNA-editing enzyme, APOBEC3G (A3G), is a potent 
antiretroviral enzyme that, when incorporated into HIV-1 virions, is associated with the 
hypermutation of viral DNA through cytidine deamination of newly synthesized reverse 
transcripts (Mariani R. et al, 2003; Stopak K. et al, 2003; Soros V., et al, 2007; Xu H et al, 2007; Yu Q. et al, 2004; Suspene R et al, 
2004).. HIV-1 virus encodes a 23-KDa protein, Vif, which has been shown to counteract 
the antiviral action of A3G preventing this mutational onslaught. One of the 
mechanisms by which Vif counteracts the antiviral action of A3G is by stimulating its 
degradation by the 26S proteasome (Stopak K. et al., 2003; Marin M. et al., 2003; Sheehy AM. et al., 2003; Conticello 
SG. et al., 2003; Mehle A. et al., 2004; Yu X. et al., 2003). Consequently, A3G is no longer available for 
recruitment into the virions. Vif binds A3G through the activation of a coordinated 
action of three classes of enzymes: E1, E2, and E3. E1 is the ubiquitin (Ub) activating 
enzyme and is responsible for transferring ubiquitin to the E2 ubiquitin-conjugating 
enzyme. E3 is a multiprotein complex that acts as an ubiquitin ligase, which specifically 
recognises the substrate and mediates its ubiquitin-dependent degradation. The E3 
complex is composed of Elongin B, Elongin C, Cullin-5 (CUL5), RING-box-2 (RBX2), and 
SOCS-box proteins (Vif), which binds to A3G and promotes its polyubiquitination on 
lysine residues (Conticello S. G. et al., 2003; Bogerd H. et al., 2004; Lui B. ert al., 2005; Marin M. et al., 2003; Mehle A. et al., 
2004a, b; Sheehy et al., 2003; Stopack K., et al., 2003; Yu X. et al., 2003; Yu Y. et al., 2004).  
It was recently proposed that Vif could function as a vehicle to transport A3G for 
proteasome degradation, but that required polyubiquitination of Vif instead of A3G 
(Dang Y. et al., 2008). Indeed, Vif is polyubiquitinated and subject to proteasome degradation 
(Akari H. et al., 2004; Mehle A. et al., 2004), and this reaction is catalyzed by the same Cul5-E3 ligase 
(Mehle A. et al., 2004). This raises the debate about the mechanism that Vif uses to destabilize 
A3G and take it for degradation in the proteasome. 
Despite some controversy, the mechanism of action of A3G in the cell has always been 
studied in the context of the Vif protein and the later has always been addressed as the 
sole responsible for the degradation of A3G in the 26S proteasome. 
In this study, we decided to model the intracellular half-life of A3G in order to better 
understand its mechanism of action. We used a novel approach that allowed us to 
introduce any desired residue at the amino-terminal domain of A3G originating a 
protein with a different half-life according to the identity of its N-terminal residue. This 
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system consists in linear Ub-protein fusions that are rapidly cleaved by Ub-specific 
proteases at the Ub-protein junction, making possible the production of otherwise 
identical proteins bearing different N-terminal residues.  
This mechanism was first described by Varshavsky and co-workers and relates the 
intracellular half-life of a protein to the identity of its N-terminal residue (Bachmair A. et al., 
1986). The set of individual amino acids can be ordered according to the half-life that 
they confer to the protein when present at its amino-terminus and that is called the 
“N-end rule”. Short-lived proteins usually contain destabilizing N-terminal residues that 
function as essential determinants of an N-terminal degradation signal, called N-
degron (Bachmair A. et al., 1986; Bachmair, A. and Varshavsky, A. 1989; Gonda D. et al., 1989; Kwon Y. T et al., 1998; Tasaki T. et al., 
2005; Varshavsky A., 1996). N-degrons can be created from a pre-N-degron through specific N-
terminal modifications that will destabilize otherwise stable polypeptides. The 
selectivity of ubiquitylation is determined mainly by the E3 Ub ligase that recognises a 
degradation signal of the target protein leading to the conjugation of Ub, in the form of 
a multi-Ub chain, to one or more of the internal Lys residues. The resulting Ub-
containing protein is then processively degraded by the 26S proteasome. 
This pathway was first discovered in 1986, and was based on the observation that 
when a chimeric gene encoding an ubiquitin-beta-galactosidase fusion protein was 
expressed in the yeast Saccharomyces cerevisiae, ubiquitin was cleaved off the nascent 
fusion protein, yielding a deubiquitinated beta-galactosidase (β- gal) (Bachmair A. et al., 1986). 
This cleavage was shown to take place at the Ub-β-gal junction, making it possible to 
expose different residues at the amino-termini of the otherwise identical β-gal 
proteins. The β-gal proteins produced displayed different half-lives in vivo, from more 
than 20 hours to less than 3 minutes, depending on the nature of the amino acid at the 
amino-terminus of β-gal (Bachmair A. et al., 1986).  
The aim of this study was to understand how A3G half-life can influence the antiviral 
activity, both at the level of viral encapsidation and catalytic activity in the cell. To 
achieve this, we used a panel of seven different N-terminal residues classified as 
primary (Arg, Phe and Leu), secondary (Asp), tertiary (Asn) and stabilizing (Met and Gly) 
residues, primary residues being the least stable. By using this strategy we were able to 
mimic the effect of Vif on A3G steady-state allowing us to monitor A3G intracellular 
activity in a Vif-free environment.  
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We showed evidence that newly synthesized A3G, with a half-life of approximately 13 
minutes, is still able to incorporate into HIV viral particles. As previously showed by 
Soros V et al., newly synthesized A3G molecules are selectively incorporated into 
virions within 1.5 hours after synthesis (Soros V. et al., 2007). Ours results showed that 
incorporation of A3G molecules occurs in a very short time after synthesis and that 
regardless of its half-life, A3G molecules are catalytically active in the very early stages 
after its synthesis. In addition, this shows evidence that Vif has to act at the very early 
stages of A3G life-time in order to avoid its incorporation into virions.  
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EXPERIMENTAL PROCEDURES 
 
Plasmids 
The full-length molecular clone of HIV-1 (pNL4.3) was obtained from the NIH AIDS 
Research and Reference Reagent Program (catalog number 114), and was used for the 
production of infectious virus. Vif defective molecular clone pNL4.3ΔVif (Karczewski, M. K., and 
K. Strebel. 1996) was used for the production of Vif-defective HIV-1 virus.  pcDNA3.1-
APOBEC3G-HA (A3G) (Stopak K et al, 2003) was used for the expression of C-terminally 
epitope-tagged human A3G proteins and was a kindly supplied by Dr. Strebel K.. 
pcDNA-HVif was obtained from the NIH AIDS Research and Reference Reagent Program 
(Nguyen, K. L., 2004 ). pcDNA3.1 Zeo(+) was obtained from the NIH (Catalog: 10077). 
pEGFP*IRES-Ub-X (where X stands for the different A3G N-terminal residues) cloning 
vector was used as the cloning vector for the subsequent cloning steps and was kindly 
supplied by Dr. Mark A. Muesing (Lubbertus C. F. et al, 2000).  
 
DNA constructs 
For the insertion of A3G downstream of the pEGFP*IRES-Ub-X sequence, A3G was 
amplified by PCR using oligos: 5’-
GAGGAGGAGGCGGGGCCCAGGCGGCCATGAAGCCTCACTTCAGAACACAGTG-3’ and 5’-
GAGGAGGAGGAGGAGGAGCCTGGCCGGCCTGGCCGTTTTCCTGATTCTGGAGAATGGC-3’, 
containing the restriction site for SfiI and ligated to the cloning vector linearized by 
restriction digestion with SfiI . This originated a bicistronic A3G expression vector, 
where transcription of the mRNA is initiated at the cytomegalovirus 
promoter/enhancer upstream of the EGFP coding sequence, along with an internal 
ribosome entry site (IRES) upstream of the Ub-X-A3G gene segment. Seven different 
amino acid sequences coding for, Met, Gly, Asn, Asp, Arg, Phe, and Leu, were inserted 
downstream of the Ub sequence and were introduced by site-directed mutagenesis. All 
constructs were subjected to sequencing analysis for the detection of undesirable 
mutations.  
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Chemicals 
Proteasome inhibitor MG-132 (10mM in DMSO) was purchased from Calbiochem (cat. 
474790). Cycloheximide was purchased from Aldrich (cat. C1988-1G) and stock solution 
was prepared in DMSO. Cell Proliferation Reagent WST-1 was purchased from ROCHE 
(cat.11644807001).  
 
Cell culture and transfections 
Human embryonic kidney (HEK) cell line 293T,  and P4 cells (HeLa-CD4 LTR-LacZ) were 
obtained from the NIH AIDS Research and Reference Reagent Program Catalog and 
were cultivated in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% foetal 
calf serum, 1X penicillin-streptomycin-fungizone mixture and L-Glutamine (Bio 
Whittaker). For transfections, 293T cells were grown in 6-well or 60-mm plates to 
about 70% confluency, as appropriate. Cells were transfected using the calcium 
phosphate precipitation method. A total of 1 to 10 μg of plasmid DNA was used for 
transfections in 6-well or 60-mm plates, unless otherwise stated. To generate VSV-G-
pseudotyped virions, 293T cells were cotransfected with a plasmid expressing the VSV-
G envelope. Total amounts of transfected DNA were kept constant in all transfections 
by adding empty-vector DNA (pcDNA 3.1Zeo+) (Invitrogen), when appropriate. Cells 
were harvested typically 40-44 h post-transfection.  
 
Virus production and infectivity assays 
Virus stocks were prepared by transfection of 293T cells with pNL4.3 or pNL4.3ΔVif in 
the presence of wild-type A3G-HA or pEGFP-IRES-Ub-X-APOBEC3GHA, as appropriate. 
Virus-containing supernatants were harvested 40 to 44 h after transfection. Cellular 
debris was removed by centrifugation (3 min, 3,000 X g), and unconcentrated clarified 
supernatants were used for infectivity assays in P4 cells. For immunoblot analysis of 
viral proteins, virus-containing supernatants (2 ml) were concentrated by 
ultracentrifugation through 1 ml of 20% sucrose in phosphate-buffered saline (PBS) as 
described previously (26). To determine viral infectivity, viral stocks were collected and 
the viral titer determined and normalized by the amount of the p24 protein detected 
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using the AIDS Vaccine Program HIV-1 p24CA Antigen Capture Assay Kit. Hela P4 cells 
were infected with 100µl of unconcentrated virus supernatant. Briefly, 1.5 X 104 cells 
were plated in a 96-well plate the day before infection. Quantification of the β-
galactosidase activity was performed in cell lysates forty-eight hours after infection, 
using a colorimetric assay based on the cleavage of chlorophenolred-β-D-
galactopyranoside (CPRG) by β-galactosidase (Roche) (27). Briefly, P4 cells were placed 
in 100 µl of lysis buffer (MgCl2 5mM, NP40 0.1% in phosphate buffered saline) and after 
30 min on ice cell lysates were incubated with 100µl of reaction buffer (CPRG 6mM in 
lysis buffer) between 5 min and 2 h at 37ºC. Optical densities in the reaction wells were 
read at 550nm with a reference filter set at 620nm.  
 
Antisera 
For detection of APOBEC3G HA-epitope-tagged, an Anti-HA HRP monoclonal antibody 
(Roche) was used. Anti-HA High Affinity Matrix (ROCHE) was used for 
immunoprecipitation of HA-epitope-tagger proteins. Detection of GFP protein was 
carried by using anti-GFP mouse monoclonal antibody (Roche). The HIV-1 capsid p24 
protein was detected using the anti-p24 anti-mouse supplied by the NIH AIDS Research 
and Reference Reagent Program (cat. 530). GAPDH was used as a loading control and 
the antibody used was purchased from Santa-Cruz Biotechnology (GAPDH 6C5). 
 
Immunoblotting.  
For the detection of intracellular proteins, whole-cell-lysates were prepared as follows. 
Transfected 293T cells were washed once with warm phosphate-buffered saline (PBS) 
and were suspended in RIPA supplemented with 0.1% of Triton X-100 and protease 
inhibitor (ROCHE) (500µl/106 cells). Cell lysates were mixed with equal volume of 
sample buffer (4% sodium dodecyl sulfate [SDS], 125mM Tris-HCL [ph= 6,8], 10% 2-
mercaptoethanol, 10% glycerol, and 0,02% bromphenol blue). Proteins were 
solubilized by boiling for 10 min at 95ºC. Proteins were separated by 12% SDS-PAGE 
(National Diagnostics) and were transferred to nylon membranes (Hybond, Amersham) 
and reacted with appropriate antibodies as described in the text. Membranes were 
then incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies 
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(Amersham Biosciences) and visualized by enhanced chemiluminescence (ECL) 
(Amersham Biosciences). 
 
Total RNA extraction and qRT-PCR.  
Total RNA was extracted from transfected 293T cells using Trizol reagent (Invitrogen) 
following manufacturer’s instructions. cDNA products were synthesized from RNA 
isolated from 2 x 106 cells, using random hexamers and Superscript II RNA polymerase 
(Invitrogen). A3G mRNA levels were quantified using SYBR Green (Invitrogen) and 
according to the manufacturer´s instructions. The primers used for the amplification of 
the different A3G constructs were as follows: A3G forward primer: 5´- 
GGCTCCACATAAACACGGTTTC -3´ (nucleotides 735 to 756); A3G reverse primer: 5´- 
AAGGGAATCACGTCCAGGAA – 3´ (nucleotides 803 to 784). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as a normalizing control with the 
following primers: 5´- GGTGGTCTCCTCTGACTTCAACA-3´, and 5´-
GTTGCTGTAGCCAAATTCGTTGT-3´. Amplification of Vif was carried using the following 
primers: 5´- TGGCATTTGGGTCAGGGAGTC -3´, and 5´- GTT GGTCTGCTAGGTCAGGGTC -
3´. Each SYBR Green reaction contained, 12.5µl 2x SYBR Green PCR mix (Invitrogen), 
0.25 of each 10µM primer, and 1µl of 1:4-diluted cDNA products. Absolute mRNA copy 
numbers were calculated by generating standard curves generated by serial dilutions 
of a plasmid containing the APOBEC3G gene and the cDNA product (GAPDH). Each 
sample was run in triplicate in an ABI 7000 (Applied Biosystems) with one cycle at 50ºC 
(2min) followed by 95ºC (10 min) and 40 at 95ºC (15s) followed by 60ºC (1 min) (Nicholas 
O. Davidson, 2006).  
 
Degradation Rate Quantitation 
For the quantification of the degradation rate of each of the Ub-X-A3GHA mutants, 
293T cells were transfected in a 60 mm plate with 10μg of plasmid DNA encoding the 
different A3G mutants. 16-20 h after transfection, cells were split in 6-well plates, and 
the next day they were treated with 100μg/ml of cycloheximide for 0, 1, 2, 3, 4 hours 
for the A3G WT, Ub-Met-A3G, and Ub-Gly-A3G transfections; 0, 1, 2, 3 hours for the 
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Ub-Asn-A3G and Ub-Asp-A3G transfections; 0, 20, 40, 60 mins for the Ub-Arg-A3G 
transfection, and 0, 5, 10, 20 mins for the Ub-Leu-A3G transfection.  
For each sample, cellular lysates were obtained and protein content analyzed by WB 
using the appropriate antibodies (as described above in material and methods). 
Quantification of band density was performed using Quantity One 4.6.3 software (Bio-
Rad Laboratories, USA). 
 
Determination of A3G deaminase activity 
For measuring A3G deaminase activity we used an in vitro sensitive and quantitative 
assay developed in Prof. Moshe Kotler lab (Norwarski R. et al. 2008). The assay was performed 
in a cell-free system and is based on PCR amplification of a synthetic ss-
deoxyoligonucleotide harboring the 5’ CCCA 3’ target sequence for A3G deamination 
referred to as substrate. For protein expression of A3G WT and Ub-X-A3G mutants, 
transfection of 293T cells was carried out as described in the section cell culture and 
transfections. Briefly, 10 µg of each plasmid DNA was used to transfect 293T cells in 60 
mm plates. Whole-cell-lysates were prepared as described above. 
Immunoprecipitation and purification of HA-tagged A3G proteins was performed by 
incubation of A3G protein from crude lysates with Anti-HA High Affinity Matrix 
(ROCHE), according to the manufacture instructions. Purified A3G proteins were 
treated with DNAse I (Invitrogen, Cat. No. 18047-019) according to the manufacturer’s 
instructions prior to incubation with a deamination substrate. Briefly, purified protein 
(40 Fmol/µl) was incubated with a ss-deoxyoligonucleotide substrate (10 Fmol/µl)) in 
the presence of RNAse H (40 µM), Tris buffer (25mM), BSA (0.1 mg/ml), for 30 mins at 
37ºC. After incubation, A3G reaction products were amplified by PCR and the PCR 
product was digested with Eco147I. Briefly, one round of PCR was performed at 94ºC (3 
min) followed by fifteen rounds at 94ºC (30 sec) and 61ºC (30 sec). The restriction 
reaction products were separated by non-denaturing (TBE) SDS-PAGE.  
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RESULTS 
 
APOBEC3G expression can be manipulated by the N-end rule pathway. 
We sought to manipulate the expression of A3G to assess whether the amount of 
protein correlates with the inhibition of viral infectivity, viral incorporation and 
deaminase activity. We conditionally destabilized A3G to ensure that its total quantity 
in the cell is similar. To accomplish this goal, we employed a technique previously 
designed to express proteins that have an N-terminal amino acid different from 
methionine (Bachmair, A., et al, 1986). This strategy will express A3G proteins with a dissimilar 
intracellular half-life. Mechanistically, it takes advantage of deubiquitylating enzymes 
that potently and rapidly cleave the junction between the C terminus of ubiquitin and 
the N terminus of a fused protein domain, in a process called deubiquitination. 
Therefore, in our work the coding sequence for human ubiquitin was fused with A3G to 
generate Ub-X-A3G, where X represents any class of destabilization amino acids. 
According to the identity of the amino acid used at N-terminus, this arrangement 
allowed us to obtain A3G variants with different steady-states. In this study, we used a 
panel of seven different amino acids that have been described to be involved in the N-
end rule pathway (Bachmair, A., et al, 1986; Gonda D.. et al, 1989; Varshavsky A., 1996). The schematic 
representation of the Ub-X-A3G fusion construct and the amino acids used at the N-
terminus of A3G is represented in figure 1.  
We used an expression vector constructed by Mark Muesing’s (Lubbertus, C. F and Muesing M, 2000) 
laboratory containing the coding sequence of EGFP under the control of the 
cytomegalovirus promoter, followed by an internal ribosome entry site (IRES) upstream 
of the Ub-X-A3G fragment. This bicistronic expression vector is central to check DNA 
transfection efficiency and provides the means to control expression of Ub-X-A3G 
gene.  
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Fig.1. Schematic representation of the A3G bicistronic expression vector, pEGFP*IRES-Ub-X-A3G-Ha. 
Transcription of the mRNA is initiated at the 
cytomegalovirus promoter/enhancer upstream of the 
EGFP coding sequence. The translation start and stop 
codon for EGFP and Ub-X-A3G is indicated. The site for 
the post-translational cleavage between Ub and X-A3G 
is indicated with a downward arrow. The amino acid 
residues used in this study are indicated, which in 
eukaryotes are classified as stabilizing and 
destabilizing according to the half-life that they confer 
to the protein (Varshavsky A., 1996). 
 
Vif has been proposed to target A3G for accelerated degradation in the 26S 
proteasome via the ubiquitin-proteasome pathway (Conticello S. et al., 2003; Liu B. et al., 2005; Marin M. et 
al., 2003; Mehle A. et al., 2004; Sheehy et al., 2003; Stopack K. et al., 2003; Yu X. et al., 2003; Yu Y. et al., 2004).  A similar 
situation occurs with the N-end substrates that are bound by a targeting complex, 
followed by formation of a substrate-linked multi-Ub chain. The ubiquitylated substrate 
is processively degraded by the 26S proteasome.  
To determine whether Ub-X-A3G follows the 26S proteasome degradation pathway in 
the absence of HIV-1 Vif protein, we substituted the first amino acid in A3G sequence 
by six different residues. We have also maintained the amino acid methione at the N-
terminus of the A3G sequence as a control for expression of wild-type deaminase in 
this system. The corresponding recombinant plasmids EGFP-IRES-Ub-X-A3G are 
isogenic except for the codon sequence of the amino acid present between Ubiquitin 
and A3G. The A3G N-terminal residues introduced synthetically cover the four classes 
of amino acids described by Varshavsky and co-workers in the N-end rule: the least 
stable or primary (Leu, Phe and Arg), followed by secondary (Asp and Glu), tertiary (Gln 
and Asn), and stabilizing (Met, Gly and Val) (Bachmair, A., et al, 1986; Gonda D. et al, 1989; Varshavsky A., 
1996).  
In order to determine the steady-state expression of A3G fusions to ubiquitin, 
according to the amino acid at the Ub-A3G junction, we transfected equal amounts of 
different Ub-X-A3G plasmids in 293T cells. The expression profiles obtained for the 
different A3G variants showed that the proteins containing stabilizing residues (Met 
and Gly), tertiary residue (Asn) and secondary residue (Asp) have higher expression 
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levels compared to proteins that have the least stable residues (Arg, Phe and Leu) (Fig. 
2 A).  
 
 
 
Fig.2. Expression of A3G mutants. (A) Wild-type A3G and N-terminal A3G mutants are indicated above as 
wt, Met, Gly, Asn, Asp, Arg, Phe, Leu. EGFP expression is shown as a control for the transfection. GAPDH is 
shown as a general control to the amount of protein loading in Western blotting. Briefly, 2μg of each 
plasmid was used to transfect 293T cells in 6-well plates. 40-44 hrs after transfection cells were washed 
twice with room-temperature PBS and lysed in cold RIPA lysis buffer. Lysates were subjected to further WB 
analysis. (B) The stability of A3G variants is regulated by the proteasome. Inhibition of proteasome 
function using MG-132 (20 µM) greatly increased the steady-state of the least-stable A3G variants: Arg-
A3G, Phe-A3G, and Leu-A3G. α-GAPDH antibody was used as a loading control. 
 
 
Similar levels of EGFP expression show a similar transcription level for the different 
constructs confirming that differences in X-A3G expression were not due to the 
efficiency of the transfection or other experimental artefact (Fig. 2A). The molecular 
weight of different X-A3G proteins was similar to wild-type deaminase showing that 
Ubiquitin was cleaved from A3G. In addition, GAPDH control indicates that differences 
regarding Ub-X-A3G expression were not due to protein loading. To discard a possible 
toxicity effect due to the chimeric A3G expression, a cell viability and proliferation 
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assay using the tetrazolium salt WST-1 (Roche) showed that the differences observed 
were not due to abnormal cell physiology. 
Figure 2B shows that the steady-state levels of least stable proteins Arg-A3G, Phe-A3G 
and Ub-Leu-A3G were detectable only when transfected cell cultures were pre-treated 
with proteasome inhibitor. Briefly, 293T cells were transfected with equal amounts of 
Ub-Arg-A3G, Ub-Phe-A3G and Ub-Leu-A3G isogenic plasmids. 36 hrs after transfection, 
cells were treated with proteasome inhibitor MG-132 (20 µM) for 4 h and analyzed by 
SDS-PAGE after lysis. Albeit more detectable than Phe-A3G, proteins Leu-A3G and Arg-
A3G were barely evident in the absence of inhibitor, whereas in the presence of 
MG132 levels of similar proteins were, as expected, correspondingly higher. Taken 
together, these results indicate that X-A3G proteins are physiological substrates of 
ubiquitin-proteasome degradation pathway dependent on the N-end rule. Therefore, 
the low level expression detected with Arg-A3G, Phe-A3G and Ub-Leu-A3G was indeed 
a consequence of the amino-terminal destabilizing residues and not dependent on the 
lower protein expression in a given moment. 
 
Stability of X-A3G variants targeted to N-end rule pathway. 
The observation that A3G is incorporated into the virion core suggested several 
possible cellular sources of the deaminase. Most likely, the mechanism of A3G virion 
incorporation depends on the amount of free deaminase in the cytoplasm capable to 
be targeted to the virion. One important variable for this mechanism is the time 
necessary for this recruitment into the virion core. It is conceivable that when A3G is 
bound to the cellular high molecular mass (HMM) complex cannot be readily rescued 
for virion incorporation. Therefore, fine-tuning different half-lives of A3G proteins can 
help to understand the time-space relationship of A3G targeting to the viral particle. 
The N-end rule of X-A3G should provide the total amount of deaminase in the cell with 
similar half-life. In order to assess whether X-A3G mutants can be used with this 
intention the kinetics of X-A3G degradation was evaluated.  To monitor the in vivo 
decay of A3G proteins we performed a cycloheximide chase analysis, as described in 
experimental procedures. We used this approach, instead of pull-chase analysis, 
because we aimed to monitor the turnover of existing proteins and to examine newly 
synthesized molecules. Due to the expected rapid degradation of X-A3G with unstable 
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amino acids, some of our constructs could only be detected by this method if the 
pulse-labeling time was less than 5 minutes and the chase times very short. This 
rational, together with the fact that the steady-state amount of unstable X-A3G would 
be very low, leaded us to use this methodology in order to avoid misinterpretations. 
In Figure 3, cycloheximide assay showed that the in vivo half-life of the different A3G 
proteins ranged from more than 4 hours to less than 5 minutes, depending on the 
nature of the amino acid residue present at the amino-terminus of A3G. Specifically, 
deubiquitinated X-A3G proteins with either Met or Gly at the amino-terminus 
displayed a relatively long half-life of more than 4 hours, similar to the half-life of 
control wt A3G. In contrast, X-A3G mutants bearing N-terminal destabilizing residues 
classified as primary amino acids exhibited very short half-lives.  Cycloheximide chase 
analysis showed that Arg-A3G half-life was approximately 28 minutes, 13 minutes for 
Phe-A3G and less than 5 minutes for Leu-A3G. In addition, the half-life of X-A3G 
proteins bearing amino-terminal residues Asn and Asp was approximately 85 minutes 
and 65 minutes, respectively. Despite some controversy, previous authors showed that 
intracellular half-life of wt A3G in the presence of Vif was reduced from the original 8 h 
to 1-2 minutes (Marin M. et al., 2003). Interestingly, the half-lives showed in the assay by the 
different A3G variants reflected an effect similar to the one observed in the presence 
of Vif. It is notorious the sharp reduction detected in the half-life of the least stable 
proteins (Arg-A3G, Phe-A3G, and Leu-A3G). Thus, it is possible to mimic the effect of Vif 
on A3G intracellular steady-state by changing the first amino acid residue in A3G. 
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Fig.  3. Cycloheximide chase analysis. 
A3G wt and N-terminal A3G variants were expressed in 293T cells (60-mm plates) and, the second day 
after transfection the cells were split in 6-well-plates and the translational inhibitor cycloheximide (100 
µg/ml) was added to each of the cell cultures. 293T cells expressing the A3G proteins were incubated with 
cycloheximide for 1, 2, 3, and 4 hours for A3G wt, Met-A3G, and Gly-A3G; 1, 2, and 3 hours for Asn-A3G 
and Asp-A3G; 20, 40, and 60 minutes for Arg-A3G and Phe-A3G, and 5, 10 , and 20 minutes for Leu-A3G. 
The zero time-point received drug-free diluent DMSO. Cellular lysates were obtained at each time point 
and the protein content was analyzed by WB using the anti-Ha HRP monoclonal antibody.  α-GAPDH 
antibody was used as a loading control. The approximate half-life value of each protein is indicated 
between brackets. Each value represents the mean relative value of three independent experiments 
obtained by band densitometry.  
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Amino-terminal A3G variants are targeted to degradation by HIV-1 Vif protein. 
Due to the nature of the N-end rule, it is conceivable the X-A3G variants could 
somehow escape the action of Vif by a different pathway of degradation. It could result 
that the alteration of the first N-terminal residue in X-A3G may affect its subcellular 
distribution allowing the protein to escape the action of Vif. In this way, and according 
to the fact that wild-type A3G stability is impaired in the presence of Vif protein (Stopack K. 
et al., 2003), we sought to determine if X-A3G constructs were capable to be targeted for 
degradation by Vif. Based on the expression profiles obtained for the different X-A3G 
constructs, those that exhibited higher steady-state (Met-A3G, Gly-A3G, Asn-A3G, and 
Asp-A3G) were expressed in the presence of Vif.  Results in Figure 4 show that Vif 
accelerates degradation of all X-A3G variations similarly, even though they were under 
the N-end rule.  Even with a low steady-state, the amount of the three least stable 
constructs (Arg-A3G, Phe-A3G, and Leu-A3G) was also reduced by Vif (data not shown). 
These results seem to indicate that Ub-X-A3G fusions and its cleavage products do not 
have deleterious effects on deaminase folding, being capable of targeted degradation 
by Vif. Moreover, Vif shows a capacity to recognize ubiquitinated X-A3G and accelerate 
its proteasomal elimination regardless of the altered pathway of degradation 
presented by the N-end rule. 
 
 
 
Fig. 4. Detection of Ub-X-A3G proteins in the presence of Vif. 293T cells were cotransfected in a 6-well 
plate with 1 µg of Ub-Met-A3G, Ub-Gly-A3G, Ub-Asn-A3G, Ub-Asp-A3G, and 3 µg of pcDNA-HVif. 40-44 h 
after transfection cells were lysed and protein content was analysed by SDS-PAGE.   
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N-terminal A3G variants incorporation into viral particles 
According to Soros V. et al., newly synthesized low molecular mass (LMM) A3G is 
preferentially recruited into HIV virions within 1.5 h after synthesis (Soros V. et al., 2007). 
Moreover, it was elegantly shown that the amount of A3G decreased substantially 
after the 1 hour peak, suggesting that once it is assembled into the cellular high 
molecular mass (HMM) complexes, it is no longer available for virion encapsidation. 
Therefore, we sought to investigate whether the least stable X-A3G proteins were still 
able to incorporate into the HIV-1 viral particles.  
Equal amounts of N-terminal X-A3G variants in the presence of HIV-1 ΔVif plasmid DNA 
were transfected into 293T cells. Two days after transfection, virions were harvested 
and after p24 normalization were analyzed for the presence of incorporated X-A3G. 
Results obtained in this experiment showed that X-A3G with a half-life of 13 min is 
incorporated into viral particles, but the least stable Leu-A3G mutant (half-life < 5min) 
was absent from all the samples analyzed (Fig. 5C).  
In addition to results of Soros V. et al., we presented data that implies a time-window 
for A3G incorporation into virions that is relatively short. Therefore, Vif must act during 
this time period to avoid A3G incorporation. However, it is not clear whether Vif acts 
before, during or after the assembly of A3G into HMM complexes. Based on previous 
work (Soros V. et al., 2007), we assumed that the least stable X-A3G proteins were associated 
into LMM and able to exert antiviral activity (Fig. 5 B).  
As shown in Figure 5, Vif-mediated degradation of A3G has to occur between 0 and 13 
minutes after A3G synthesis before its assembly into HMM complexes and virion 
incorporation, given those 13 minutes is the minimum half-life of X-A3G to be 
incorporated into virions. It is interesting to note that the amount of X-A3G 
incorporation into virions is increasing from Phe-A3G to Asn-A3G, possibly reflecting a 
controlled inclusion of APOBEC into HIV-1 particles. Because, 85 minutes is the 
determined half-life of Asn-A3G, that is consistent with previous results that show 
preferentially recruitment of A3G into HIV virions within 1.5 h after synthesis (Soros V. et al., 
2007). Hence, artificial fine-tuning of protein steady-state expression is a useful tool to 
monitor A3G its activity over-time inside the cell the time by providing evidence of the 
shortest time-frame necessary for its incorporation into HIV-1ΔVif virions. 
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Phenotypic analysis of N-terminal A3G mutants 
We have shown that the alteration of the first amino acid in A3G is capable of 
modelling its half-life and consequently manipulate its time-dependent activity in the 
cell. While all X-A3G, with the exception of Leu-A3G, were capable to be incorporated 
into HIV-1ΔVif virions, we hypothesized that viral infectivity could be reduced similarly. 
This proposal stems from the assumption that the presence of A3G into virions is 
sufficient and necessary to influence its antiviral activity.Therefore, to examine if X-A3G 
variants were active against HIV-1, we tested all X-A3G isogenic constructs for their 
ability to inhibit viral infectivity in the absence and presence of Vif protein. Viral stocks 
were produced by transfection of pNL4.3ΔVif and pNL4.3 into 293T cells with A3G wt 
and N-terminal A3G variants.  Infectivity values were obtained after infection of HeLa 
P4 cells with the viral stocks produced (Fig. 5 A, B). In the presence of Vif, it is shown 
that all X-A3G constructs were unable to inhibit infection when compared to A3G wt 
and variations observed among the different constructs were not significant (p<0.001) 
(Fig. 5 A). In contrast, the relative viral infectivity obtained in the absence of Vif and 
presence of different X-A3G showed differential effects. As illustrated in Figure 5 B, X-
A3G proteins bearing stabilizing amino acids, Met and Gly, were able to inhibit HIV-
1ΔVif infection comparably to A3G wt. Interestingly, X-A3G proteins bearing tertiary 
(Asn) and secondary (Asp) amino terminal residues also exhibited antiviral activities 
similar to A3G wt, Met-A3G, and Gly-A3G. We were expecting a reduction in the 
antiviral activity of these A3G variants, since Asn and Asp are considered destabilizing 
residues with lower half-life and lower steady state expression. Nevertheless, the 
results consistently showed an activity of these A3G variants comparable to A3G wt. 
Thus, the total amount of Asp-A3G and Asn-A3G in the cell at 65 min and 85 min of half 
life, respectively, was enough to be incorporated into virions and have antiviral effect 
similar to wild-type. In contrast, X-A3G variants bearing the least stable residues, Arg 
and Phe, only vaguely inhibited HIV-1ΔVif infection (33% of A3G wt activity), and the 
Leu-A3G protein did not display any antiviral effect in the absence of Vif (Fig. 5 B). 
Hence, X-A3G show an ability to be incorporated shortly into virion particles but that 
does not correlate directly with its antiviral effect.  
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Fig. 5. Infectivity assay and A3G virion incorporation. HIV-1 virions were produced by co-transfecting 
293T cells in 6-well plates, with equal amounts (1 µg) of A3G wt and Ub-X-A3G plasmids in the presence of 
3 µg of pNL4.3 (A) or pNL4.3ΔVif (B). VSV-G plasmid (0.1 µg) was used in all transfections to generate VSV-
G-pseudotyped virions. DNA amounts were adjusted to 5 µg using empty pcDNA3.1 vector DNA. 40-44 
hours after transfection, VSV-G pseudo-typed virions were collected (100 µl), normalised for the presence 
of p24 protein, and used to infect Hela P4 cells (1.5X10
4 
cells per well). 40 h after infection of P4 cells, the 
single-cycle titter of viruses produced was determined by quantification of the β-galactosidase activity in 
P4 lysates, using CPRG assay. β-gal activity was determined by measuring the absorbance at 550/620nm. 
A3G wt was used as a control for infection inhibition. Relative infectivity values presented here are the 
result of the four independent experiments. (C) The remaining virus stocks (1.9 ml) were used for 
detection of intravirion A3G protein. After collecting virus-containing supernatants cellular debris was 
removed by centrifugation (3 min, 3,000 X g), and clarified supernatants (1.9  ml) were concentrated by 
ultracentrifugation through 1 ml of 20% sucrose in phosphate-buffered saline (PBS) as described 
previously (Kao, S., et al., J.Virol. 2003). After centrifugation, viral pellet was subjected to immunoblot detection of 
intravirion A3G content using anti-Ha HRP monoclonal antibody. We performed this assay four times and 
the results obtained were always similar to the one represented here. The data are averages of the four 
replicates with the indicated standard deviations. (D) Relative virion incorporation was determined by 
calculating the mean relative values of the three independent experiments measured by band 
densitometry of incorporated X-A3G proteins. 
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It was possible that differences in X-A3G expression could somehow be related to 
differences in transcription. Although, EGFP was measured and normalized, to 
overcome this hypothesis. We performed real-time PCR in order to confirm the 
presence of equal amounts of mRNA transcripts in all the samples used for the 
production of viral stocks. Total RNA was obtained from the transfected 293T cells and 
was analysed for the presence of equal amounts of A3G wt and X-A3G variants. Equal 
X-A3G and GAPDH mRNA transcripts (Fig. 6 A, B) were detected in all the samples 
analysed showing that the variations observed in figure 5 B were not due to variations 
in the amount of cells transfected. We also confirmed the presence of equal Vif mRNA 
transcripts in cells transfected with HIV-1 wt (Fig. 6 C). Quantification of mRNA levels 
from all the samples analysed showed that variations observed were not significant 
(p<0.001). These results confirmed that the observed differences in infectivity showed 
in Figure 5 B were indeed due to the steady-state of each X-A3G variant that was used. 
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Fig. 6. qRT-PCR. A3G, GAPDH, and Vif mRNA levels were quantified using SYBR Green (Invitrogen) and 
according to the manufacturer's instructions. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
used as a normalizing control. Absolute mRNA copy numbers were calculated by generating standard 
curves generated by serial dilutions of plasmids containing the A3G, and Vif sequences and the cDNA 
product (GAPDH). Each sample was run in triplicate in an ABI 7000 with one cycle at 50ºC (2min) 
followed by 95ºC (10 min) and 40 at 95ºC (15 s) followed by 60ºC (1 min). (Nicholas O. Davidson, 2006). 
SD A3G= 0.928; SD GAPDH= 1.656; SD Vif= 2.08.  
 
Deaminase activity of A3G amino-terminal variants  
There is a clear link between A3G deaminase activity and its antiviral activity. 
Moreover, it has been shown by Soros et al that newly synthesized A3G and not pre-
existing A3G already assembled into inactive cellular high molecular mass complexes, is 
encapsidated into budding virions (Soros V. et al., 2007). Therefore, we sought to determine if 
all X-A3G proteins displayed enzymatic activity in an in vitro deamination assay. This 
was a qualitative assessment to evaluate if shorter and longer half-life variants of the 
deaminase might show different catalytic activities.    
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To investigate the enzymatic activity of X-A3G variants, we performed an in vitro 
deamination assay developed in Kotler’s lab (Norwarski R. et al. 2008). In this procedure a 
synthetic ss-deoxyoligonucleotide substrate harboring a 5’ CCCA 3’ target sequence for 
A3G deamination was incubated with immunoprecipitated X-A3G constructs. The 
objective of this assay was to determine if newly synthesized, or more mature, A3G 
proteins displayed intracellular enzymatic activity. Surprisingly, the results obtained 
showed that the enzymatic activity of individual X-A3G proteins was similar, despite 
different half-lives exhibited. As demonstrated in Figure 7, Leu-A3G with a half-life of 
less than 5 minutes was able to deaminate 5’ CCCA 3’ substrate. Moreover, when 
different X-A3G that exhibit increasing half-lives was used, the amount of resultant 
enzymatic products was maintained. 
These results indicate that enzymatic activity of A3G in the cell is not dependent on its 
half-life. Since the amount of resultant small oligonucleotide is maintained steady from 
5 minutes to 85 minutes of A3G half-life, it is possible that this quantity of deamination 
results from enzyme that is active in LMM. 
Therefore, the increasing amount of A3G in steady state expression does not correlate 
with the enzymatic activity of A3G indicating that between 5 minutes and 13 minutes 
A3G can be assembled into inactive cellular HMM complexes.  
 
Fig. 7. A3G catalytic activity is not dependent on the protein steady-state. (A) A synthetic ss-
deoxyoligonucleotide (10 Fmol/µl) containing a central 5’ CCCA 3’ target sequence for A3G deamination 
was incubated with immunoprecipitated A3G protein. Deamination of C3 in the 5’ C1 C2 C3 A 3’ sequence, 
which introduces an Eco147I restriction site in the deaminated substrate following PCR amplification, is 
shown by the formation of a 40b.p cleavage product. 
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DISCUSSION 
In this work we sought to investigate the relationship between A3G half-life and its 
antiviral activity. It has been well demonstrated that Vif protein is capable of recruiting 
A3G to degradation via ubiquitination/proteasome. Therefore, reducing A3G steady 
state is a major strategy to eliminate antiviral activity by impeding its virion 
incorporation. The time A3G needs to be incorporated into virus particles is important 
to assess how promptly Vif can act to induce its degradation. In addition, these results 
provide evidence for how long A3G should exist in the cytoplasm in order to be a 
component of a viral particle. 
It was elegantly demonstrated by Warner Greene’s laboratory that newly synthesized 
A3G is preferentially recruited into HIV virions within 1.5 h after synthesis (Soros V. et al., 
2007). By pulse-chase radiolabeling it was possible to show that assembly of A3G in 
cytoplasmic high molecular mass (HMM) complexes occurred after 30 minutes of 
synthesis, restricting the enzyme to be included in the viral particle. Therefore, we 
wanted to ask whether viable A3G proteins with a half-life shorter than 30 minutes 
could be incorporated into virions and have an antiviral activity.   
In order to understand the mechanism of short-lived A3G and to monitor over-time its 
activity inside the cell, we decided to fine-tune the intracellular half-life of A3G by 
targeting it to the N-end rule pathway. Moreover, to evaluate the time required for 
A3G incorporation into virion particles, fine-tuning the half-life of A3G alone has the 
advantage to test its activity independently from Gag synthesis. 
The method used in this study showed that A3G variants with different stabilities are 
capable to be targeted for proteasomal degradation in a Vif-independent manner. 
These results provide evidence that N-end rule can be a useful tool to study A3G 
protein and its antiviral effects in a Vif-free environment.  
Ubiquitylation by the N-end rule pathway has been shown to be mediated by multiple 
N-recognins that contain a zinc-finger-like domain termed the UBR box (Tasaki T et al., 2005; 
Kwon YT. et al., 2003). The mammalian genome encodes at least seven UBR box-containing 
proteins, named UBR1 through to UBR7 (Tasaki T et al., 2005). UBR box proteins generally 
contain specific signatures unique to E3 Ub ligases or a substrate recognition subunit of 
the E3 complex (Tasaki T et al., 2005). HIV-1 Vif protein is post-translationally modified by 
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ubiquitin and has been shown to interact with proteins belonging to the HECT E3 
ubiquitin ligase family (Nedd4 and AIP4), and with a ring finger E3 ubiquitin complex 
containing Elongin B and C, Cullin 5, and Rbx 2 (Conticello S. G. et al., 2003; Bogerd H. et al., 2004; Lui B. ert al., 
2005; Marin M. et al., 2003; Mehle A. et al., 2004a, b; Sheehy et al., 2003; Stopack K., et al., 2003; Yu X. et al., 2003; Yu Y. et al., 2004). 
Since all these E3 ubiquitin ligases are expressed in T lymphocytes, and are involved in 
Vif-targeted degradation of A3G, we raise the question as to whether A3G is targeted 
by the same, or other, E3 ligases, in the absence of Vif. In this context, it is interesting 
to note that even if the degradation pathway is altered it does not alter the capacity of 
A3G to have an antiviral activity of be degraded by Vif. Therefore, A3G degradation 
might follow a common pathway whether it is caused by the N-end rule or Vif-induced. 
Results obtained in infectivity assays confirmed the importance of A3G steady-state 
expression for the maintenance of its antiretroviral activity. Ours results with 
homogenous populations of A3G having different half-lives show that its incorporation 
into virions occurs in a very short time after synthesis. We showed evidence that A3G 
with a half-life of approximately 13 minutes, is able to be incorporate into HIV viral 
particles. These results indicate that to counteract A3G activity and impede its 
incorporation into virions, Vif has to act at the very early stages of A3G life-time.  
Our results are somewhat different from Soros et al that previously showed by pulse-
chase that A3G is selectively incorporated into virions within 1.5 hours after synthesis 
(Soros V. et al. 2007). However, it is technically difficult to detect specific low amount of A3G 
incorporation into virions when pulse-chase is performed, which does not occur when 
all A3G population in a cell has the same intracellular half-life. Moreover, we are 
observing A3G incorporation into viral particles independently of Gag synthesis. We 
observe in our assays short-lived A3G proteins with t1/2=13 min already incorporated 
into virions indicating that it can be recruited by Gag during virus assembly between 5 
to 13 minutes after A3G synthesis. Thus, it seems likely that A3G can be associated 
with Gag during virus assembly and not necessarily simultaneous with Gag expression. 
These results also bring the possible conclusion that Vif must act during 13 minutes 
after A3G synthesis to promote its degradation and reduce its half-life to less than 5 
minutes, which seems to be the minimum time from A3G incorporation into virions.  
The recruitment of A3G into virions is ultimately disadvantageous to the virus. 
Therefore we assessed whether A3G half-life affected its incorporation into virions and 
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consequently viral infectivity. Our results show that the amount of A3G into virion is 
not directly correlated with its half-life as A3G variants with t1/2=30 minutes to 
t1/2=85 minutes have similar virion incorporation. Moreover, it is interesting to 
observe the discrepancy between intracellular expression of X-A3G variants and its 
viral incorporation. In contrast to other X-A3G variants, the amount of Phe-A3G 
present in virions is very similar to that expressed intracellularly. The fact that the 
majority of Phe-A3G with t1/2=13 min is incorporated into virions suggests that it is 
present in intracellular LMM and available in totality for virus inclusion. This 
observation confirms previous the results of Warner Green’s laboratory showing that 
A3G is present in LMM complexes during the first 30 minutes after synthesis (Soros V. et al. 
2007). In contrast to Phe-A3G, all other X-A3G variants are highly expressed in the cell 
and the amount of X-A3G incorporated into virions is steadily similar. The result 
showing that the amount of A3G into virions increases from t1/2=13 min to t1/2=28 
min and then remains constant is compatible with the assumption that A3G can only 
be incorporated into virions between 13 to 28 minutes after synthesis. Since it was 
showed that A3G is present on HMM after 30 minutes, these results are attuned with 
the hypothesis proposed by Soros et al that the presence of X-A3G into HMM 
complexes may impede its virion incorporation (Soros V. et al. 2007). 
The higher amount of A3G into virions appears to be reached with a half-life superior 
to 28 minutes. When the antiviral properties of these A3G variants are assayed, we 
observe that a minimum infectivity is obtained with t1/2=65 min. Therefore, a 
discrepancy is present between the amount of A3G into virions and its antiviral activity 
from 13 minutes to 65 minutes of half-life. The incorporation of Arg-A3G (t1/2=28 min) 
into virions is higher than that of Phe-A3G (t1/2=13 min) but an increase in the antiviral 
effect is not observed. Furthermore, when similar comparison is made between Arg-
A3G (t1/2=28 min) and Asp-A3G (t1/2=65 min), the amount of protein into virions is 
alike but the antiviral activity is higher with Asp-A3G. This disparity among virion-
incorporated A3G and viral infectivity may indicate that a threshold of A3G capable of 
antiviral activity can only be overcome when the protein half-life is around 65 minutes. 
Conversely, it can also be hypothesized that cellular co-factors required for A3G 
antiviral activity are not readily incorporated into virions, but are rescued by the 
deaminase to the particle at a later stage of viral assembly between 28 to 65 minutes 
after A3G synthesis. 
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It was reported that virion-associated A3G is derived from intracellular LMM complexes 
(Soros V. et al.2007). Our results show that enzymatic activity of intracellular A3G is constant 
from t1/2=13 min until t1/2=4 h. Therefore, it is possible that the amount of A3G in 
LMM active form is available for virion incorporation during this half-life interval, 
confirming previous results of A3G virion incorporation.  
It has been suggested that cytokines, such as IL-2 and IL-5, produced in lymphoid 
tissues during cell-cell interactions are responsible for the formation of HMM 
complexes (Kreisberg JF et al., 2006). Therefore, A3G could be inactivated in HMM RNA/protein 
complexes which in turn might confer the permissive phenotype for HIV-1 infection 
(Kreisberg JF et al., 2006). Thus, it would be interesting to test whether the activity of specific E3 
ligases could explain why in certain cells A3G is present in LMM complexes and in 
others it exists as HMM. Therefore, the reduction of A3G half-life to escape 
recruitment to the HMM and regulate its activity in the cell is a conceivable hypothesis. 
How the cell can accomplish this goal is a matter of discussion. We have shown in this 
work that X-A3G can follow the proteasome degradation pathway in a Vif-independent 
manner. This indicates that A3G can be targeted to degradation by cellular specific E3 
ligases, other than Vif. Although we have artificially modelled A3G half-life by 
introducing destabilizing residues at the amino-terminus, post-translational 
modifications can occur in proteins targeted by the N-end rule to proteasome 
degradation. Thus, in the absence of Vif we cannot exclude the possibility that A3G 
suffers a post-translational modification that could remove, or introduce, an amino-
acid residue different for methionine. Thus, post-translational modification could 
expose amino acid residues and consequently trigger a cascade of events that 
ultimately would lead A3G to proteasome degradation.  
Although the above hypothesis might seem acceptable, our results show that that the 
activity of A3G is very similar for every half-life variants. We showed that the antiviral 
activity of A3G does not seem to increase with the diminishing of protein half-life. We 
should stress that these experiments were performed at the late stages of viral 
replication during viral incorporation. Hence, there is a lack of information about the 
role of cellular A3G half-life during initial stages of viral infection, mainly during reverse 
transcription. If deamination is a major antiviral strategy for viral infectivity, it is 
conceivable that an increase amount of cellular A3G might abrogate initial steps of HIV-
1 infectivity. Therefore, based on the results presented in this work we speculate that 
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to increase the putative antiviral activity of cellular A3G during reverse transcription, a 
strategy should be implemented to disassemble HMM and consequently release active 
A3G. In this case the total amount of A3G is increased with consequent improvement 
of its antiviral activity. 
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ABSTRACT 
Identification of protein biding partners in Vif and A3G proteins is one of the major 
challenges for the development of new antiviral drugs. Here, we present a novel 
approach to study the in vivo interaction of Vif and A3G. The strategy used in this study 
is based on an oligomerization-assisted interaction whereby fragments of Vif and A3G 
are fused to independently folding and interacting domains of homodimerizing GCN4 
leucine zipper-forming sequences. Reassembly of the two interacting domains was 
assessed in vivo and proved to be a useful tool for a rapid screening of Vif-A3G 
interacting domains. We show that the C’terminal region of Vif alone is not sufficient to 
induce A3G degradation and that binding of Vif to A3G must involve an additional co-
factor that is probably linked to the N-terminus of Vif and may be essential for the 
interaction and consequent degradation of A3G. We also show the importance of the 
topological orientation of Vif-A3G for an efficient interaction indicating that it must 
occur in a parallel orientation when both proteins are in close proximity. Our results 
show that Vif-targeted degradation of A3G is specific and supports the previous 
hypothesis of an involvement of a specific co-factor in this interaction. 
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INTRODUCTION 
The Human Immunodeficiency Virus type-1 (HIV-1) Viral Infectivity Factor protein (Vif) 
is a 23KDa protein that plays an important role in HIV-1 replication. Vif is expressed late 
in the retrovirus life cycle and is required to overcome the antiviral activity of the host 
cell’s APOBEC3G (A3G) and APOBEC3F (A3F).  In the absence of Vif, A3G and A3F are 
incorporated into HIV-1 virions and carried to the target cell where they will deaminate 
cytidines in viral minus-strand DNA during reverse transcription (RT), resulting in G-to-
A hypermutation, which will lead to the premature degradation of the newly 
synthesized viral DNA (Harris RS et al., 2003; Mangeat B et al., 2003; Mariani R et al., 2003; Zhang H et al., 2003). Vif 
neutralizes the antiviral activity of A3G and A3F by forming a RING-finger E3 ubiquitin 
complex containing Elongin B and C, Cullin 5, and Rbx2 to form an E3 ubiquitin ligase 
complex, and uses all these key domains to recruit these proteins for 
polyubiquitination and proteasomal degradation (Conticello SG et al., 2003; Liu B et al., 2005; Marin M et al., 
2003; Mehle A et al., 2004; Sheehy AM et al., 2003; Stopak et al., 2003; Yu X et al., 2003; Yu X et al., 2004). Vif may also 
neutralize A3G antiviral through other independent mechanisms that do not involve 
proteasomal degradation (Kao S. et al, 2003; Kao S. et al, 2004; Mehle A. et al, 2004; Santa-Marta M. et al, 2005; Stopak K. 
et al, 2003). 
The SLQ144LQXLA150 Vif motif is the most conserved sequence in Vif and it is required 
for degradation of A3G and A3F by the Vif-Cul5-E3 ligase complex but unnecessary for 
binding (Mariana Marin et al, 2003). Conversely, binding of Vif to A3G and A3F is necessary for 
their degradation by the Vif-Cul5-E3 ligase (Mariana Marin et al, 2003). It was previously 
suggested that one region of Vif was responsible for binding to A3G, whereas another 
region comprising the conserved SLQLQXLA motif was responsible for mediating A3G 
degradation in the proteasome (Mariana Marin et al, 2003). 
The N-terminal region of Vif has been implicated in its binding to an N-terminal region 
of A3G (amino acids 54-124) and also contributes to species-specific recognition (Marin M, 
et al., 2003; Schrofelbauer, B. et al, 2006; Simon, V., 2005; Tian, C. et al, 2006; Indrani P. et al, 2006). Although, the regions 
of Vif involved in binding to A3G remain poorly defined. The DRMR region of Vif, 
localized at the N-terminal region of Vif (a.as 14-17), was showed to be critical for the 
strength of binding with A3G (Schrofelbauer, B. et al, 2006). However, coimmunoprecipitation 
assays have demonstrated that additional binding sites were required for a 
stabilization of this interaction, and that the region 128 of A3G could interact with Vif 
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at amino acid 15 or 17 (Schrofelbauer B. et al, 2006). More recently, the interaction of Vif with 
A3G has been mapped to amino acids 40 to 44 (YRHHY) of HIV-1 (Mehle A., et al, 2007; Russel R. and 
Pathak V., 2007). However, other amino acids in Vif may also contribute to A3G binding.  
A striking feature of HIV-1 Vif is the high concentration of conserved tryptophans in its 
N-terminal region (Lee T. H., et al, 1986), which may play a role in a differential recognition of 
A3G and A3F, by Vif (Tian, C. et al, 2006). Furthermore, Mehle et al. demonstrated that amino 
acids 40 to 71 in the N-terminus of Vif contain a nonlinear binding site for A3G and that 
His 42/43 are important for Vif-A3G binding and Vif-mediated degradation of A3G in 
vivo (Mehle A., et al, 2007). Recently, a new Vif motif comprising amino acids 52 to 72 was 
identified, and was shown to be important for the interaction and for the Vif-mediated 
degradation and virion exclusion of A3G (He Z. et al. 2008). 
In this work we aimed to study the in vivo interaction between Vif and A3G through 
oligomerization assisted by the interaction between two GCN4 leucine zipper domains. 
Homodimerizing GCN4 parallel coiled-coil leucine zipper-forming sequences (ZIP) are 
known to interact in vivo and this type of coiled coil interaction has been intensively 
used as a rapid and efficient in vivo screening strategy for identification of interacting 
pairs of heterodimerizing polypeptides (Pelletier JN, e tal., 1999; Newman JR, 2003; Alber T. 1992; Arndt KM,et al., 
2000). In addition, leucine zippers have also been found to associate in an anti-parallel 
orientation. In this study, we decided to use both parallel and antiparallel leucine 
zipper-sequence domains to study the importance of interacting domains between Vif 
and A3G, as well as to ascertain on the spatial orientation of this interaction. 
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EXPERIMENTAL PROCEDURES 
 
Plasmids  
pcDNA3.1-A3G-HA (1) was used for the expression of C-terminally epitope- tagged wild 
type human A3G protein and was a kindly supplied by Strebel K.. pcDNA-HVif was 
obtained from the NIH AIDS Research and Reference Reagent Program (Nguyen, K. L., 2004 ). 
pcDNA3.1 Zeo(+) was obtained from the NIH (Catalog number: 10077). 
Homodimerizing GCN4 parallel coiled-coil leucine zipper (Zip) in fusion with β-
lactamase fragments was kindly supplied by W. Michnick and has been previously 
described (Galarneau et al, 2002). The plasmid pEGFP-C1 was obtained from Clontech. Anti-
parallel GCN4 leucine zipper domains were kindly supplied by Regan L. (Thomas J., et al., 2004). 
The Vif-defective molecular clone pNL4.3ΔVif has been previously described (Karczewski, M. 
K., and K. Strebel. 1996) and was used for the production of virus stocks. 
 
DNA constructs  
GCN4 leucine zipper (Zip) was obtained from the original plasmid pcDNA3.1-Zip-15a.a-
BLF[1] (Galarneau et al, 2002) and was used as the cloning vector for the subsequent steps. For 
the insertion of A3G, Vif, Vif SLQ, Vif C-terminal region (amino acids 98 to 192), and 
EGFP downstream of the Zip sequence and in fusion with a 15 a.a flexible polypeptide 
linker (GGGGS)3, each sequence was amplified by PCR using specific oligonucleotides 
(A3G: Zip-Apo-F- XhoI and Zip-Apo-R-ClaI; Vif and Vif SLQ: Zip-Vif-Full-XhoI and Zip-Vif-
R-ClaI; Vif 92-192: Zip-VifC-XhoI and Zip-Vif-R-ClaI) containing the restriction site 
XhoI/ClaI and ligated to the Zip vector linearized with XhoI/ClaI to remove the BLF[1] 
sequence. This originated the plasmids Zip-A3G, Zip-Vif, Zip-VifSLQ, Zip-Vif 98-192, and 
Zip-EGFP. Mutation of SLQ region in pcDNA-HVif was accomplished by PCR-based 
mutagenesis of pcDNA-HVif originating the Vif SLQ>AAA mutant. Vif SLQ>AAA mutant 
was generated using oligos: SLQ-Vif-NIH-F and SLQ-Vif-NIH-R. 
For the insertion of A3G and Vif upstream of the Zip sequence, both sequences were 
PCR amplified with specific oligonucleotides (A3G: APO-F-RI and APO-GGG-R-NotI; Vif: 
Vif-R1 and Vif-GGG-R-NotI) containing restriction site EcorI/NotI and coding in frame 
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for a 15 a.a flexible polypeptide linker (GGGGS)3. PCR product was digested and ligated 
into the EcorI/NotI site of the linear vector, originating the plasmids A3G-Zip and Vif-
Zip.  
The anti-parallel GCN4 leucine zipper (CZ) was covalently linked to the Vif sequence by 
linearization of the plasmid (Zip-Vif) with the restriction enzymes NotI/AscI to remove 
the original Zip sequence and replace it by CZ, which had been PCR amplified using 
specific primers (Zip-AP-NotI-F and Zip-AP-AscI-R) containing the restriction site 
NotI/AscI. This led to the creation of the plasmid CZ-Vif. 
A PCR-generated anti-parallel GCN4 leucine zipper (NZ) was inserted downstream of 
the A3G sequence by one round of PCR using specific oligos (A3G-HA-Not-F and A3G-
GGG-AP-R), which introduced an A3G epitope tagged N-terminal HA and 15 a.a flexible 
polypeptide linker (GGGGS)3 at the C-terminal domain of A3G originating the plasmid 
A3G-NZ. PCR product was gel purified and was subjected to a second PCR (A3G-HA-
amp-F and A3G-AP-R), which inserted the antiparallel leucine zipper (NZ) downstream 
of the A3G and linker sequences. The final PCR product was purified and digested with 
the restriction enzymes NotI/XhoI and inserted into the linear vector pcDNA3.1 Zeo+.  
All constructs were subjected to sequencing analysis for the detection of undesirable 
mutations. The sequence of primers used is listed in table 1 at the end of this section. 
 
Antisera 
For detection of APOBEC3G HA-epitope-tagged, an anti-HA HRP monoclonal antibody 
(Roche) was used. Vif protein was detected using the anti-Vif anti-rabbit antibody (cat# 
2221) supplied by the NIH AIDS Research and Reference Reagent Program Catalog. 
Detection of GFP protein was carried by using anti-GFP mouse monoclonal antibody 
(Roche). GAPDH was used as a loading control and the antibody used was purchased 
from Santa-Cruz Biotechnology (GAPDH 6C5: sc-32233).  
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Cell culture and transfections 
Human embryonic kidney (HEK) cell line 293T,  and P4 cells (HeLa-CD4 LTR-LacZ) were 
obtained from the NIH AIDS Research and Reference Reagent Program Catalog and 
were cultivated in Dulbeco`s modified Eagle’s medium (DMEM) containing 10% foetal 
calf serum, 1X penicillin-streptomycin-fungizone mixture and L-Glutamine (Bio 
Whittaker). For transfections, 293T cells were grown in 6-well plates to about 70% 
confluency. Cells were transfected using the calcium phosphate precipitation method. 
A total of 2 to 3 μg of plasmid DNA per well was used, unless otherwise stated. Total 
amounts of transfected DNA were kept constant in all samples of any given experiment 
by adding empty-vector DNA (pcDNA3.1Zeo+) as appropriate. Cells were harvested 
typically 40-44hrs post-transfection.  
 
Immunoprecipitation analysis 
For coimmunoprecipitation analysis of A3G and Vif, cell lysates were prepared as 
follows. Cells were washed once with PBS and lysed in 300 µl of lysis buffer (50 mM 
Tris, pH 7.5, 150 mM NaCl, 0.5% Triton X-100). The cell extracts were clarified at 13,000 
_ g for 3 min, and the supernatant was incubated on a rotating wheel for 1 h at 4°C 
with Anti-HA High Affinity Matrix (ROCHE). Immune complexes were washed three 
times with 50 mM Tris, 300 mM NaCl, and 0.1% Triton X-100, pH 7.4. Bound proteins 
were were eluted from beads by heating them in sample buffer for 5 min at 95°C and 
analyzed by immunoblotting. 
 
Immunoblotting  
For the detection of intracellular proteins, whole-cell-lysates were prepared as follows. 
Transfected 293T cells were washed once with room-temperature phosphate-buffered 
saline (PBS) and were suspended in RIPA supplemented with 0, 1% of Triton X and anti-
protease (500µl/106 cells). Cell lysates were mixed with equal volume of sample buffer 
(4% sodium dodecyl sulfate [SDS], 125mM Tris-HCL [ph= 6,8], 10% 2-mercaptoethanol, 
10% glycerol, and 0,02% bromphenol blue). Proteins were solubilized by boiling for 10 
min at 95ºC. Proteins were separated by 12% SDS-polyacrylamide gel electrophoresis 
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and were transferred to polyvinylidene difluoride membranes and reacted with 
appropriate antibodies as described in the text. Membranes were then incubated with 
horseradish peroxidase (HRP)-conjugated secondary antibodies (Amersham 
Biosciences, Piscataway,NJ) and visualized by enhanced chemiluminescence 
(Amersham Biosciences). 
 
Preparation of virus stocks 
Virus stocks were prepared by transfection of 293T cells with appropriate plasmid 
DNAs. Virus-containing supernatants were harvested 40 to 44 hours after transfection. 
Cellular debris was removed by centrifugation (3 min, 3,000 X g), and unconcentrated 
clarified supernatants were used for infectivity assays. For determination of viral 
infectivity, unconcentrated clarified supernatants were used for the infection of HeLa 
P4 cells.  
 
Infectivity assay  
To determine viral infectivity, viral stocks were collected and the viral titer determined 
and normalized by the amount of the protein p24 detected by immunoassay. Hela P4 
cells were infected with 100µl of unconcentrated virus supernatant. Briefly, 1,5X104 
cells were plated in a 96-well plate the day before infection. Forty-eight hours after 
infection of P4 cells, the single-cycle titer of viruses produced was determined by 
quantification of the β-galactosidase activity in P4 lysates, using a colorimetric assay 
based on the cleavage of chlorophenolred-β-D-galactopyranoside (CPRG) by β-
galactosidase (Eustice D., et al. 1991). Briefly, following elimination of the supernatant, the P4 
cells were lysed in 100µl of lysis buffer (MgCl2 5mM, NP40 0,1% in phosphate buffered 
saline) and 100µl of reaction buffer (CPRG 6mM in lysis buffer) was added to the cell 
lysates and incubated from between 5 min and 2 h at 37ºC. Optical densities in the 
reaction wells were read at 550nm with a reference filter set at 620nm.  
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Table 1. 
Oligonucleotide Sequence (5’ – 3’) 
Zip-Apo-F- XhoI ccg ctc gag aag cct cac ttc aga aac aca gtg g 
Zip-Apo-R-ClaI cca tcg atg gtt aag cat aat cag gaa cat cgt aag gat atc cac cgt ttt cct gat tct gga 
gaa tgg 
SLQ-Vif-NIH-F ctg cta  gtg cca agt atg ctg ctg ctc cta cct tgt tat gtc ctg ctt 
SLQ-Vif-NIH-R gca gca tac ttg gca cta gca gca tta ata aaa 
Zip- Vif-Full- XhoI ccg ctc gag gaa aac aga tgg cag gtg atc att g 
Zip-Vif-R- ClaI cca tcg atg gct aca gat ctt ctt cag aga tga gtt tct gct cgt gtc cat tcg ttg tat ggc tc 
Zip-VifC-F-XhoI ccg ctc gag gac cta gca gac caa cta att cat ctg 
Zip-Vif-R-ClaI cca tcg atg gct agt gtc cat tcg ttg tat ggc 
GFP-XhoI-F ccg ctc gag gtg agc aag ggc gag gag c 
GFP-ClaI-R cca tcg atg gtc act tgt aca gct cgt cca tgc cga g  
Vif-R1 cgg aat tcc gat gga gaa ccg gtg gca gg 
 Vif-GGG-R-NotI ttt tcc ttt tgc ggc cgc ggt gtc cat tca ttg tat ggc tcc 
APO-F-RI cgg aat tcc gat gaa gcc tca ctt cag aaa cac ag 
APO-GGG-R-NotI ttt tcc ttt tgc ggc cgc gtg aac ctc cac ctc cgg acc cac cac ctc cag agc cac cgc cac 
cgt ttt cct gat tct gga gaa tgg c                                                                    
Zip-AP-NotI-F aag gaa aaa acg cgg ccg cac cat ggc aag cga gca gct gg 
Zip-AP-AscI-R agg cgc gcc cct gcg cga gtt ttt ttt cca atg 
A3G-HA-Not-F aag gaa aaa agc ggc cgc taa cct ata tgt atc ctt acg atg ttc ctg att atg ctt cta agc ctc 
A3G-GGG-AP-R gcc tgc aat tct ttt ttg agg gct gaa cct cca cct cct ccg gac cca cca cct cca gag cca 
ccg cca ccg ttt tcc tga ttc tgg aga atg gc 
A3G-AP-R ccg ctc gag tta ctg cgc cag ttc ctt ttt cag agc ttg taa ctc cca ctt cag ctg cgc aag ttc 
ttt ttt gtt tgc ctg caa ttc ttt ttt gag gg 
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RESULTS 
 
Functional analysis of leucine zipper fusion proteins. 
In order to study the in vivo interaction between Vif and A3G we used a strategy that 
allows for the spatially directed association of Vif and A3G proteins by oligomerization- 
assistance of two dimerizing GCN4 leucine zipper (Zip) domains. 
This way, we fused both proteins to the N-terminal and C-terminal domains of the Zip 
sequence. Both N- and C-terminal fusions were expressed in vivo and tested for their 
ability to functionally interact with each other.  
First, we examined the ability of Vif fusion proteins to degrade A3G WT and Z-A3G in 
293T cells (Fig. 1). Western blot analysis showed that both Vif fusion proteins were able 
to degrade A3G WT indicating that the presence of Zip in fusion with Vif did not have 
any deleterious effect on its activity (Fig. 1 C). The same was observed for Z-A3G fusion 
protein, which was equally degraded by Vif WT and Z-Vif (Fig. 1 D). The Z-VifSLQ 
mutant, in which the SLQ domain in Vif was replaced by alanines, was used as a control 
for the absence of A3G degradation confirming the integrity of our constructs (Fig. 1 D).  
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Fig.1. Analysis of Vif fusion proteins functionality. (A), (B) Schematic representation of A3G and Vif 
leucine zipper fusion proteins. 293T cells were cotransfected in 6-well-plates with the plasmids (C) A3G WT 
(1 µg) in the presence of Vif-Z (2 µg) and Z-Vif (2 µg) or (D) Z-A3G (1 µg) in the presence of Vif WT (2 µg), Z-
VifSLQ (2 µg), and Z-Vif (2 µg). 40-44 h later cells were lysed and subjected to western blot analysis.  
 
 
C-terminal domain of Vif is necessary but not sufficient to suppress A3G 
Previous work demonstrated that the N-terminal region of Vif was involved in binding 
to A3G (Marin M, et al., 2003; Schrofelbauer, B. et al, 2006; Simon, V., 2005; Tian, C. et al, 2006; Indrani P. et al, 2006). 
Regarding this, we constructed a Vif fusion protein where the N-terminal region had 
been replaced by the Zip sequence. In this way, the presence of leucine zipper 
sequence at the N-terminal region of Vif would allow the protein to functionally 
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interact with Z-A3G. Therefore, we used this system to evaluate whether the C-
terminal domain of Vif alone was sufficient to suppress the activity of A3G. To achieve 
this, the C-terminal portion of Vif was fused to Zip (Z-Vif 98-192) and the ability of the 
fusion protein to carry Z-A3G for degradation and inhibit its antiviral activity was tested 
(Fig. 2). Interestingly, Z-Vif 98-192, which contains the HCCH and the SLQ motifs, had 
no detectable effect on Z-A3G steady-state (Fig 2 B, lane 2) and was not able to 
suppress its antiviral activity (Fig. 2 D). 
In contrast, the same was not observed when the Z-Vif was used instead of Z-Vif 98-
192. In fact, degradation of Z-A3G protein was higher than the one observed in the 
presence of Vif WT, as seen in figure 2 B (lanes 3 and 4). This seems to indicate that the 
fusion of A3G and Vif to Zip allowed a stabilization of both proteins in a way that 
favoured this interaction. Therefore, we conclude that despite the interaction of Vif 
and A3G through the N-terminal Zip domain, the C-terminal portion of Vif was not 
sufficient to carry Z-A3G for degradation. This result indicates that the C-terminal 
domain of Vif is necessary but not sufficient to suppress A3G, suggesting that the 
interaction between Vif and A3G must require specific domains localized at the N-
terminal region of Vif protein that were absence in this construct. 
 
Vif-A3G interaction through oligomerization assisted by antiparallel leucine zippers 
Parallel and antiparallel coiled coils usually associate because of the interaction of 
hydrophobic residues that are buried at the peptide-peptide interface and also due to 
charge-charge interactions between “edge” positions (Aber T. 1992; Adamson J. G. et al., 1993; Lupas A. 
1996).  
In order to study the topology of the Vif-A3G interaction we fused strongly interacting 
antiparallel leucine zippers to the N- and C-terminal domains of Vif and A3G, 
respectively. By changing the placement of charge-charge interactions, that could 
result in charge-charge clashes in the parallel orientation, we aimed to test whether 
antiparallelism would favour the interaction between Vif and A3G in order to better 
understand the topology of this interaction. The results obtained showed that the 
antiparallel orientation of Vif-A3G did not favour the interaction between the two 
fusion proteins resulting in less than 25 % degradation of A3G. (Fig. 2 C, lane 2). 
Cooperation of Vif’s N-and C-terminal domains for A3G degradation 
 88 
 
Interestingly, antiparallel interaction resulted in an efficient inhibition of A3G antiviral 
activity (Fig. 2 D). This was the only situation where A3G activity was inhibited in the 
absence of degradation. As seen in Fig 2 D, A3G activity was greatly inhibited when 
both proteins interacted in a parallel orientation. The only exception occurred when 
the N-terminal domain of Vif was absent (Z-Vif 98-192). 
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Fig. 2. Analysis of A3G fusion protein degradation by parallel and antiparallel leucine zipper orientations. 
(A) Schematic representation of the A3G and Vif leucine zipper fusion proteins used. 293T cells were 
cotransfected in 6-well-plates with the plasmids: (B) Z-A3G (1 µg) in the presence of Vif WT (2 µg), Z-Vif (2 
µg), or Zip-Vif 98-192 (2 µg) plasmids; (C) A3G-NZ (1 µg) in the presence of CZ-Vif (2 µg), or Vif WT (2 µg) 
plasmids. 40-44 h later cells were lysed and subjected to western blot analysis.(D) Phenotypic analysis of 
A3G Zip fusions antiviral activity: HIV-1ΔVif virions were produced by cotransfecting 293T with pNL4.3ΔVif 
(3 µg) in the presence of WT or Zip fusion proteins in the same conditions as described above. 48 h after 
transfection viruses were collected and used to infect HeLa P4 cells (1.5X10
4
). Relative infectivity values 
were detected by measuring the absorbance of β-gal activity at 550/620nm, in a CPRG assay.  
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One of the advantages of this strategy is that it allowed us to fuse both Vif and A3G to 
the C- and N- terminal domains of the Zip sequence. First, we showed that Z-Vif was 
able to degrade Z-A3G protein and inhibit the antiviral activity of the latest (Fig. 2 B, D).  
In a different attempt to assess the topology of the in vivo interaction of both proteins, 
we decided to express both proteins upstream and in fusion with the leucine zipper 
sequence. The schematic representation of the Zip fusions is represented in figure 3 A.  
Initially, we expected to observe the same degradation profile in both cases, as all the 
fusion proteins were shown to be active in the context of their ability to inhibit HIV-1 
infection (Z-A3G and A3G-Z) and A3G WT antiviral activity (Z-Vif and Vif-Z) (Fig. 3 E). 
However, when we cotransfected A3G-Z in the presence of Vif-Z the same was not 
observed. In fact, Vif-Z only slightly reduced the expression of A3G-Z in 293T cells, 
when compared to Vif WT (Fig. 3 C, lane 2).  
The explanation for this discrepancy must rely on the inability of Vif-Z protein to 
interact with the Cullin5-EloB/C complex and carry A3G-Z protein for degradation. 
Homodimerizing leucine zipper interactions are very strong interactions and we 
hypothesized that when Vif-Z is coexpressed with A3G-Z, the C-terminal domain of 
both fusion proteins is in such a close proximity that does not allow the Vif-Cul5-BC 
complex to be formed and consequently, ubiquitination of A3G-Z protein does not 
occur. In the first situation, when Z-Vif is coexpressed in vivo with Z-A3G, the 
interaction occurs through the N-terminal domain of both proteins, allowing the C-
terminal domain of Z-Vif protein to be free to recruit the Cullin5-EloB/C complex and 
suppress the activity of Z-A3G.  
These results show, once more, the importance of the C-terminal domain of Vif to carry 
an efficient degradation of A3G protein and are in agreement with previously work that 
showed that the interaction between Vif and A3G alone is not sufficient to suppress 
the activity of A3G (Yu, X., et al., 2003; Mariana Marin et al, 2003).  
Furthermore, following the same approach used for Z-A3G, we coexpressed A3G-Z in 
the presence of Vif WT, Z-Vif, and Z-Vif 98-192 in 293T and looked for A3G-Z 
degradation. The schematic representation of the expected spatial orientation of the 
fusion proteins is represented in figure 3 B. Interestingly, when compared with the 
results showed in figure 2 B, neither Z-Vif or Z-Vif 98-192 were able to take A3G-Z for 
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degradation (Fig. 3 D) and inhibit its antiviral activity (Fig. 3 E). This seems to indicate 
that both proteins need to be in close proximity in order for Vif to be able to inhibit 
A3G. 
 
Fig. 3. Analysis of degradation profiles of A3G-Z fusion protein. (A), (B) Schematic representation of A3G 
and Vif leucine zipper fusion proteins used. 293T cells were cotransfected in 6-well-plates with the 
plasmids A3G-Z (1 µg) in the presence of Vif WT (2 µg), Vif-Z (2 µg) (C) or with Z-Vif (2 µg) and Z-Vif98-192 (2 
µg) plasmids (D). 48 h later cells were lysed and subjected to western blot analysis. (E) Phenotypic analysis 
of A3G-Z antiviral activity in the presence HIV-1ΔVif virus. Viral stocks were produced by transfection of 
293T in the same conditions as described above. 48 h after transfection viruses were collected and used to 
infect HeLa P4 cells (1.5X10
4
). Relative infectivity values were detected by measuring the absorbance of β-
gal activity at 550/620nm, in a CPRG assay.  
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Specific in vivo interaction between Vif and A3G  
To determine whether the interaction between Vif and A3G was specific for these two 
proteins we constructed a plasmid encoding the protein EGFP downstream and in 
fusion with the Zip sequence (Z-EGFP). Next, we coexpressed Z-EGFP and Z-Vif in 293T 
cells and determined if the EGFP fusion protein was degraded by Vif.  
The result obtained showed that the steady-state of the Z-EGFP protein was not 
affected by the presence of Vif, indicating that the Vif protein was unable to take EGFP 
protein for degradation despite the interaction through their N-terminal Zip domain.  
This led us to conclude that the interaction between Vif and A3G is specific for these 
two proteins requiring the involvement of specific domains in the N-terminal region of 
Vif.  
 
 
Fig. 4. Determination of EGFP degradation by Vif.  (A) Schematic representation of EGFP and Vif Zip 
fusions. (B) 293T cells were cotransfected in 6-well-plates with the plasmids Z-EGFP (1 µg) in the presence 
of Vif WT (2 µg) or Z-Vif (2 µg). 48 h later cells were lysed and subjected to western blot analysis. 
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DISCUSSION 
In vitro binding assays and cell based assays have been commonly used to identify 
binding regions between Vif and A3G. However, these approaches offered some 
disadvantages as the in vitro processing steps make it difficult to assess the in vivo 
significance of the results. In addition, cell based assays are often complicated due to 
the relative instability or mislocation of Vif deletion mutants, probably due to improper 
folding. 
In this study, we used a novel approach for studying the Vif-A3G interaction in vivo. The 
strategy used ensures that both proteins will be brought together, regardless of their 
structure, in a directed and productive manner and provided a valuable toll in 
understanding the role of Vif’s N- and C-terminal domains in the in vivo interaction 
with A3G.  
Our results showed that both Vif and A3G were able to interact through their leucine 
zipper N-terminal domain. However, Z-Vif 98-192, which contains only the C-terminal 
domain of Vif, was not able to induce the degradation of A3G despite having all the 
domains required for the recruitment of Cul5, EloB and EloC E3 ubiquitin ligase 
complex. Therefore, we concluded that the reduced ability of Vif to mediate A3G 
degradation could not be attributed to a reduced interaction with the E3 ligase 
complex. It is possible that the absence of one or more specific domains in the N-
terminus of Vif may have interfered with the binding to A3G. In fact, a previous work 
reported the existence of a Vif mutant, VifL72S, that had its ability to suppress A3G 
reduced in 75% despite being able to efficiently bind to A3G and assemble with the 
ubiquitin ligase complex (He Z. et al. 2008). 
In addition, it was recently found that in one particular human T cell line, CEM-T4, A3G 
and A3F were unable to block HIV-1 replication, even in the absence of Vif (Han Y. et al., 
2008). Further analysis indicated that this cell line lacked a cellular factor that was very 
critical for A3G/A3F antiviral activity. They suggested that in order to A3G/A3F inhibit 
HIV-1 replication it required the presence of a cell factor that was present in some 
human cell lines but absent in others.  
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Thus, it is possible that the binding of Vif to A3G must involve an additional co-factor 
that is probably linked to the N-terminus of Vif and may be responsible for the 
interaction and consequent degradation of A3G. 
When we tested the topology of Vif-A3G interaction, antiparallel orientation resulted 
in only approximately 25% degradation of A3G indicating that this orientation did not 
favour the interaction of Vif with A3G. However, despite not being degraded, A3G 
antiviral activity was inhibited. Thus, Vif may use an alternative mechanism to 
inactivate A3G without accelerating its destruction in the 26S proteasome.  
From an evolutionary perspective, it is possible that the topology of Vif-A3G interaction 
may have evolved from an antiparallel to a parallel interaction favouring inactivation of 
A3G through proteasomal degradation. 
In general, these results underline the importance of the topological orientation of Vif 
and A3G for an efficient degradation of the latest. We suggest, based on our results, 
that Vif-A3G interaction is indirect and can be abrogated by changing the spatial 
orientation of the two proteins. In addition, the presence of a co-factor favouring the 
interaction between both proteins is an appealing hypothesis.  
Interaction of Vif with EGFP through the Zip domain did not result in EGFP degradation. 
This result shows that the Vif-targeted degradation of A3G is specific and supports the 
previous hypothesis of an involvement of a specific additional co-factor in the 
interaction between Vif and A3G.  
Specific residues in both Vif and A3G have been previously described as being involved 
in the binding between the two proteins. However, in the present study, binding 
between both proteins through specific regions was overcome by the presence of Zip 
domain. Then, if the C-terminal domain of Vif is not sufficient to target A3G for 
degradation in the proteasome, it is possible that the N-terminal domain of Vif may be 
involved in the binding to A3G through a specific co-factor that it’s linked to it.  
In conjunction, our results support a previous report that raises the hypothesis of the 
existence of an endogenous co-factor that may be required for an efficient interaction 
and subsequent inactivation of A3G in the cell.  
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This strategy also proved to be efficient in providing a general approach for protein 
dissection and interaction domains studies, and can be used in the future as a novel 
approach for a rapid in vivo screening of Vif-A3G interacting domains. It also offers the 
advantage of allowing it to be done in an in vivo environment without any deleterious 
effect on the structure and activity of the proteins. 
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ABSTRACT 
The Vif-APOBEC3G interaction is of particularly interest in a way that it provides a 
compelling target for novel therapeutic strategies for treating HIV-1 infections. 
Disruption of A3G-Vif interaction is predicted to rescue A3G expression and virion 
packaging, therefore stimulating natural antiviral infectivity. In order to facilitate the 
rational design of inhibitors of the A3G-Vif interaction molecular genetics experiments 
using alanine-scanning mutations and multiple substitutions at key residues have been 
employed to define features of APOBEC3G that are involved in the interaction with Vif. 
To study this interaction, we used a β-lactamase complementation assay in which the 
inactive domains of the enzyme are fused to each of the proteins in question. The 
interaction of our complementary proteins will result in a functional β-lactamase 
capable of hydrolysing a substrate measurable by spectrophotometry. In this study, we 
produced several mutants of both Vif and A3G bearing mutations on key residues that 
are thought to be crucial for the interaction between these two proteins. As a result, we 
were able to achieve a quantitative assessment of HIV-1 Vif-A3G interactions, which 
allowed us to do a fine dissection of the regions involved in this interaction. We also 
used this strategy to study the interaction of Vif with other members of the APOBEC 
family. The results obtained indicate that the DRMR region in Vif may be involved in the 
selection of the APOBEC to inactivate. In addition, interaction of Vif with APOBEC2 (A2) 
indicates that the antiviral activity of the enzyme may not be necessarily dependent on 
the interaction with Vif. We suggest that despite the ability of A2 to interact with Vif, an 
additional co-factor may be required in order to A2 to be able to exert antiviral action. 
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INTRODUCTION 
APOBEC3G (A3G) is a single-stranded DNA cytidine deaminase that targets retroviral 
minus-strand DNA and has potent antiviral activity against diverse retroviruses. In 
order to successfully replicate in their hosts, lentiviruses such as HIV-1 and simian 
immunodeficiency virus (SIV) encode the Vif protein, which induces polyubiquitination 
and degradation of multiple APOBEC3 (A3) molecules (Conticello SG. et al, 2003; Liu B. et al. 2005; Liu B. et 
al. 2004; Marin M. et al. 2003; Mehle A. et al. 2004; Sheehy A. et al. 2003; Stopak A. et al. 2003; Yu X  et al. 2003). All members 
of the A3 family have one (A3A, A3C, and A3H) or two (A3B, A3DE, A3F, and A3G) 
cytidine deaminase motifs containing a conserved consensus sequence that 
coordinates Zn2+, a glutamic acid residue involved in proton shuttling, and critical 
aromatic residues involved in RNA binding (Jarmuz A et al. 2002). Followed by A3G, APOBEC3F 
(A3F) displays the most potent effects against HIV (Bishop KN et al 2004). Other A3 family 
members, A3A, A3B, and A3C have weaker anti-HIV-1 activities and are only partially 
degraded by Vif (Marin M. et al. 2008). APOBEC2 (A2) is a member of the family of 
polynucleotide cytidine deaminases (CDAs). However, like other editing enzymes of the 
cytidine deaminase superfamily, A2 has low, but definite, intrinsic cytidine deaminase 
activity (Liao W. et al. 1999).  
Disruption of A3G-Vif interaction is predicted to rescue A3G expression and virion 
packaging, therefore stimulating natural antiviral infectivity. Identification of protein 
biding partners between Vif and A3G proteins is one of the major challenges for the 
development of new antiviral drugs.  
In vitro binding assays and cell based assays have been commonly used to identify 
binding regions between Vif and A3G. However, these approaches offer some 
disadvantages as the in vitro processing steps make it difficult to assess the in vivo 
significance of the results, and cell based assays are often complicated due to the 
relative instability or mislocation of Vif deletion mutants, probably due to improper 
folding (Marin M  et al, 2003).  The yeast two-hybrid analysis method it’s been commonly used 
in the study of protein-protein interactions (Fields S and Song O. 1989), although this method has 
significant limitations, in particular because it must be made in yeast, it requires 
nuclear importation and function, it can be confounded by proteins that activate 
transcription in the absence of a binding partner, and originates abundant false 
positives (Magliery T. J., et al, 2004). In order to circumvent some of these problems a number of 
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assays have been developed, which include bacterial two-hybrid systems and 
functional interaction traps based on fusion of dissected fragments (Hays, L. et al. 2000; Pelletier 
et al., 1999; 9; Zhu, H. et al. 2001). 
In this work we used a new strategy based on interaction-assisted folding of rationally 
designed fragments of enzymes for studying Vif-A3G interactions. Protein Fragment 
Complementation Assays (PCA) have been used for many purposes, including the study 
of protein folding (Ladurner, A. et al, 1997; de Prat Gay et al, 1994), gene structure (Ullmann A. et al, 1967), the 
role of primary sequence in determining tertiary structure of proteins (Taniuchi, H. et al, 1971), 
the role of tertiary structure elements in enzyme catalysis (Shiba, K. et al, 1992), to probe 
macromolecular assembly (Tasayco, M. L. et al, 1992), and to test theories on protein evolution 
(Bertolaet, B. L. et al, 1995). More recently, Pelletier and others (5, 6, 7, 18, 20) have used the protein 
fragment complementation approach for the in vivo detection of protein-protein 
interactions. PCA relies on engineering reporter protein fragments that exhibit no 
functional activity by themselves and do not spontaneously fold. When these 
fragments are fused to interacting proteins, the interaction of the hybrid proteins will 
bring the two reporter fragments into proximity. The fragments will then fold into the 
active 3D structure of the complete reporter protein. Several proteins have been 
described as reporter proteins in PCAs such as, β-lactamase, dihydrofolate reductase, 
Renilla, luciferases, and GFP and yellow fluorescent protein (YFP) (Galarneau et al, 2002; Spotts, J. 
M., et al, 2002; Remy, I. et al., 2001; Paulmurugan, R., et al, 2002; Luker, K. E., et al, 2004; Ghosh, I., et al, 2000; Hu, C. D., et al, 2002; 
Remy, I., et al, 2004). GFP and YFP PCAs have particularly been simple for detection and library 
screening of cytosolic, membrane, and nuclear protein-protein and protein-RNA 
interaction (Remy, I., et al, 2004; Remy, I., et al 2004; de Virgilio, M., 2004; Rackham, O. et al, 2004).  
We used the PCA technique based on the enzyme TEM-1 β-Lactamase to study the 
interaction between HIV-1 Vif and the human A3G protein. This strategy is well 
described elsewhere (Michnick SW et al. 2000; Pelletier JN et al, 1998) and offers the advantage of 
allowing us to perform the assays in an in vivo system, without the requirement for co-
immunoprecipitation assays. In parallel, we have also used co-immunoprecipitation in 
order to do a comparative analysis and validate the results obtained. 
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EXPERIMENTAL PROCEDURES 
 
Plasmids 
pcDNA3.1-A3G-HA (1) was used for the expression of C-terminally epitope- tagged wild 
type human A3G protein and was a kindly supplied by Strebel K.. pcDNA-HVif was 
obtained from the NIH AIDS Research and Reference Reagent Program (Nguyen, K. L., 2004 ). 
pcDNA3.1 Zeo(+) was obtained from the NIH (catalogue: 10077). The Vif-defective 
molecular clone pNL4.3ΔVif has been previously described (Karczewski, M. K., and K. Strebel. 1996) 
and was used for the production of virus stocks. Homodimerizing GCN4 parallel coiled-
coil leucine zipper (Zip) in fusion with β-lactamase fragments was kindly supplied by W. 
Michnick and has been previously described (Galarneau et al, 2002). HVif mutants YRHHY>A5, 
DRMR>A4 and DRMR>SEMQ without the SLQ>A3 mutation used in the degradation 
assays were a kind gift from Pathak V. 
 
DNA constructs 
Fragments of β-lactamase were obtained from the original plasmid pcDNA3.1-Zip-
15a.a-BLF[1] (ZIP-B1 and ZIP-B2) and pcDNA3.1-Zip-15a.a-BLF[2] (Galarneau et al, 2002) and was 
used as the cloning vector for the subsequent steps. Each cloning vector was linearized 
with restriction enzymes NotI/AscI to remove Zip sequence. For the insertion of HVif, 
A3G-HA, A3F-HA, A3C-HA, A2-HA in fusion with β-lactamase fragment , each sequence 
was amplified by PCR using specific oligonucleotides (HVif: Not-HVif-F and Asc-HVif-R; 
A3G-HA: apo3g-amp-F and 4BL-B1-Asc-R; A3F-HA: F-not and R-Asc; A3C-HA: Apo3C-F-
Not and Apo3C-R-Asc; A2-HA: a2F-Not and a2R-Asc). PCR products were digested with 
NotI/AscI restriction enzymes and ligated to linear vector. This originated the plasmids: 
Vif-B2, A3G-B1, A3G-B2, A3F-B1, A3C-B1, and A2-B1. 
Mutation of SLQ region in pcDNA-HVif was accomplished by PCR overlap method of 
pcDNA-HVif originating the Vif SLQ>AAA mutant. Vif SLQ>AAA mutant was generated 
using oligos: SLQ-Vif-NIH-F and SLQ-Vif-NIH-R. Substitution of Vif YRHHY and DRMR 
regions by alanines was accomplished by PCR using specific oligonucleotides (Vif 
YRHHY: Vif-YRHHY-F and Vif-YRHHY-R; Vif DRMR: Vif-DRMR-F and Vif-DRMR-R). Vif 
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DRMR region was replaced by SEMQ sequence by PCR using oligonucleotides: Vif-
SEMQ-F and Vif-SEMQ-R, originating Vif SEMQ plasmid DNA. Vif YRHHY, DRMR, and 
SEMQ mutations were introduced as described in the previous originated Vif SLQ>AAA 
sequence.  
A3G mutants R122A, W127L, and D128K were generated by PCR using specific 
oligonucleotides (A3G R122A: A3g-R122A-F and A3g-R122A-R; A3G W127L: A3g-127L-F 
and A3g-127L-R; A3G D128K: A3g-D128K-F and A3g-D128K-R). All Vif and A3G PCR 
generated mutants were digested with restriction enzymes NotI/AscI and ligated to the 
linear vector in fusion with β-lactamase fragment. This originated the plasmids: 
VifSLQ>A3-B2, VifSLQ>A3 + YRHHY>A5-B2, VifSLQ>A3 + DRMR>A4-B2, VifSLQ>A3 + SEMQ>A4-B2, A3GR122A-B1, 
A3GW127L-B1, A3GD128K -B1. All constructs were subjected to sequencing analysis for the 
detection of undesirable mutations. The sequence of primers used is listed in table 2 at 
the end of this section. 
 
Antisera 
For detection of A3G HA-epitope-tagged, an anti-HA HRP monoclonal antibody (Roche) 
was used. Anti-HA High Affinity Matrix (ROCHE) was used for co-immunoprecipitation 
assays. Vif protein was detected using the anti-Vif anti-rabbit antibody (catalogue 
number: 2221) supplied by the NIH AIDS Research and Reference Reagent Program 
Catalogue. Detection of GFP protein was carried by using anti-GFP mouse monoclonal 
antibody (Roche). GAPDH was used as a loading control and the antibody used was 
purchased from Santa-Cruz Biotechnology (GAPDH 6C5: sc-32233).  
 
Cell culture and transfections 
Human embryonic kidney (HEK) cell line 293T,  and P4 cells (HeLa-CD4 LTR-LacZ) were 
obtained from the NIH AIDS Research and Reference Reagent Program Catalogue and 
were cultivated in Dulbeco`s modified Eagle’s medium (DMEM) containing 10% foetal 
calf serum, 1X penicillin-streptomycin-fungizone mixture and L-Glutamine (Bio 
Whittaker). For transfections, 293T cells were grown in 60-mm plates to about 70% 
confluency. Cells were transfected using the calcium phosphate precipitation method. 
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A total of 30 μg of plasmid DNA was used, unless otherwise stated. Total amounts of 
transfected DNA were kept constant in all samples of any given experiment by adding 
empty-vector DNA pcDNA3.1 empty plasmid DNA as appropriate. Cells were harvested 
typically 40-44hrs post-transfection.  
 
Immunoprecipitation analysis 
For coimmunoprecipitation analysis of A3G and Vif, cell lysates were prepared as 
follows. Cells were washed once with PBS and lysed in 500 µl of lysis buffer (50 mM 
Tris, pH 7.4, 50 mM NaCl, 1 mM NaCl, and 1% Triton X-100) containing complete 
protease inhibitor cocktail (Roche). The cell extracts were clarified at 13,000 _ g for 3 
min, and the supernatant was incubated on a rotating wheel overnight at 4°C with 
Anti-HA High Affinity Matrix (ROCHE). Immune complexes were washed three times 
with 50 mM Tris, pH 7.4, 50 mM NaCl, 1 mM NaCl, and 1% Triton X-100 pH 7.4. Bound 
proteins were eluted from beads by heating them in sample buffer for 5 min at 95°C 
and analyzed by immunoblotting. 
 
Preparation of virus stocks 
Virus stocks were prepared by transfection of 293T cells with appropriate plasmid 
DNAs. Virus-containing supernatants were harvested 40 to 44 hours after transfection. 
Cellular debris was removed by centrifugation (3 min, 3,000 X g), and unconcentrated 
clarified supernatants were used for infectivity assays. For determination of viral 
infectivity, unconcentrated clarified supernatants were used for the infection of HeLa 
P4 cells.  
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Infectivity assay 
To determine viral infectivity, viral stocks were collected and the viral titer determined 
and normalized by the amount of the protein p24 detected by immunoassay. Hela P4 
cells were infected with 100µl of unconcentrated virus supernatant. Briefly, 1,5X104 
cells were plated in a 96-well plate the day before infection. Forty-eight hours after 
infection of P4 cells, the single-cycle titer of viruses produced was determined by 
quantification of the β-galactosidase activity in P4 lysates, using a colorimetric assay 
based on the cleavage of chlorophenolred-β-D-galactopyranoside (CPRG) by β-
galactosidase (Eustice D., et al. 1991). Briefly, following elimination of the supernatant, the P4 
cells were lysed in 100µl of lysis buffer (MgCl2 5mM, NP40 0,1% in phosphate buffered 
saline) and 100µl of reaction buffer (CPRG 6mM in lysis buffer) was added to the cell 
lysates and incubated from between 5 min and 2 h at 37ºC. Optical densities in the 
reaction wells were read at 550nm with a reference filter set at 620nm.  
 
β-Lactamase PCA colorimetric assay 
HEK 293T cells were split 24h before transfection at 1x105 in 6-well plates in DMEM 
containing 10% fetal calf serum, 1X penicillin-streptomycin-fungizone mixture and L-
Glutamine (Bio Wittaker). Cells were transfected with 1µg of each plasmid DNA using 
the calcium phosphate precipitation method. 48 hrs after transfection 5x106 cells were 
washed twice with PBS and resuspended in 100µl of 100mM phosphate buffer, ph 7.0, 
then lysed by three freeze-thaw cycles. Cell debris was removed by centrifugation at 
16,000g for 2 min at 4ºC. To test B-Lactamase activity, 100µl of phosphate buffer 
(100mM, ph 7.0) was added to each well to a final concentration of 60 mM, containing 
2µl of 10 mM nitrocefin (final concentration 100µM) and 20 µl of cell lysates, and 
diluted with deionised water.  
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Table 2. 
Oligonucleotide Sequence (5’ – 3’) 
apo3g-amp-F ata aga atg cgg ccg cta aac tat atg aag cct cac ttc aga aac aca 
gtc 
4BL-B1-Asc-R acc gcc acc ggc gcg cca aga agc gta gtc cgg aac gtc 
F-not ata aga atg cgg ccg cta aac tat atg tac ccg tac gac gtt ccg gac 
tac gct tct gcc cag aag gaa gag gct gc 
R-asc acc gcc acc ggc gcg cca ctc gag aat ctc ctg cag ctt g 
Apo3C-F-Not ata aga atg cgg ccg cta aac tat atg tac ccg tac gac gtt ccg gac 
tac gct tct aat cca cag atc aga aac ccg atg 
Apo3C-R-Asc acc gcc acc ggc gcg cca ctg gag act ctc ccg tag cct tc 
a2F-Not ata aga atg cgg ccg cta aac tat atg tac ccg tac gac gtt ccg gac 
tac gct tct gcc cag aag gaa gag gct gc 
a2R-Asc acc gcc acc ggc gcg cca ctt cag gat gtc tgc caa ctt ctc 
Not-HVif-F ata aga atg cgg ccg cta aaa tgg aga acc ggt ggc agg 
Asc-HVif-R acc gcc acc ggc gcg ccc gtg tcc att cat tga atg gct ccc 
A3G-R122A-F cgt tgc cgc act cta cta ctt ctg 
 A3G-R122A-R cag aag tag tag agt gcg gca acg 
A3G-127L-F cct cta cta ctt ctt gga ccc aga tta c 
A3G-127L-R gta atc tgg gtc caa gaa gta gat gag g 
A3G-D128K-F cta ctt ctg gaa gcc aga tta cca g 
A3G-D128K-R ctg gta atc tgg ctt cca gaa gta g 
SLQ-Vif-NIH-R ctg cta gtg cca agt atg ctg  ctg ctc ct acct tgt tat gtc ctg ctt  
SLQ-Vif-NIH-F gca gca tac ttg gca cta agc agc att taa taa aa 
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Vif-SEMQ-F agc gaa atg cag att aac acc tgg aag cgc ctg 
Vif-SEMQ-R cca ggt gtt aat ctg cat ttc gct cac ctg cca cac aat cat cac c 
Vif-YRHHY-F gca  gct gca gct gct gag agc acc aac ccc aag att ag 
Vif-YRHHY-R cg caa agc taa gga ctg gtt cgc agc gct gca gca gct gct gag agc 
Vif-DRMR-F gca gct gca gct att aac acc tgg aag cgc ctg  
Vif-DRMR-R cca ggt gtt aat agc tgc agc tgc cac ctg cca  cac aat cat cac c 
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RESULTS 
 
The Protein Fragment Complementation (PCA) strategy. 
In order to study the interaction of Vif with A3G and other APOBEC proteins, a new 
strategy based on protein-assisted folding of rationally designed fragments of enzymes 
was used based on the enzyme TEM-1 β–lactamase (EC :3.5.2.6). This involves a simple 
colorimetric in vitro assay using the CENTA substrate. TEM-1 β–lactamase is a relatively 
small monomeric protein that has been well characterized functionally and structurally 
(Matagne A. et al., 1998; Philipon A. et al., 1998). It has been shown to be easily expressed and it is not 
toxic to prokaryotic and eukaryotic cells (Matagne A. et al., 1998; Philipon A. et al., 1998). Furthermore, 
PCA based on β–lactamase can be used in eukaryotes and many prokaryotes without 
any detectable background activity (Galarneau A. et al., 2002). A schematic representation of the 
PCA principle is represented in figure 1.  
 
 
 
 
Fig.1. β-lactamase protein fragment 
complementation. Interaction between two 
proteins (A and B) fused to fragments of β-
lactamase brings fragments into proximity 
allowing correct folding and reconstitution of 
enzyme activity. The in vivo assay uses a 
substrate (CENTA) that is hydrolysed by the of 
β-lactamase enzyme. Hydrolysis rates are 
determined by measuring absorbance at 450 
nm.  Figure adapted from: Galarneau, A. et 
al., 2002. Nat. Biotechnol. 20: 619-622. 
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Detection of HIV-1 Vif and human A3G interactions using the PCA principle.  
The interaction between Vif and A3G has been extensively studied and characterization 
of specific domains involved in the binding between the two proteins is crucial for the 
design of new therapeutic strategies. In order to study this interaction, we replaced the 
GCN4 leucine zipper (ZIP) sequence from the original plasmid by Vif and A3G proteins. 
Interaction between Vif and A3G proteins will bring the two fragments of the β–
lactamase, termed here as B1 and B2, together allowing the reconstitution of the 
reporter enzymatic activity. Therefore, by using the PCA principle we aim to 
characterize several specific domains that have been previously shown to be involved 
in Vif-A3G interaction. First, we wanted to validate PCA technique by studying the in 
vivo interaction between A3G and Vif wild-type proteins. This way, we fused both 
proteins to each of the fragments of the β-lactamase enzyme and expressed them in 
vivo in 293 T cells. Two days after transfection cell lysates were analyzed for the 
presence β-lactamase enzymatic activity, which would be indicative of an interaction 
between Vif and A3G. We can see from figure 2 B, that β-lactamase hydrolysis rate was 
highest in the presence of Vif SLQ>AAA-B2 and A3G-B1. In vivo detection of Vif-A3G 
interaction by PCA it’s possible when we replace the SLQ region in Vif by alanines, as 
Vif is no longer able to carry A3G for proteasomal degradation. This will allow us to 
increase the detection of both proteins in the cell lysates and consequently, if 
interaction occurs, the two fragments of β-lactamase will come into proximity and 
enzymatic activity is restored. As shown in the lower panel of figure 2 B, when Vif wild-
type is used, interaction with A3G will lead to the degradation of both proteins in the 
proteasome and consequently no enzymatic activity is detected. Therefore, we decided 
to continue our assays using the SLQ mutated version of Vif instead of wild-type Vif.  
In addition, when A3G-B1 and A3G-B2 were expressed together in 293T we detected a 
high hydrolysis rate of CENTA substrate, similar to the one obtained for Vif SLQ>AAA-B2 and 
A3G-B1 (Fig. 2 B upper panel). Thus, in vivo dimerization of A3G can be used in order to 
test the general applicability of PCA assay. 
In addition, we also tested the generalizability of PCA by testing the in vivo interaction 
of two known interacting pairs of GCN4 homodimerizing leucine zipper (ZIP) proteins 
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(Fig. 5 C). Non-interaction proteins, A3G-B1 and Zip-B2 were also used as a negative 
control of interaction (Fig. 5 C). 
 
Fig 2. Validation of PCA colorimetric assay. A. Schematic representation of Vif, VifSLQ>A3 and A3G fusions to 
the β-lactamase fragments B2 and B1, respectively. B. Upper panel: In vivo hydrolysis rate (abs. unit 
measured at 450 nm) of CENTA for Vif, VifSLQ>A3 and A3G interacting pairs of proteins. Hydrolysis rate of 
CENTA for fusion proteins alone is also represented as negative controls. Mean hydrolysis rate was 
determined for three independent experiments and normalized for cell number and protein content. 
Briefly, 20 µg of each plasmid, Vif-B2, Vif SLQ>A3–B2, A3G-B1, ZIP-B1, and ZIP-B2, and 10 µg of each A3G-B1 and 
A3G-B2 was used for transfections in 60-mm plates. DNA amounts were adjusted to 30 µg using empty 
pcDNA3.1 vector DNA. 48 hrs after transfections, media was removed and cells were washed twice in PBS 
and were suspended in 100 µl of 100 mM phosphate buffer (K2HPO4 50mM, pH=7) for the PCA assay. 
Lower panel: Western blotting analysis of cell lysates and co-immunoprecipitation. 1/3 of the HEK 293T 
cells transfected for the PCA assay were collected for co-immunoprecipitation of Vif and A3G proteins 
using Anti-HA-High-Affinity-Matrix (ROCHE). C. Homodimerizing GCN4 leucine zipper are known to interact 
in vivo and were tested to assess the generalizability of the assay. The data are averages of triplicates with 
the indicated standard deviations. 
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PCA efficiency is dependent on protein concentration. 
Detection of Vif-A3G interaction using PCA is dependent on the hydrolysis rate of 
CENTA substrate by active β-lactamase enzyme. Therefore, intracellular concentration 
of proteins is crucial for a reliable quantification of protein-protein interactions. In 
order to determine the best concentration of intracellular Vif and APOBEC proteins we 
tested different concentrations of intracellular Vif and A3G fusion proteins for the 
intensity of CENTA hydrolysis rate. We transfected different rations of Vif-B2 and A3G-B1 
in 293T cells and looked for the intensity of the signal obtained for CENTA hydrolysis. 
The results obtained indicate that the higher the concentration of both proteins the 
higher the signal obtained (Fig. 3). Thus, we decided to use ratio A3G (10 µg):Vif (20 µg) 
in the subsequent experiments as this was the ratio that allowed us to better detect 
A3G-Vif interaction.  
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Fig.3. Intensity of the signal obtained by the hydrolysis rate of CENTA substrate it’s directly related to 
the amount of both proteins expressed in the cells. 293 T were transfected with increasing amounts of 
either Vif SLQ>A3-B2 or A3G-B1 protein: A3G plasmid DNA quantity was kept constant (10 µg) and increasing 
amounts of Vif was used (0, 5, 10, 20 µg). In parallel, we kept Vif plasmid DNA quantity constant (20 µg) 
and added increasing amounts of A3G (0, 3, 5, 10 µg). DNA quantities were adjusted to a total of 30 µg by 
adding empty pcDNA3.1 vector DNA, when appropriate. 48 hours after transfection media was removed 
and cells were washed twice in PBS and were suspended in 100 µl of 100 mM phosphate buffer (K2HPO4 
50mM, pH=7) for the PCA assay. Upper panel:   in vivo hydrolysis rate (abs. unit measured at 450 nm) of 
CENTA for the combination of protein concentration used. Lower panel: The data are averages of 
triplicates with the indicated standard deviations. Lower panel: Western blotting analysis of cell lysates 
and co-immunoprecipitation. 1/3 of the HEK 293T cells transfected for the PCA assay were collected for 
co-immunoprecipitation of Vif and A3G proteins using Anti-HA-High-Affinity-Matrix (ROCHE). The data are 
averages of triplicates with the indicated standard deviations. 
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Analysis of A3G and Vif mutations using PCA 
Different approaches have been employed to define regions in Vif and A3G that are 
required for their in vivo interaction. One of the key residues that have been 
extensively studied is the residue 128 in A3G. This region is responsible for the species-
specific recognition of A3G by Vif, which is aspartic acid in humans and lysine in African 
green monkey (AGM) (Bogerd H. et al., 2004; Mangeat B. et al., 2004; Schrofelbauer B. et al., 2004; Xu H. et al., 2004). In 
addition, Huthoff and Malim demonstrated that amino acids 124-127 are involved in 
A3G encapsidation into virions, whereas amino acids 129-130 are involved in Vif 
response (Huthoff H. and Malim M., 2007). It has been suggested that amino acid 122 may also be 
involved in virion encapsidation (Huthoff H. and Malim M., 2007) but this remains to be confirmed.  
Therefore, we used the mutants A3G R122A and A3G W271L to study the interaction 
with Vif by PCA. This way, each protein sequence was fused to one of the fragments of 
β-lactamase enzyme.  
As shown in figure 4 A, there was a sharp reduction in the ability of the mutants, 
A3GR122A –B1 and A3GW271L –B2, to interact with Vif-B2, Vif YRHHY>A5-B2, Vif DRMR>A4-B2, and Vif 
DRMR>SEMQ-B2. This seems to indicate that A3G residues 122 and 127 may also play a role 
in the interaction with Vif. The effect of A3G R122A, W127L mutations was also tested 
in an infectivity assay in which both A3G mutants were co-expressed with Vif wt and 
HIV-1ΔVif plasmids. The ability of A3G mutants to inhibit HIV-1 infection was absent 
(Fig. 4 B). This must be due to the inability of both mutants to be encapsidated into 
viral particles as it was previously suggested by Huthoff and Malim (Huthoff H. and Malim M., 
2007). 
According to our results (fig. 4 A) alanine-substitutions in Vif YRHHY and DRMR regions 
resulted in a weak interaction with A3G wt and mutants indicating that the two distinct 
regions in Vif may be equally important for the interaction with A3G. This was also 
confirmed in an infectivity assay, which showed the equal inability of both Vif YRHHY 
and DRMR mutants to overcome A3G wt protein (Fig. 4 B). This is interesting in a way 
that both Vif YRHHY and Vif DRMR regions have been previously described as being 
involved in the differential inhibition of A3G and A3F, respectively (Russel R. and Pathak V., 2007). 
The ability of those Vif mutants to overcome A3G R122A, W127L, and D128K mutants 
was also assessed in an infectivity assay (Fig. 4 B). As seen in figure 4 B, HIV-1 infectivity 
was slightly reduced by A3G R122A and W127L in the presence of both YRHHY and 
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DRMR Vif mutants (Fig. 4 B). However, this reduction was minimal when compared to 
A3G wt and D128K mutant proteins.  
Finally, it is interesting to note that despite the weak interaction between Vif mutants 
and A3G wt, interaction with A3G R122A, W127L mutants is always weaker when 
compared to A3G wt (Fig. 4 A). This again, may reinforce our suggestion that A3G 
residues 122 and 127 may also play a role in the interaction with Vif.  
A3G D128K mutant protein was unable to interact with Vif-B2 and that is in accordance 
with previous work (Schrofelbauer at al., 2004).  In addition, Vif SEMQ mutant, which has been 
shown to interact with A3G wt and D128K mutant (Schrofelbauer B. et al. 2006), displayed a weak 
interaction with A3G D128K protein when compared to A3G wt (Fig. 4 A). However, Vif 
SEMQ was able to counteract both A3G wt and D128K mutant in an infectivity assay 
rescuing infectivity nearly at the same level detected for W127L A3G mutant (Fig. 4 B). 
Therefore, residue 128 may be important for the species-specific recognition of A3G by 
Vif, but may not necessarily be involved in the interaction with Vif.  
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Fig. 4.  A. Effect of Vif and A3G mutations in the interaction. Top panel: In vivo hydrolysis rate (abs. unit 
measured at 450 nm) of CENTA for the interaction of Vif, VifDRMR, Vif YRHHY, and VifSEMQ with and A3G wt, 
R122A, W127L, and D128K mutants. Hydrolysis rate of CENTA for fusion proteins alone is also represented 
as negative controls. Mean hydrolysis rate was determined for three independent experiments and 
normalized for cell number and protein content. Briefly, 10 µg of each A3G plasmid, and 20 µg of each Vif 
plasmid DNA were used for transfections in 60-mm plates. DNA amounts were adjusted to 30 µg using 
empty pcDNA3.1 vector DNA when appropriate. 48 hrs after transfections, media was removed and cells 
were washed twice in PBS and were suspended in 100 µl of 100 mM phosphate buffer (K2HPO4 50mM, 
pH=7) for the PCA assay. The data are averages of triplicates with the indicated standard deviations. Lower 
panel: Western blotting analysis of cell lysates and co-immunoprecipitation. 1/3 of the HEK 293T cells 
transfected for the PCA assay were collected for co-immunoprecipitation of Vif and A3G proteins using 
Anti-HA-High-Affinity-Matrix (ROCHE).  
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Fig. 4 B. Infectivity assay. HIV-1ΔVif virions were produced by cotransfecting 293T with pNL4.3ΔVif (15 µg) 
in the presence of 5 µg of each A3G plasmid, and 10 µg of each Vif plasmid. DNA amounts were adjusted 
to 30 µg using empty pcDNA3.1 vector DNA when appropriate. 48 h after transfection viruses were 
collected and used to infect HeLa P4 cells (1.5X10
4
). Relative infectivity values were detected by measuring 
the absorbance of β-gal activity at 550/620nm, in a CPRG assay. The data are averages of triplicates with 
the indicated standard deviations. 
 
 
PCA analysis of Vif interaction with A3F, A3C, and A2. 
The involvement of some deaminases, other than A3G, in HIV-1 infection, as well as the 
role of Vif in overcoming their action is still poorly understood. Therefore, we decided 
to use PCA assay to study the interaction of human and SIV Vif with A3F, A3C, and A2, 
and compare it with the results obtained for A3G.   
We have showed that any of the Vif DRMR and YRHHY mutations were able to abolish 
the interaction with A3G wt. This way, we decided to use the same strategy to study 
the importance of those regions for the interaction with A3F, A3C, and A2. As seen in 
figure 5 A, the strongest interaction is detected between Vif and A3G wt proteins. 
Interaction of Vif wt with A3F was detected, although with a lower signal (Fig. 5 A), 
which is in accordance with previous reports showing that the anti-HIV-1 effect of A3F 
is significantly lower than that of A3G (Holmes R. et al. 2007; Zennou V. et al. 2006). As observed for 
A3G, Vif DRMR and YRHHY mutants were also unable to interact with 
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A3F (Fig. 5 A) indicating an equal involvement of those regions in the interaction with 
both A3G and A3F.  
Interaction of Vif wt with A3C was shown to be very weak when compared to A3G, 
A3F, and A2 (Fig 5 A) and no inhibition of HIV-1ΔVif infection was detected (Fig. 5 B). 
This is in accordance with previous reports which showed that A3C is relatively 
resistant to Vif action (Langlois MA  et al. 2005; Yu Q. et al. 2004; Doehle BP. et al. 2005). However, when we 
replaced Vif DRMR region by alanines it was notable the increase in the interaction 
with A3C (Fig. 5 A).  The increase in the signal detected may be a result of the 
substitution of DRMR region by alanines that may have altered the charge of the 
protein allowing its interaction with A3C. If this is the reason why Vif DRMR>A4 was 
able to interact with A3C, then it is possible that this region of Vif may be important for 
the selection of the deaminase to which it will interact. In addition, A3C was not able to 
interact with Vif SEMQ (Fig. 5 A). However, it has been reported has having a potent 
antiviral activity against SIV (Yu Q. et al. 2004).  In addition, Vif SEMQ was not able to rescue 
HIV-1Δvif infectivity in the presence of A3C (Fig. 5 B). In fact, only Vif DRMR>A4 mutant 
was able to rescue infectivity to a level near to what was obtained in the presence of 
A2. 
Substitution of Vif YRHHY to alanines resulted in a reduction in the interaction with all 
the APOBEC proteins analyzed (Fig. 5 A). We had seen before that Vif YRHHY>A5 
mutant was unable to interact with both A3G and A3F. Interestingly, this mutation also 
abolished interaction with A2 by PCA (Fig. 5 A). In fact, interaction of A2 with Vif wt, Vif 
DRMR>A4 and Vif SEMQ was also detected, with exception to Vif YRHHY>A5 mutant. It 
appears that, with exception for Vif YRHHY>A5 mutant, A2 follows a similar interaction 
pattern to A3G. However, A2 was not able to inhibit HIV-1 ΔVif infection in an 
infectivity assay (Fig. 5 B), which is not surprising as there is no evidence of an effect of 
A2 on HIV-1 replication. This is an indication that APOBEC antiviral activity may not be 
necessarily dependent on the interaction with Vif.  
When, we replaced the DRMR region in Vif by SEMQ it was detected a reduction in its 
ability to interact with A3F and A3C (Fig. 5 A). Also, Vif SEMQ protein was not able to 
rescue infectivity in the presence of A3F indicating that this region is not involved in 
the interaction with A3F (Fig. 5 B).  
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Fig. 5. A. Interaction of Vif wt and Vif mutants with A3F, A3C, and A2 deaminases. Top panel: In vivo 
hydrolysis rate (abs. unit measured at 450 nm) of CENTA for the interaction of Vif, VifDRMR, Vif YRHHY, and 
VifSEMQ with and A3G, A3F, A3C, and A2 deaminases. Hydrolysis rate of CENTA for fusion proteins alone is 
also represented as negative controls. Mean hydrolysis rate was determined for three independent 
experiments and normalized for cell number and protein content. Briefly, 20 µg of each Vif plasmid and 10 
µg of each A3G plasmid DNA was used for transfections in 60-mm plates. DNA amounts were adjusted to 
30 µg using empty pcDNA3.1 vector DNA when appropriate. 48 hrs after transfections, media was 
removed and cells were washed twice in PBS and were suspended in 100 µl of 100 mM phosphate buffer 
(K2HPO4 50mM, pH=7) for the PCA assay. Mean hydrolysis rate was determined for three independent 
experiments and normalized for cell number and protein content. The data are averages of triplicates with 
the indicated standard deviations. Lower panel: Western blotting analysis of cell lysates and co-
immunoprecipitation. Co-immunoprecipitation of Vif and A3G proteins was performed using Anti-HA-High-
Affinity-Matrix (ROCHE). 
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Fig. 5 B. Infectivity assay. HIV-1ΔVif virions were produced by cotransfecting 293T with pNL4.3ΔVif (15 µg) 
in the presence of 5 µg of each APOBEC plasmid, and 10 µg of each Vif plasmid. DNA amounts were 
adjusted to 30 µg using empty pcDNA3.1 vector DNA when appropriate. 48 h after transfection viruses 
were collected and used to infect HeLa P4 cells (1.5X10
4
). Relative infectivity values were detected by 
measuring the absorbance of β-gal activity at 550/620nm, in a CPRG assay. The data are averages of 
triplicates with the indicated standard deviations. 
 
 
DISCUSSION 
The interaction of Vif with A3G has been extensively studied. However, the role of 
other deaminases such as A3F, A3C and A2, in HIV-1 replication is still poorly 
understood. Of these, only A3G and A3F are described as having antiretroviral activity. 
A3C is a good candidate to study as it is expressed in cells targeted by HIV-1 (Jarmuz A et 
al.2002) and A3C-induced mutations occur at levels that allow replication to persist and 
may therefore play a role in driving viral diversity (Bourara K. et al. 2007). Furthermore, it has 
been shown that A3C exerts potent antiviral activity against SIV (Yu Q. et al. 2004) but it is 
relatively resistant to human Vif (Langlois MA  et al. 2005; Yu Q. et al. 2004; Doehle BP. et al. 2005).  
In order to clarify the mechanism involved in the interaction of Vif with A3G, we used 
both proteins in fusion to fragments of β-lactamase, carrying mutations in regions that 
Assessement of Vif-A3G interaction based on PCA 
 120 
 
had been previously described as being crucial for this interaction. Particularly, we 
studied the importance of Vif D14RMR and Y40RHHY regions for the in vivo 
interaction with A3G wild-type and mutant proteins. We showed by PCA that both Vif 
DRMR and YRHHY regions were equally involved in the interaction with A3G and A3F, 
as substitution to alanines resulted in inability to interact with those proteins. Our 
results contradict a previous report by Russel R. and Pathak V.., which identified Vif 
DRMR and YRHHY regions as being critical for independent interactions with A3F and 
A3G, respectively  (Russel R. and Pathak V., 2007). It was also reported by the same authors that 
Vif binding to A3G D128K mutant was dependent on the YRHHY region of Vif (Russel R. and 
Pathak V., 2007). However, we did not detect interaction between Vif mutants and A3G 
D128K mutant protein, despite Vif SEMQ being able to counteract both A3G wt and 
D128K mutant in an infectivity assay. An explanation for that may be that residue 128 
may be important for the species-specific recognition of A3G by Vif, but may not 
necessarily be involved in the interaction with Vif. Therefore, we suggest that further 
clarification must be carried in the future in order to clarify the involvement of those 
two regions in Vif interaction with A3G, A3F, and A3G D128K. 
We have also studied the involvement of A3G regions 122, 127 and 128 in the 
interaction with Vif wt and mutants. Alteration of 128 residue in A3G from aspartic acid 
to lysine resulted in inhibition of the interaction with Vif wt, which is in agreement with 
previous work (Bogerd H. et al., 2004; Mangeat B. et al., 2004; Schrofelbauer B. et al., 2004; Xu H. et al., 2004). In 
addition, mutations in both regions of A3G protein, R122A and W127L, resulted in a 
sharp reduction in the ability to interact with Vif. This led us to conclude that those two 
regions in A3G may not only be important for the interaction with Gag, as previously 
demonstrated by Huthoff and Malim (Huthoff H. and Malim M., 2007) but also for the interaction 
with Vif.  
Interaction of Vif wt, Vif YRHHY, and Vif SEMQ with A3C was shown to be very weak 
when compared to A3G, A3F, and A2 and no inhibition of HIV-1ΔVif infection was 
detected. However, it is interesting to note that when we replaced Vif DRMR region by 
alanines interaction with A3C was recovered. This led us to suggest that the DRMR 
region in Vif may be involved in the selection of the APOBEC to inactivate. This was also 
clear in our infectivity assay, as Vif DRMR was able to rescue HIV-1 infectivity in the 
presence of A3C. 
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The function of A2 is still unknown, although it was proposed to be an RNA-editing 
enzyme in analogy with APOBEC1 (Anant S. et al.2001; Liao W. et al. 1999). In this case, A2 would be 
the only proposed RNA-editing enzyme apart from adenosine deaminases (Schaub M. and W. 
Keller, 2002) to be widely expressed among vertebrates. This way, it could be interesting to 
study the effects of A2 on HIV-1 replication and its relation to Vif. Therefore, we have 
used PCA to assess the interaction of A2 with Vif. In our PCA assay, A2 displayed ability 
to interact with all Vif proteins used, with exception to Vif YRHHY mutant. This is 
interesting in a way that A2 is not reported as having activity against HIV-1 and that 
was confirmed by us in an infectivity assay showing that A2 was not able to inhibit HIV-
1 infectivity in any of the assays performed. In this way, it is possible that the antiviral 
activity of a deaminase may not be a pre-requisite for Vif to interact with it.  
Alternatively, it is possible that despite the ability of A2 to interact with Vif, an 
additional co-factor may be required in order to A2 to be able to exert antiviral action. 
Our hypothesis is also supported by a recent report suggesting that in order to 
A3G/A3F inhibit HIV-1 replication it required the presence of a cell factor that was 
present in some human cell lines but absent in others (Han Y. et al., 2008). If this is the case, 
there is an urgent need for clarification of which co-factor that is present in certain cell 
lines and absent in others, is playing a role in APOBEC HIV-1 restriction. 
Overall, PCA strategy was proven to be a simple and sensitive assessment of the in vivo 
interaction of Vif with A3G and other members of the APOBEC family. This technique 
was shown to be highly reproducible with a low probability of false-negatives and we 
believe that it could be used in future to clarify about specific domains that may be 
involved in the interaction between Vif and APOBEC proteins.  
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1. General Discussion 
 
1.1. Background 
 
HIV-1 is a complex retrovirus that encodes an accessory protein, Vif, which is required 
for production of infectious virus in a cell-type specific manner (Fisher A. G. et al., 1987; Strebel K. et 
al., 1987). In the past few years, remarkably advances in elucidating Vif function were 
made based on the finding that it inactivates a cellular antiviral factor named 
APOBEC3G (A3G). Tremendous progress has been made since the identification of A3G 
as a novel innate defense mechanism against HIV-1 infection. It is now widely known 
that viruses lacking functional Vif genes have their ability to replicate in non-permissive 
cell types (cells without A3G) severely impaired. Conversely, other cell lines (e.g. SupT1, 
Jurkat, CEM-SS) are permissive to HIV-1 infection and allow replication of Vif-defective 
viruses.  
One of the mechanisms that Vif uses to counteract A3G is by stimulating its 
degradation in the 26S proteasome (Cullen BR, 2006; Mangeat B and Trono D., 2005; Chiu Y. and Greene W., 2006). 
If A3G escapes Vif action, it will be free to be incorporated into budding HIV-1 virions 
and exert its antiviral activity in the next infected cell. Therefore, understanding how 
A3G functions in the cell and how Vif reacts to counteract its activity in vivo is crucial 
for the design of novel antiretroviral therapies.  
In this dissertation we aimed at understanding the mechanism of action of A3G, the 
structure-function relationship between Vif and A3G, as well as the in vivo interaction 
of both proteins.  
The major conclusions of this work are discussed in detail at the end of each chapter 
and will be stated next as general conclusions. 
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2. General Conclusions 
 
In chapter 2, we modelled A3G half-life in order to better understand the initial steps 
of its mechanism of action. This was an artificial fine-tuning of A3G steady-state that 
proved to be useful as a model to study its mechanism of action and to monitor its 
activity inside the cell over the time as well as its incorporation into the HIV-1 virions.  
• We have showed that A3G follows the proteasome degradation pathway in a 
Vif-independent manner, indicating that A3G may be targeted by specific cellular E3 
ligases, which do not include Vif.  
 
• We showed that newly synthesized A3G, with less than five minutes of life, is 
already active in the cell and that A3G, with a half-life of approximately 13 minutes, is 
still able to incorporate into HIV viral particles. These results indicate that, in order to 
counteract A3G activity, Vif has to act at the very early stages of A3G life-time in order 
to avoid its incorporation into virions. 
 
These findings showed us the importance of the A3G steady-state levels for the 
maintenance of its antiretroviral activity and point out that modelling A3G steady-state 
can predict how protein half-life can influence the antiviral activity of the deaminase, 
both at the level of its catalytic activity in the cell and viral encapsidation. 
 
In chapter 3, we used a strategy to study the in vivo interaction of Vif-A3G based on an 
oligomerization-assisted interaction whereby fragments of Vif and A3G were fused to 
independently folding and interacting domains of homodimerizing GCN4 leucine 
zipper-forming sequences.  
• We showed that the C-terminal region of Vif alone is not sufficient to induce 
A3G degradation and that binding of Vif to A3G must involve an additional co-factor 
that is probably linked to the N-terminus of Vif and may be essential for the interaction 
and consequent degradation of A3G. 
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• We showed the importance of the topological orientation of Vif-A3G for an 
efficient interaction indicating that it must occur in a parallel orientation and both 
proteins must be in close proximity. 
 
• We showed that Vif-targeted degradation of A3G is specific for these two 
proteins supporting the hypothesis of an involvement of a specific co-factor in this 
interaction.  
 
This was a novel approach that proved to be efficient in studying Vif-A3G interaction 
domains in vivo.  
 
In chapter 4 we also assessed the Vif-A3G interaction using a Protein Complementation 
Assay (PCA). To study this interaction, we used a β-lactamase complementation assay 
in which the inactive domains of the enzyme were fused to each of the proteins in 
question. The interaction of our complementary proteins will result in a functional β-
lactamase capable of hydrolysing a substrate measurable by spectrophotometry. 
• We were able to achieve a quantitative assessment of HIV-1 Vif-A3G 
interactions, which allowed us to do a fine dissection of the regions involved in this 
interaction. 
 
• We showed that some mutations in A3G protein that had been described as 
being involved in the interaction with HIV-1 Gag, were also important for the 
interaction with Vif. 
 
• We also studied the interaction of Vif with other members of the APOBEC 
family. By using PCA strategy we found a new region in Vif that may be important for 
the selection of the APOBEC protein to inactivate. 
 
• By studying the interaction of Vif with A2 protein we reached the conclusion 
that an additional co-factor may be required in order to A2 to be able to exert antiviral 
action. This hypothesis had also been suggested by us in chapter 3 and it is also 
supported by other authors. Therefore, we provided supporting information for a new 
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direction of the study of Vif-A3 problematic regarding the involvement of an additional 
co-factor. 
 
We will next discuss the excitement new opportunities that stand for the development 
of novel anti-HIV-1 therapies that exploit the interplay between Vif and A3G. We will 
also discuss it in light of the results presented in this dissertation. 
  
3. Integrative Discussion 
 
3.1. Therapeutic strategies based on Vif and A3G. 
 
To date, the most successful HIV antiviral drugs in the market are those that target the 
HIV enzymes reverse transcriptase (RT) and protease (PR). More recently, drugs that 
target HIV integrase (IN) (β- diketo compounds [Hazuda DJ. et al., 2000] or pyranodipyrimidines 
[Pannecouque C. et al., 2002; Witvrouw M. et al., 2004]) and HIV entry, including T20, a synthetic peptide 
that disrupts virus-to-cell fusion (Wild CT. et al., 1994) were also developed.  
Recent advances in the study of the biological role of HIV-1 Vif and A3G, together with 
progress in deciphering how Vif counteracts A3G opened new opportunities to develop 
anti-HIV drugs. The most obvious target is the interaction between Vif and A3G. 
However, understanding the mode of action of Vif and A3G alone can also provide a 
number of attractive targets.  
In chapter 2 of this dissertation, we assessed the mechanism of action of A3G. By 
monitoring A3G activity inside the cell over the time, we were able to do a fine-tuning 
of the temporal distribution of A3G since the time it is translated until its incorporation 
into the virion. This was an innovative approach that extended the actual knowledge 
on the mechanism of action of A3G allowing the future development of new drugs. By 
showing that A3G follows the proteasome degradation pathway in a Vif-independent 
manner, we suggest that A3G may be targeted by cellular specific E3 ligases, which do 
not include Vif. Therefore, blocking the interaction of A3G with its specific E3 ligase 
could be a therapeutic approach to increase the amount of the antiviral protein in the 
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cell. However, a lot of work would have to be done to find which E3 ligase is indeed 
interacting with A3G. 
Vif forms an E3 ubiquitin ligase complex containing Elongin B and C, Cullin 5, and Rbx2, 
and uses all these key domains to recruit A3G for polyubiquitination and proteasomal 
degradation (Conticello SG et al., 2003; Liu B et al., 2005; Marin M et al., 2003; Mehle A et al., 2004; Sheehy AM et al., 2003; 
Stopak et al., 2003; Yu X et al., 2003; Yu X et al., 2004). Therefore, the interaction of Vif with the E3 ligase 
complex it’s another potential target, which could prevent A3G ubiquitination and 
degradation.  
In addition, based on our results, it would be interesting to determine if A3G protein, in 
the absence of Vif, would suffer a post-translational modification that could expose 
amino acid residues that could trigger a cascade of events that would ultimately lead to 
proteasome degradation. If that is proved to happen, a therapeutic approach using 
dipeptide inhibitors of the N-end rule pathway could be used to inhibit Ub conjugation 
and consequently increase the intracellular half-life of the protein providing a better 
anti-retroviral response.   
Enhancing A3G, and A3F (also an HIV-1 inhibitor), activities and inhibiting Vif function 
are attractive therapeutic strategies. However, care must be taken when attempting to 
upregulate A3G expression as A3G mRNA is highly expressed in some tumor cells (Jarmuz 
A. et al., 2002) and this could potentially induce tumor formation.  
 
3.1.1. High molecular mass A3G as a therapeutic target. 
 
A3G exists has either an enzimatically active low-molecular-mass (LMM) form or as an 
enzimatically inactive high-molecular-mass (HMM) ribonucleoprotein complex larger 
than 2 MDa (Chiu YL. et al., 2005). It’s the LMM A3G form that is responsible for the post-entry 
block to HIV-1 infection in resting CD4 T cells. In the HMM complexes A3G is inactive in 
its ability to inhibit HIV-1 replication.  
It was recently found that A3G molecules are synthesized as a LMM form and within 
1.5 hours after synthesis they are assembled into HMM complexes where they become 
inactive (Soros V. et al., 2007). Apparently, it is during this period, before assembling into HMM 
complexes, that A3G molecules are selectively incorporated into virions (Soros V. et al., 2007). 
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Our results extended this knowledge by giving more detailed information on the time-
window between A3G synthesis and incorporation into virions. We showed that A3G 
molecules with approximately 13 minutes of life are already incorporated, whereas less 
than 5 minutes old A3G are not. Based on previous authors (Soros V. et al., 2007) we assumed 
that those were LMM newly synthesized molecules that were able to exert antiviral 
activity in the cell and that was confirmed by us through an infectivity assay. Therefore, 
our results indicate that in order to prevent encapsidation of A3G Vif has to act within 
a 5 to 13 minute time-window after its synthesis. 
The fact the LMM A3G is a post-entry restriction factor suggests a potential therapeutic 
strategy. Therapeutic strategies that could induce the formation of LMM A3G 
complexes, or instead, disrupt HMM A3G complexes could enable A3G to exert its 
antiviral activity, rendering a cell resistant to HIV-1 infection. 
However, the conversion of LMM into HMM complexes after T cell activation requires 
careful assessment in terms of the signals and molecular pathways that induce this 
response. 
 
3.1.2. In vivo Vif-A3G interaction as a potential therapeutic target. 
 
Blocking the in vivo binding of Vif to A3G is certainly one of the most obvious 
therapeutic strategies. Several authors reported that Vif may function at several levels 
to prevent incorporation of A3G into viral particles, either by promoting degradation of 
A3G in the proteasome or by sequestering A3G from sites of virion assembly impairing 
A3G incorporation into viral particles. (Kao S. et al., 2007; Santa-Marta M. et al., 2005; Mehle A. et al., 2004b; 
Stopak K. et al., 2003). Preventing the binding of Vif to A3G may result in two outcomes: 1) 
inhibition of A3G proteasomal degradation and, 2) increase the amount of A3G at the 
membrane site of viral assembly and budding resulting in a higher level of A3G 
incorporation into virions. However, it is important to note that Vif is also taken for 
degradation in the proteasome since it binds directly to the SCF complex and other E3-
Ub-ligases independently of A3G. Therefore, disruption of Vif-A3G interaction in a way 
that would prevent the proteolytic degradation of A3G could also prevent Vif 
degradation and the effect of increasing levels of Vif in the cell is still unclear. 
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Features of Vif and A3G domains involved in the interaction between the two proteins 
have been extensively studied in the last few years. A detailed knowledge of the 
interacting domains involved in this interaction is extremely important for the rational 
design of new antiviral drugs. To date, several regions in Vif and A3G proteins have 
been mapped and the effect on the interaction has been studied.  
The first region being described as essential for the in vivo interaction of Vif and A3G 
was the amino acid 128 in A3G. This region is responsible for the species-specific 
recognition of A3G by Vif, which is aspartic acid in humans and lysine in African green 
monkey (AGM) (Bogerd H. et al., 2004; Mangeat B. et al., 2004; Schrofelbauer B. et al., 2004; Xu H. et al., 2004). 
Substitution of D128 in human A3G for K128, found in African Green Monkey (AGM) 
A3G, results in a mutant (D128K-A3G) deaminase that is resistant to the effect of Vif. It 
is the charge of this amino acid at position 128 in A3G that markedly influences the 
interaction with Vif indicating that the Vif-A3G interaction is dependent on 
electrostatic forces (Shcrofelbauer B. et al., 2006). Thus, therapeutic compounds that could target 
this region of A3G could be effective in preventing Vif-A3G interaction. Importantly, 
molecules targeting amino acid 128 are not predicted to interfere with A3G enzymatic 
activity, which is conferred by other domains of the protein (Navarro F. et al., 2005; Li J. et al., 2004). 
In addition to this region of A3G, other regions in Vif and A3G have been identified that 
proved to be potential targets for drugs.  
The N-terminal region of Vif has been implicated in binding to A3G, whereas the 
SLQ144LQXLA150 motif in the C-terminal domain is responsible for degradation of A3G 
and A3F by the Vif-Cul5-E3 ligase complex (Marin M, et al., 2003; Schrofelbauer, B. et al, 2006; Simon, V., 2005; 
Tian, C. et al, 2006; Indrani P. et al, 2006). Several regions have been described as being involved in 
the Vif-A3G interaction and are described in more detail in chapters 3 and 4.  
In chapter 3, we confirmed the previous observation that the N-terminal region of Vif is 
involved in binding to A3G, and extended it by showing that binding of Vif to A3G must 
involve an additional cofactor that is probably linked to the N-terminus of Vif. It was 
recently found that in one particular human T cell line, CEM-T4, A3G and A3F were 
unable to block HIV-1 replication, even in the absence of Vif (Han Y. et al., 2008). Further 
analysis indicated that this cell line lacked a cellular factor that was very critical for 
A3G/A3F antiviral activity. These results indicated that in order to A3G/A3F inhibit HIV-
1 replication it required the presence of a cell factor that was present in some human 
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cell lines but absent in others. Our results support this previous report, indicating that 
the binding of Vif to A3G must involve an additional cofactor, and extended it by 
showing that it is probably linked to the N-terminus of Vif. The involvement of one (or 
more) cofactor may then be responsible for the interaction and consequent 
degradation of A3G. This observation leads to a new research direction that could 
result in the discovery of new drug targets.   
Despite the extensive work that has been developed by many authors to define regions 
that are crucial for the interaction between the two proteins, there are still 
controversial data. Therefore, clarification of conflicting results is required prior to the 
rational design of molecules to efficiently block this interaction. 
The work presented in this dissertation (chapters 3 and 4) represent novel approaches 
that proved to be efficient in providing a general approach for protein dissection and 
interaction domains studies, and can be used in the future as a novel approach for a 
rapid in vivo screening of Vif-A3G interacting domains. It also offers the advantage of 
allowing it to be done in an in vivo environment without any deleterious effect on the 
structure and activity of the proteins.  
 
3.2.  Potential consequences of Vif-based drugs.  
 
HIV-1 is a highly recombinant virus with a huge evolutionary potential. One of the key 
factors responsible for this, is the high mutational rates due to the poor fidelity of 
reverse transcriptase (Mansky LM. And Temin HM., 1995). Recombination is also another factor 
responsible for the evolutionary potential of HIV-1 and some authors suggest that it’s 
even more powerful in shaping HIV-1 evolutionary patterns that mutation (Levy DN. Et al., 
2004). The high rates of HIV-1 replication (10 
10 viral particles are produced each day 
within an infected individual), together with the high rates of recombination and 
mutation, can result in a substantial cost to the virus.  
Previous reports suggested that the HIV-1 population in infected individuals is mainly 
composed of non-infectious, mutated viruses (Bourinbaiar AS., 1994; Li Y., 1992; Sanchez G. et al., 1997). It 
has been suggested that even a small increase in the mutational rate of HIV-1 could 
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lead to a genetic meltdown of the viral quasispecies in a phenomenon called “error 
catastrophe” (Eigen M., 1971; Eigen M., 2002).  
Therefore, antiviral therapies that could enhance the mutational rate of HIV-1 are 
attractive. One possible strategy would be to inhibit Vif action and consequently allow 
A3 proteins to exert their mutational onslaught during HIV-1 reverse transcription. A3G 
and, to a lesser extend A3F, antiviral mechanisms result in genome degradation, 
incomplete cDNA synthesis, and a detrimentally high mutation rate within the HIV-1 
genome, which has been largely attributed to deamination of the viral cDNA (Mariani R. et 
al., 2003; Goff SP 2003; Gu Y. and Sundquist WI. 2003; Harris R. S. et al., 2002; Klarman G. J. et al., 2003; Mangeat B. et al., 2003).   
Antiviral drugs that could inhibit Vif and enhance A3G/A3F activity are emerging as 
attractive targets (Mezei M. and Minarovits J., 2006; Carr JM et al., 2006; Stopak K. and Greene WC., 2005; Fessel J., 2005). 
However, care must be taken when designing new antiviral drugs as incomplete Vif 
inhibition could result in an increase in A3G intracellular concentration just enough to 
exert an intermediate level of mutational pressure on the HIV-1 genome resulting in a 
“sub-error catastrophe”. This could accelerate viral evolution instead of inducing a 
population collapse (Fig.1) resulting in antiretroviral resistance (Berkhout B. and de Ronde A., 2004) 
and in immune escape.  
Therefore, the potential outcome of a Vif-based intervention must be examined 
rigorously both in vitro and in vivo prior to clinical deployment. In addition, A3G and 
A3F may also function through other mechanisms that do not necessarily require 
deamination (Chiu YL. Et al., 2005; Bishop KN. Et al., 2006; Soros VB. Et al., 2007).  
Despite some controversy remaining on that subject, a therapeutic strategy that could 
amplify this non-mutagenic phenotype without enhancing cytidine deamination may 
be an alternative to suppress viral replication. 
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(Figure from: Pillai SK. et al., Retrovirology.2008) 
Fig. 1. Possible effects of Vif inhibition on HIV-1 population. The extent of HIV-1 hypermutation is directly 
proportional to the concentration of A3 in the cell (Suspene R. et al., 2004). A highly effective Vif inhibitor 
could result in a significant increase in A3 intracellular levels leading to viral error catastrophe (red zone). 
However, if a drug is not efficient enough in inhibiting Vif, that could fail to induce a mutational meltdown 
in HIV-1 and instead it will accelerate viral evolution and drug resistance (yellow zone).  
 
In summary, A3G and A3F proteins have appeared in the war against HIV-1 as part of 
our innate immune system. The antiretroviral action of these proteins is overtaken by 
the action of HIV-1 Vif protein. In the past 6 years, since the discovery of A3G as an 
antiviral factor, many advances have been made in trying to understand its mechanism 
of action in the cell and how Vif acts in order to counteract its activity.  
However, despite Vif-A3G interplay being an attractive target for future therapeutic 
strategies, there are still questions that remain to be answered and controversial 
points that need to be clarified. Determination of A3G and Vif high-resolution structure 
will certainly give a huge impulse in the clarification of many unanswered questions 
and will be crucial for the development of novel therapeutic strategies. 
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